Heterocyclic compounds and uses thereof

Heterocyclic compounds are developed to inhibit cGAS, addressing the need for therapeutic agents that target cGAS, offering treatment options for diseases like inflammation and cancer by modulating its activity.

JP2024542128APending Publication Date: 2024-11-13VENTUS THERAPEUTICS US INC

Patent Information

Application Number
JP2024526803
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-08
Filing Date
2022-11-07
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

There is a need for therapeutic agents that specifically target cyclic GMP-AMP synthase (cGAS) to treat diseases associated with inappropriate cGAS activity and consequent undesired type I interferon activity.

Method used

Development of heterocyclic compounds that inhibit cGAS activity, including specific heteroaryl or heterocyclyl structures with various substituents, which can be administered to modulate cGAS activity and treat associated diseases.

Benefits of technology

The heterocyclic compounds effectively inhibit cGAS, providing therapeutic benefits in treating diseases such as inflammation, autoimmune diseases, cancer, and other disorders by modulating cGAS activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542128000001_ABST
    Figure 2024542128000001_ABST
Patent Text Reader

Abstract

The present invention relates to a compound of formula (I): JPEG2024542128000208.jpg3250 [wherein, rings A, R 1 , R 2 , R 3 and m are as described herein. The present invention relates to the use of compounds of formula (I) and their pharma- ceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, labeled isotopes or tautomers in the treatment of cGAS-related diseases and disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 276,927, filed November 8, 2021, the contents of which are incorporated herein by reference in their entirety.

[0002] FIELD OF THE INVENTION The present invention relates to inhibitors of cyclic GMP-AMP synthase. The inhibitors described herein are useful for treating diseases or disorders associated with cyclic GMP-AMP synthase. In particular, the present invention relates to compounds and pharmaceutical compositions that inhibit cyclic GMP-AMP synthase, methods for treating diseases or disorders associated with cyclic GMP-AMP synthase, and methods for synthesizing these compounds. [Background technology]

[0003] background Abnormal accumulation of cytoplasmic DNA induces type I interferons and other cytokines, which are important for antimicrobial defense, but can also induce autoimmunity. This DNA signaling pathway requires the stimulator of interferon genes (STING) adaptor protein and the transcription factors NF-κB and IRF3, but the mechanism of DNA sensing remained unclear until recently. It is now understood that mammalian cytoplasmic extracts synthesize cyclic GMP-AMP (cGAMP) from ATP and GTP in the presence of DNA, but not RNA, in vitro (WO2014099824). DNA transfection or DNA virus infection of mammalian cells also induces cGAMP production. cGAMP binds to STING, leading to IRF3 activation and interferon-β (IFNβ) induction. Thus, cGAMP is the first cyclic dinucleotide in metazoans, and it functions as an endogenous second messenger that induces interferon production in response to cytoplasmic DNA.

[0004] cGAMP synthase (cGAS) is an enzyme that mediates the synthesis of cyclic GMP-AMP and belongs to the nucleotidyltransferase family. Overexpression of cGAS activates the transcription factor IRF3 and induces IFNβ in a STING-dependent manner. Knockdown of cGAS inhibits IRF3 activation and IFNβ induction by DNA transfection or DNA virus infection. cGAS binds to DNA in the cytoplasm and catalyzes cGAMP synthesis. These findings indicate that cGAS is a cytoplasmic DNA sensor that induces interferon induction by producing the second messenger cGAMP.

[0005] The essential role of cGAS in cytoplasmic DNA sensing has been established in various pathogenic bacteria, viruses, and retroviruses (US20210155625). Furthermore, cGAS is essential for various other biological processes, such as cellular senescence and the recognition of ruptured micronuclei in the surveillance of potentially cancerous cells. Summary of the Invention [Problem to be solved by the invention]

[0006] There is a need for therapeutic agents that target cGAS. Small molecule inhibitors that are specific for cGAS would be extremely valuable for treating diseases caused by inappropriate cGAS activity and resulting undesired type I interferon activity. The present invention is intended to fulfill this unmet need associated with current cGAS inhibitory therapies. [Means for solving the problem]

[0007] summary In one embodiment, the present invention provides a compound of formula (I): [ka] [During the ceremony, Ring A is a 5- to 10-membered heteroaryl or a 3- to 10-membered heterocyclyl; R 1 is H, -SR 4 , -S(O)R 4, -S(O)2R 4 , -N(R 4 )2, -CN, C1-C6 alkyl, C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the alkyl, aryl or heteroaryl optionally has one or more R 5 provided that when ring A is 1-isoquinolinyl, R 1 is not pyridinyl; R 2 is H or C1-C6 alkyl; Each R 3 are independently halogen, -CN, -OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, -SR 8 , -S(O)2R 8 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 6 or replaced by 2 R's 3 together with the atom to which they are attached, form a C3-C8 cycloalkyl, a C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 7 or replaced by 2 Germinal R 3 combine with the carbon atom to which they are attached to form oxo; R 4 is H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; Each R 5 are independently -OH, halogen, -C(O)OH, C-C alkyl, C-C alkoxy, C-C alkenyl, or C-C alkynyl, wherein said alkyl, alkoxy, alkenyl, or alkynyl is optionally substituted with halogen, OH, or NH; Each R 6 are independently halogen, -OH, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally halogen, —OH, —NH, —NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl) or 2 R's 6 combine with the atoms to which they are attached to form atoms or 2 Germinal R 6 combine with the carbon atom to which they are attached to form oxo; Each R 7 are independently halogen, -OH, -C(O)OR 8 , C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; 2 R's 7 together with the atom to which they are attached, C3-C8 cycloalkyl, C6-C 10 forming an aryl, a 5- to 10-membered heteroaryl, or a 3- to 10-membered heterocyclyl; 2 Germinal R 7 combine with the carbon atom to which they are attached to form oxo; R 8 is H, -OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl optionally comprises one or more R 9 is replaced by; R 9 Ha-(CH2) n -NHC(O)-(CH2) p -OR 10 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally halogen, —OH, —NH, —NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl); R 10 is C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally contains one or more halogen atoms, —OH, —CO(OH), —(CH) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl or C6-C 10 substituted with aryl; m is an integer from 0 to 4; n is an integer from 0 to 6; and and p is an integer of 0 to 6. or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof.

[0008] In one embodiment, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further comprise an additive, diluent, or surfactant.

[0009] In certain embodiments, the present invention provides a method of treating a disease or disorder associated with the regulation of cGAS, comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, or a pharmaceutical composition thereof.

[0010] In certain aspects, the present invention provides a method of inhibiting cGAS, comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, or a pharmaceutical composition thereof.

[0011] In certain aspects, the present invention provides a method of treating or preventing a disease or disorder disclosed herein, comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof, or a pharmaceutical composition thereof.

[0012] In certain aspects, the present invention provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, or a pharmaceutical composition of the present invention.

[0013] In one aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, or a pharmaceutical composition thereof, for use in the manufacture of a medicament for inhibiting cGAS.

[0014] In certain aspects, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof, or a pharmaceutical composition thereof, for use in the manufacture of a medicament for the treatment or prevention of a disease or disorder disclosed herein.

[0015] In certain aspects, the present invention provides the use of a compound of the present invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof in the manufacture of a medicament for the treatment of a disease or disorder disclosed herein.

[0016] In certain aspects, the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, for use in the treatment or prevention of a disease or disorder disclosed herein.

[0017] In certain aspects, the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, for use in treating a disease or disorder disclosed herein.

[0018] In certain embodiments, the present invention provides intermediates described herein (eg, intermediates selected from those described in the Examples) suitable for use in the methods of making the compounds described herein.

[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the singular includes the plural unless clearly interpreted otherwise from the context. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. The references mentioned herein are not admitted to be prior art to the present invention. In case of conflict, the present specification, including definitions, will control. Furthermore, the materials, methods, and examples are for illustrative purposes only and not intended to be limiting. In the event of a conflict between the chemical structure and the name of a compound disclosed herein, the chemical structure will control.

[0020] Other features and advantages of the invention will be apparent from the following detailed description and claims.

[0021] Detailed Description The present invention relates to compounds and compositions capable of inhibiting cGAS. The present invention relates to methods for treating, preventing, or alleviating diseases or disorders in which cGAS plays a role, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof. The methods of the present invention can be used to treat a variety of cGAS-mediated diseases and disorders by inhibiting cGAS activity. The present invention also relates to methods for making these compounds, pharmaceutical compositions containing them, and their use in treating disorders in which cGAS is involved, including, but not limited to, inflammation, autoimmune diseases, cancer, infection, diseases or disorders of the central nervous system, metabolic diseases, cardiovascular diseases, respiratory diseases, kidney diseases, liver diseases, eye diseases, skin diseases, lymphatic diseases, rheumatic diseases, psychiatric diseases, graft-versus-host disease, or allodynia.

[0022] In one embodiment, the present invention provides a compound of formula (I): [ka] [In the formula, rings A, R 1 , R 2 , R 3 and m are listed here.] or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof.

[0023] Details of the present invention are described below. Methods and materials similar or equivalent to those described herein can be used in practicing or testing the present invention, and a description of the methods and materials is provided below. The characteristics, objects, and advantages of the present invention will be apparent from the description and claims. In this specification and the appended claims, the singular also includes the plural unless clearly indicated otherwise by the context. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited herein are incorporated herein by reference in their entirety.

[0024] definition The articles "a," "an," and "an" are used herein to refer to one or more than one (i.e., at least one) of an object. For example, "an element" refers to one element or more than one element.

[0025] The term "and / or" is used herein to mean "and" or "or," unless stated otherwise.

[0026] The term "optionally substituted" means that a chemical moiety (e.g., an alkyl group) can be (but is not necessarily) substituted with other substituents (e.g., heteroatoms). For example, an optionally substituted alkyl group can be a fully saturated alkyl chain (i.e., pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents that are not hydrogen. For example, it can be bonded at any point along the chain to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus, the term "optionally substituted" also means that a chemical moiety can include other functional groups, but does not necessarily have any additional other functional groups. Suitable substituents used for optional substitution of the groups described include halogen, oxo, -OH, -CN, -COOH, -CHCN, -O-(C-C)alkyl, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, -O-(C-C)alkenyl, -O-(C-C)alkynyl, (C-C)alkenyl, (C-C)alkynyl, -OH, -OP(O)(OH), -OC Examples of alkyl groups include, but are not limited to, (O)(C-C)alkyl, -C(O)(C-C)alkyl, -OC(O)O(C-C)alkyl, -NH, -NH((C-C)alkyl), -N((C-C)alkyl), -NHC(O)(C-C)alkyl, -C(O)NH(C-C)alkyl, -S(O)(C-C)alkyl, -S(O)NH(C-C)alkyl, and S(O)N((C-C)alkyl). Substituents may themselves be optionally substituted. As used herein, "optionally substituted" also refers to substituted or unsubstituted as defined below.

[0027] As used herein, the term "substituted" means that the specified group or moiety bears one or more suitable substituents, where the substituent may be attached to the specified group or moiety at one or more points. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl is attached by a bond to an atom of the aryl or is fused to the aryl, sharing two or more common atoms.

[0028] As used herein, the term "unsubstituted" means that the specified group bears no substituents.

[0029] Unless otherwise specifically defined, the term "aryl" refers to a cyclic, aromatic hydrocarbon group having one to three aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl, or naphthyl. When containing two aromatic rings (e.g., bicyclic), the aromatic rings of the aryl group can be joined at a single point (e.g., biphenyl) or fused (e.g., naphthyl). An aryl group is optionally substituted at any point of attachment with one or more substituents, e.g., 1 to 5 substituents. Examples of substituents include, but are not limited to, -H, -halogen, -O-(C-C)alkyl, (C-C)alkyl, -O-(C-C)alkenyl, -O-(C-C)alkynyl, (C-C)alkenyl, (C-C)alkynyl, -OH, -O-P(O)(OH), -OC(O)(C-C)alkyl, -C(O)(C-C)alkyl, -OC(O)O(C-C)alkyl, -NH, NH((C-C)alkyl), N((C-C)alkyl), -S(O)-(C-C)alkyl, -S(O)NH(C-C)alkyl, and -S(O)N((C-C)alkyl). The substituents may themselves be optionally substituted. Additionally, when containing two fused rings, aryl groups as defined herein can have a saturated or partially unsaturated ring fused to a fully unsaturated aromatic ring. Examples of ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.

[0030] Unless otherwise specifically defined, "heteroaryl" means a monovalent monocyclic or polycyclic aromatic radical of 5 to 24 ring atoms containing one or more ring heteroatoms selected from N, O, S, P, Se, or B, with the remainder of the ring atoms being C. Heteroaryl, as defined herein, also means a bicyclic heteroaromatic group in which the heteroatoms are selected from N, O, S, P, Se, or B. Heteroaryl, as defined herein, also means a tricyclic heteroaromatic group in which the heteroatoms are selected from N, O, S, P, Se, or B. The aromatic radical is optionally substituted independently with one or more substituents described herein. Examples are furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolinyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolyl Indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl , tetrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1λ 2-pyrrolo[2,1-b]pyrimidine, dibenzo[b,d]thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4]thiazinyl, benzoxazolyl, benzisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [1,2,4]triazolo[1,5-a]pyridinyl, benzo[1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[4 ,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, thiazolo[5,4-d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl and derivatives thereof. Additionally, when containing two or more fused rings, heteroaryl groups as defined herein can have one or more saturated or partially unsaturated rings, for example, a 5-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from N, O, S, P, Se, or B, or a 6-membered heteroaromatic ring containing 1 to 3 nitrogens, fused to a fully unsaturated aromatic ring, wherein the saturated or partially unsaturated ring contains 0 to 4 heteroatoms selected from N, O, S, P, Se, or B, and is optionally substituted with one or more oxo. In heteroaryl ring systems containing more than two fused rings, the saturated or partially unsaturated ring may be further fused to a saturated or partially unsaturated ring as described herein.Examples of ring systems of these heteroaryl groups include, for example, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuranyl, benzofuranonyl, indolinyl, oxindolyl, indolyl, 1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-onyl, 7,8-dihydro-1H-isoquinolinyl, 1,6-dihydro-2H-pyrazolo[3,4-c]pyridin-7-on ... including hydro-6H-pyrido[3,2-b]pyrrolidinyl, 8H-pyrido[3,2-b]pyrrolidinyl, 1,5,6,7-tetrahydrocyclopenta[b]pyrazolo[4,3-e]pyridinyl, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolidine, pyrazolo[1,5-a]pyrimidin-7(4H)-onyl, 3,4-dihydropyrazino[1,2-a]indol-1(2H)-onyl or benzo[c][1,2]oxaborol-1(3H)-olyl.

[0031] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine.

[0032] "Alkyl" refers to a straight or branched chain saturated hydrocarbon containing from 1 to 12 carbon atoms. Examples of (C1-C6) alkyl groups include, but are not limited to, methyl (-CH3), ethyl (-CH2CH3), propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.

[0033] "Alkoxy" refers to a straight or branched chain saturated hydrocarbon containing 1 to 12 carbon atoms including a terminal "O" in the chain, i.e., -O(alkyl). Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.

[0034] "Alkenyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2 to 12 carbon atoms. An "alkenyl" group contains at least one double bond within the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl. Alkenyl groups can be unsubstituted or substituted. As defined herein, alkenyl can be straight or branched.

[0035] "Alkynyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2 to 12 carbon atoms. An "alkynyl" group contains at least one triple bond within the chain. Examples of alkenyl groups include ethynyl, propargyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl. Alkynyl groups can be unsubstituted or substituted.

[0036] The term "alkylene" or "alkylenyl" refers to a divalent alkyl group. Any of the above monovalent alkyl groups can become alkylene by abstracting a second hydrogen atom from the alkyl. Alkylene, as defined herein, can be a C1-C6 alkylene. Alkylene can further be a C1-C4 alkylene. Typical alkylene groups include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and the like.

[0037] "Cycloalkyl" refers to a group of 3 to 10 carbon atoms (e.g., C3-C 12 , C3-C 10or C3-C8). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, bicyclo[2.2.2]octenyl, decahydronaphthalenyl, octahydro-1H-indenyl, cyclopentenyl, cyclohexenyl, cyclohexa-1,4-dienyl, cyclohexa-1,3-dienyl, 1,2,3,4-tetrahydronaphthalenyl, octahydropentalenyl, 3a,4,5,6 Examples of cycloalkyls include, but are not limited to, 7,7a-hexahydro-1H-indenyl, 1,2,3,3a-tetrahydropentalenyl, bicyclo[3.1.0]hexanyl, bicyclo[2.1.0]pentanyl, spiro[3.3]heptanyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]hept-2-enyl, bicyclo[2.2.2]octanyl, 6-methylbicyclo[3.1.1]heptanyl, 2,6,6-trimethylbicyclo[3.1.1]heptanyl, adamantyl, and derivatives thereof. In the case of polycyclic cycloalkyls, only one of the rings in the cycloalkyl need be non-aromatic.

[0038] "Heterocyclyl," "heterocycle," or "heterocycloalkyl" refers to a saturated or partially unsaturated 3- to 10-membered monocyclic, 7- to 12-membered bicyclic (fused, bridged, or spirocyclic), or 11- to 14-membered tricyclic ring system (fused, bridged, or spirocyclic), having one or more heteroatoms (e.g., O, N, S, P, Se, or B), e.g., 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms or, e.g., 1, 2, 3, 4, 5, or 6 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, unless otherwise specified.Examples of heterocycloalkyl groups are piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, isoindolinyl, indolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, 1,2,3,6-tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, pyranyl, morpholinyl, tetrahydrothiopyranyl, 1,4-diazepanyl, 1,4-diaze ... -oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 2,6-diazaspiro[3.3]heptanyl, 1,4-dioxa-8-azaspiro[4.5]decanyl, 1,4-dioxaspiro[4.5]decanyl, 1-oxaspiro[4.5]decanyl, 1-azaspiro[4.5]decanyl, 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-yl, 7'H-spiro[cyclohexane-1,5'-furo[3,4-b]pyridin]-yl, 3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridin]-yl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexan-3-yl, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl, 3,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridinyl 2-azaspiro[3.5]nonanyl, 2-methyl-2-azaspiro[3.5]nonanyl, 2-azaspiro[4.5]decanyl, 2-methyl-2-azaspiro[4.5]decanyl, 2-oxa-azaspiro[3.4]octanyl, 2-oxa-azaspiro[3.4]octan-6-yl, and the like.

[0039] The term "haloalkyl," as used herein, refers to an alkyl group, as defined herein, that is substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, and the like.

[0040] The term "haloalkoxy," as used herein, refers to an alkoxy group, as defined herein, that is substituted with one or more halogens. Examples of haloalkoxy groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, and the like.

[0041] As used herein, the term "cyano" refers to a substituent having a carbon atom connected to a nitrogen atom by a triple bond, ie, C≡N.

[0042] As used herein, the term "amine" refers to primary (R-NH, R≠H), secondary (R-NH, R≠H), and tertiary (R-N, R≠H) amines. Substituted amine is intended to mean an amine in which at least one of the hydrogen atoms has been replaced with a substituent.

[0043] As used herein, the term "amino" refers to a substituent containing at least one nitrogen atom. Specifically encompassed by the term "amino" are -NH, -NH(alkyl) or alkylamino, -N(alkyl) or dialkylamino, amido, carboxamido, urea, and sulfamido substituents.

[0044] The term "solvate" refers to a complex of variable stoichiometry formed by a solute and a solvent. For the purposes of the present invention, such a solvent may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. A solvate in which water is the solvent molecule is typically referred to as a hydrate. Hydrates include compositions containing stoichiometric amounts of water and compositions containing variable amounts of water.

[0045] The term "isomer" refers to compounds that have the same composition and molecular weight but differ in physical and / or chemical properties. The structural differences can be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With respect to stereoisomers, the compounds of formula (I) can have one or more asymmetric carbon atoms and can occur as racemates, racemic mixtures, and individual enantiomers or diastereomers.

[0046] The present invention also provides isotopically labeled compounds of formula (I), also referred to herein as "labeled isotopes", e.g., 2 H and 14 C labeled are also contemplated. Deuterated (i.e., 2 H or D) and carbon-14 (i.e., 14 C) Isotopes are particularly preferred due to their ease of preparation and detectability. Furthermore, substitution with heavy isotopes such as deuterium can offer certain therapeutic advantages (e.g., increased in vivo half-life or reduced dosage requirements) due to greater metabolic stability and may therefore be preferred in certain circumstances. Isotopically labeled compounds of formula (I) can generally be prepared according to methods similar to those disclosed in the following schemes and / or examples, substituting the appropriate isotopically labeled reagent for the non-isotopically labeled reagent.

[0047] The present invention also includes pharmaceutical compositions comprising an effective amount of the disclosed compounds and a pharmaceutically acceptable carrier. Representative "pharmaceutically acceptable salts" include, for example, water-soluble and water-insoluble salts, such as acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulanate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, fionate, gluceptate, gluconate, glutamate, glycolyllarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, Includes laurate, magnesium, malate, maleate, mandelate, mesylate, methyl bromide, methyl nitrate, methyl sulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methene-bis-2-hydroxy-3-naphthoate, eimbonate), pantothenate, phosphate / hydrogen phosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.

[0048] A "patient" or "subject" is a mammal, such as a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey.

[0049] An "effective amount" when used in conjunction with a compound is an amount effective to treat or prevent a disease or disorder in a subject as described herein.

[0050] The term "carrier" as used in this disclosure includes carriers, excipients, and diluents and means a substance, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, that is involved in carrying or transporting a drug from one organ or part of the body to another organ or part of the body of a subject.

[0051] The term "treatment" with respect to a subject refers to the amelioration of at least one symptom of a disorder in a subject. Treatment includes curing, amelioration, or at least partial alleviation of a disorder.

[0052] The term "disorder," as used herein, unless otherwise specified, means, and is interchangeable with, disease, condition, or pathology.

[0053] As used herein, the terms "administer," "administering," or "administration" refer to the direct administration of a disclosed compound or a pharmaceutically acceptable salt of a disclosed compound, or a composition to a subject, or the administration of a prodrug derivative or analog of the compound or a pharmaceutically acceptable salt of the compound, or a composition, that is capable of forming an equivalent amount of the active compound in the subject's body, to a subject.

[0054] The term "prodrug," as used herein, refers to a compound that is convertible in vivo by metabolic means (eg, by hydrolysis) to a disclosed compound.

[0055] Compounds of the Invention The present invention relates to compounds or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, labeled isotopes, or tautomers thereof that can inhibit cGAS and are useful in treating diseases and disorders associated with the regulation of cGAS. The present invention also relates to compounds or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, labeled isotopes, or tautomers thereof that may be useful in inhibiting cGAS.

[0056] In one embodiment, the present invention provides a compound of formula (I): [ka] [During the ceremony, Ring A is a 5- to 10-membered heteroaryl or a 3- to 10-membered heterocyclyl; R 1 is H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2, -CN, C1-C6 alkyl, C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the alkyl, aryl or heteroaryl optionally has one or more R 5 provided that when ring A is 1-isoquinolinyl, R 1 is not pyridinyl; R 2 is H or C1-C6 alkyl; Each R 3 are independently halogen, -CN, -OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, -SR 8 , -S(O)2R 8 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 6 or replaced by 2 R's 3 together with the atom to which they are attached, form a C3-C8 cycloalkyl, a C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 7 or replaced by 2 Germinal R 3combine with the carbon atom to which they are attached to form oxo; R 4 is H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; Each R 5 are independently -OH, halogen, -C(O)OH, C-C alkyl, C-C alkoxy, C-C alkenyl, or C-C alkynyl, wherein said alkyl, alkoxy, alkenyl, or alkynyl is optionally substituted with halogen, OH, or NH; Each R 6 are independently halogen, -OH, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally halogen, —OH, —NH, —NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8, -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl) or 2 R's 6 combine with the atoms to which they are attached to form atoms or 2 Germinal R 6 combine with the carbon atom to which they are attached to form oxo; Each R 7 are independently halogen, -OH, -C(O)OR 8 , C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; 2 R's 7 together with the atom to which they are attached, C3-C8 cycloalkyl, C6-C 10 forming an aryl, a 5- to 10-membered heteroaryl, or a 3- to 10-membered heterocyclyl; 2 Germinal R 7 combine with the carbon atom to which they are attached to form oxo; R 8 is H, -OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl optionally comprises one or more R 9 is replaced by; R 9 Ha-(CH2) n -NHC(O)-(CH2) p -OR10 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally halogen, —OH, —NH, —NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl); R 10 is C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally contains one or more halogen atoms, —OH, —CO(OH), —(CH) n -NHC(O)-(CH2) p -OR 8, -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl or C6-C 10 substituted with aryl; m is an integer from 0 to 4; n is an integer from 0 to 6; and and p is an integer of 0 to 6. or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof.

[0057] In certain embodiments, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof: Ring A is heteroaryl or heterocyclyl; R 1 H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2, —CN, C1-C6 alkyl, aryl, or heteroaryl, wherein the aryl or heteroaryl optionally contains one or more R 5 with the proviso that when A is 1-isoquinolinyl, R 1 but not pyridinyl; R 2 is H or C1-C6 alkyl; Each R 3 are independently halogen, -CN, -OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclyl, wherein the alkyl, cycloalkyl, heterocyclyl, or heteroaryl optionally is one or more R6 is replaced by or two R's 3 together with the intervening atoms form a C3-C8 cycloalkyl, aryl, heterocyclyl, or heteroaryl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally contains one or more R 7 is replaced by; or two R's 3 combine with the carbon atom to which they are attached to form oxo; R 4 is H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or aryl; Each R 5 are independently -OH, halogen, -C(O)OH, C-C alkyl, C-C alkoxy, C-C alkenyl, or C-C alkynyl, wherein said alkyl, alkoxy, alkenyl, or alkynyl is optionally substituted with halogen, OH, or NH; Each R 6 are independently halogen, -OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8, -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , substituted with C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, heteroaryl, heterocyclyl or alkylaryl; or two R's 6 together with the intervening atoms form a C3-C8 cycloalkyl, aryl, heterocyclyl, or heteroaryl; or two R's 6 combine with the carbon atom to which they are attached to form oxo; Each R 7 are independently halogen, -OH, -C(O)OR 8 , C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl or aryl; or two R's 7 together with the intervening atoms form a C3-C8 cycloalkyl, aryl, heterocyclyl, or heteroaryl; or two R's 7 combine with the carbon atom to which they are attached to form oxo; Each R 8 is independently H, —OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl optionally is selected from the group consisting of one or more R 9 is replaced by; Each R 9 Independently -(CH2)n -NHC(O)-(CH2) p -OR 10 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C3 cycloalkyl, heterocyclyl, heteroaryl or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , substituted with C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl or alkylaryl; Each R 10 are independently C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally contains one or more halogen, —OH, —CO(OH), —(CH2) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl or aryl; m is an integer from 0 to 4; n is an integer from 0 to 6; and p is an integer between 0 and 6 Provide something.

[0058] In certain embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof has the formula (Ia): [ka] is a compound of

[0059] In certain embodiments, a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of R 4 is methyl.

[0060] In certain embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof has the formula (Ia-1): [ka] (wherein m is 0, 1 or 2). is a compound of

[0061] In certain embodiments, a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of R 4 is methyl.

[0062] In certain embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof has the formula (Ia-1-i): [ka] is a compound of

[0063] In certain embodiments, a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of R 4 is methyl.

[0064] In certain embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof has the formula (Ia-1-ii): [ka] wherein q is 0, 1, 2, 3, or 4. is a compound of

[0065] In certain embodiments, a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of R 4 is methyl.

[0066] In certain embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof has the formula (Ia-2): [ka] wherein m is 0, 1, 2, or 3. is a compound of

[0067] In certain embodiments, a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of R 4 is methyl.

[0068] In certain embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof has the formula (Ia-2-i): [ka] (wherein m is 1, 2 or 3.) is a compound of

[0069] In certain embodiments, a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of R 4 is methyl.

[0070] In certain embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof has the formula (Ia-2-ii): [ka] wherein q is 0, 1, 2, 3, or 4. is a compound of

[0071] In certain embodiments, a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of R 4 is methyl.

[0072] In certain embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of Formulas (Ia-5) to (Ia-13): [ka] wherein q is 0, 1, 2, 3, or 4, and m is 0, 1, 2, or 3. is a compound of

[0073] In certain embodiments, a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of R 4 is methyl.

[0074] In certain embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of Formulas (Ia-14) to (Ia-33): [ka] [ka] wherein q is 0, 1, 2, 3, or 4, and m is 0, 1, 2, or 3. If m>0, then R 3 It is understood that may replace the NH group of ring A.

[0075] In certain embodiments, a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof is selected from the group consisting of R 4 is methyl.

[0076] In some embodiments, R 4 is methyl.

[0077] In some embodiments, R 1 is H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2, -CN, C1-C6 alkyl, C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the alkyl, aryl or heteroaryl optionally has one or more R 5provided that when ring A is 1-isoquinolinyl, R 1 is not pyridinyl.

[0078] In some embodiments, R 1 is H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2, -CN, C1-C6 alkyl, C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the alkyl, aryl or heteroaryl optionally has one or more R 5 is replaced by .

[0079] In some embodiments, R 1 is H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2, -CN, C1-C6 alkyl, C6-C 10 It is aryl or 5- to 10-membered heteroaryl.

[0080] In some embodiments, R 1 is H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2, -CN, C1-C6 alkyl, C6-C 10 aryl or 5-10 membered heteroaryl, wherein the alkyl, aryl or heteroaryl is one or more R 5 is replaced by .

[0081] In some embodiments, R 1 is optionally 1 or more R 5 C6-C substituted with 10 It is aryl.

[0082] In some embodiments, R 1 is C6-C 10 It is aryl.

[0083] In some embodiments, R 1 is an R of 1 or more 5 C6-C substituted with 10 It is aryl.

[0084] In some embodiments, R 1 is optionally 1 or more R 5 is a 5- to 10-membered heteroaryl substituted with

[0085] In some embodiments, R 1 is a 5- to 10-membered heteroaryl.

[0086] In some embodiments, R 1 is an R of 1 or more 5 is a 5- to 10-membered heteroaryl substituted with

[0087] In some embodiments, R 1 is H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2, —CN, C1-C6 alkyl, aryl, or heteroaryl. In some embodiments, R 1 is H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2, —CN, C1-C6 alkyl, or aryl. In some embodiments, R 1 is H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2, —CN, or C1-C6 alkyl. In some embodiments, R 1 is H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2 or -CN. In some embodiments, R 1 is H, -SR 4 , -S(O)R 4, -S(O)2R 4 or -N(R 4 )2. In some embodiments, R 1 is H, -SR 4 , -S(O)R 4 or -S(O)2R 4 In some embodiments, R 1 is H, -SR 4 or -S(O)R 4 In some embodiments, R 1 is H or -SR 4 In some embodiments, R 1 is H. In some embodiments, R 1 Ha-SR 4 In some embodiments, R 1 -S(O)R 4 In some embodiments, R 1 -N(R 4 )2. In other embodiments, R 1 is —CN. In some embodiments, R 1 -S(O)2R 4 In some embodiments, R 1 is C1-C6 alkyl. In some embodiments, R 1 is aryl. In some embodiments, R 1 is heteroaryl.

[0088] In some embodiments, R 1 is optionally 1 or more R 5 In certain embodiments, R 1 is optionally 1 or more R 5 and heteroaryl substituted with

[0089] In some embodiments, R 1is hydrogen, -SCH, -SCHCH, -CH, -CHF, -CF, -CHCH, -(CH)CH, -(CH)CH, -CN, -CHCHOCH, -NH, -NH(CH), -N(CH), -CH(CHCH), -CH(CHH)(CHCH), 3-chlorophenyl, 3-fluorophenyl, 3-methoxyphenyl, 2-fluoropyridinyl. 1 is -SCH3.

[0090] In certain embodiments, if A is 1-isoquinolinyl, then R 1 is not pyridinyl.

[0091] In some embodiments, R 2 is C1-C6 alkyl. In some embodiments, R 2 is methyl (C1). In some embodiments, R 2 is ethyl (C2). In some embodiments, R 2 is n-propyl (C3). In some embodiments, R 2 is isopropyl (C3). In some embodiments, R 2 is n-butyl (C4). In some embodiments, R 2 is tert-butyl (C4). In some embodiments, R 2 is sec-butyl (C4). In some embodiments, R 2 is isobutyl (C4). In some embodiments, R 2 is n-pentyl (C5). In some embodiments, R 2 is 3-pentanyl (C5). In some embodiments, R 2 is amyl (C5). In some embodiments, R 2 is neopentyl (C5). In some embodiments, R 2 is 3-methyl-2-butanyl (C5). In some embodiments, R 2 is tertiary amyl (C5). In some embodiments, R 2 is n-hexyl (C6).

[0092] In certain embodiments, R2 is H.

[0093] In certain embodiments, R2 is not methyl.

[0094] In some embodiments, R 2 is a C2-C6 alkyl.

[0095] In some embodiments, R 2 is H or C2-C6 alkyl.

[0096] In certain embodiments, ring A is a 5- to 10-membered heteroaryl or a 3- to 10-membered heterocyclyl.

[0097] In certain embodiments, ring A is a 5-10 membered heteroaryl.

[0098] In certain embodiments, ring A is a 3- to 10-membered heterocyclyl.

[0099] In some embodiments, ring A is heteroaryl. In some embodiments, ring A is heterocyclyl. In some embodiments, ring A is 5- or 6-membered heterocyclyl. In some embodiments, ring A is 5- or 6-membered heteroaryl.

[0100] In certain embodiments, ring A is a 5-membered heterocyclyl.

[0101] In certain embodiments, Ring A is a 5-membered heterocyclyl containing one heteroatom, including, but not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione.

[0102] In some embodiments, Ring A is tetrahydrofuranyl. In some embodiments, Ring A is dihydrofuranyl. In some embodiments, Ring A is tetrahydrothiophenyl. In some embodiments, Ring A is dihydrothiophenyl. In some embodiments, Ring A is pyrrolidinyl. In some embodiments, Ring A is dihydropyrrolyl. In some embodiments, Ring A is pyrrolyl-2,5-dione.

[0103] In certain embodiments, Ring A is a 5-membered heterocyclyl containing two heteroatoms, including, but not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.

[0104] In some embodiments, Ring A is dioxolanyl. In some embodiments, Ring A is oxasulfuranyl. In some embodiments, Ring A is disulfuranyl. In some embodiments, Ring A is oxazolidin-2-one.

[0105] In certain embodiments, Ring A is a 5-membered heterocyclyl containing 3 heteroatoms, including, but not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl.

[0106] In some embodiments, Ring A is triazolinyl. In some embodiments, Ring A is oxadiazolinyl. In some embodiments, Ring A is thiadiazolinyl.

[0107] In certain embodiments, ring A is a 6-membered heterocyclyl.

[0108] In certain embodiments, Ring A is a 6-membered heterocyclyl containing one heteroatom, including, but not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.

[0109] In some embodiments, Ring A is piperidinyl. In some embodiments, Ring A is tetrahydropyranyl. In some embodiments, Ring A is dihydropyridinyl. In some embodiments, Ring A is thianyl.

[0110] In certain embodiments, Ring A is a 6-membered heterocyclyl containing two heteroatoms, including, but not limited to, piperazinyl, morpholinyl, dithianyl, dioxanyl.

[0111] In some embodiments, Ring A is piperazinyl. In some embodiments, Ring A is morpholinyl. In some embodiments, Ring A is dithianyl. In some embodiments, Ring A is dioxanyl.

[0112] In certain embodiments, Ring A is a 6-membered heterocyclyl containing 3 heteroatoms, including, but not limited to, triazinanyl.

[0113] In certain embodiments, ring A is triazinanyl.

[0114] In certain embodiments, ring A is [ka] wherein m is 0, 1, 2, or 3. is.

[0115] In certain embodiments, ring A is [ka] wherein m is 0, 1, 2, or 3. is.

[0116] In certain embodiments, ring A is [ka] wherein m is 0, 1, 2, or 3. is.

[0117] In certain embodiments, ring A is [ka] wherein q is 0, 1, 2, 3, or 4. is.

[0118] In certain embodiments, ring A is [ka] wherein q is 0, 1, 2, 3, or 4. is.

[0119] In certain embodiments, ring A is [ka] wherein q is 0, 1, 2, 3, or 4. is.

[0120] In certain embodiments, q is an integer selected from 0 to 3. In certain embodiments, q is an integer selected from 0 to 2. In certain embodiments, q is an integer selected from 0 and 1. In certain embodiments, q is an integer selected from 1 to 4. In certain embodiments, q is an integer selected from 1 to 3. In certain embodiments, q is an integer selected from 1 and 2. In certain embodiments, q is an integer selected from 2 to 4. In certain embodiments, q is an integer selected from 2 and 3.

[0121] In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4.

[0122] In certain embodiments, ring A is a 5-membered heteroaryl.

[0123] In certain embodiments, Ring A is a 5-membered heteroaryl containing one heteroatom, including, but not limited to, pyrrolyl, furanyl, and thiophenyl.

[0124] In some embodiments, ring A is pyrrolyl. In some embodiments, ring A is furanyl. In some embodiments, ring A is thiophenyl.

[0125] In certain embodiments, Ring A is a 5-membered heteroaryl containing two heteroatoms, including, but not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.

[0126] In some embodiments, Ring A is imidazolyl. In some embodiments, Ring A is pyrazolyl. In some embodiments, Ring A is oxazolyl. In some embodiments, Ring A is isoxazolyl. In some embodiments, Ring A is thiazolyl. In some embodiments, Ring A is isothiazolyl.

[0127] In certain embodiments, Ring A is a 5-membered heteroaryl containing 3 heteroatoms, including, but not limited to, triazolyl, oxadiazolyl, and thiadiazolyl.

[0128] In some embodiments, ring A is triazolyl. In some embodiments, ring A is oxadiazolyl. In some embodiments, ring A is thiadiazolyl.

[0129] In certain embodiments, Ring A is a 5-membered heteroaryl containing 4 heteroatoms, including but not limited to tetrazolyl.

[0130] In certain embodiments, ring A is tetrazolyl.

[0131] In certain embodiments, ring A is a 6-membered heteroaryl.

[0132] In certain embodiments, Ring A is a 6-membered heteroaryl containing 1 heteroatom, including but not limited to pyridinyl.

[0133] In certain embodiments, ring A is pyridinyl.

[0134] In certain embodiments, Ring A is a 6-membered heteroaryl containing two heteroatoms, including, but not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl.

[0135] In some embodiments, Ring A is pyridazinyl. In some embodiments, Ring A is pyrimidinyl.

[0136] In certain embodiments, Ring A is pyridazinyl, pyrimidinyl, and pyrazinyl.

[0137] In certain embodiments, ring A is a 6-membered heteroaryl containing 3 or 4 heteroatoms, including, but not limited to, triazinyl and tetrazinyl, respectively.

[0138] In some embodiments, ring A is triazinyl. In some embodiments, ring A is tetrazinyl.

[0139] In certain embodiments, ring A is a 5-membered heteroaryl containing at least two heteroatoms independently selected from N, O, and S.

[0140] In certain embodiments, ring A is a 5-membered heteroaryl containing two heteroatoms independently selected from N, O, and S.

[0141] In certain embodiments, ring A is [ka] (wherein m is 0, 1 or 2). is.

[0142] In certain embodiments, ring A is [ka] is.

[0143] In certain embodiments, ring A is [ka] is.

[0144] In certain embodiments, ring A is [ka] is.

[0145] In certain embodiments, ring A is [ka] wherein q is 0, 1, 2, 3, or 4. is.

[0146] In certain embodiments, ring A is [ka] is.

[0147] In certain embodiments, ring A is [ka] is.

[0148] In certain embodiments, ring A is [ka] is.

[0149] In certain embodiments, ring A is [ka] is.

[0150] In certain embodiments, ring A is [ka] is.

[0151] In certain embodiments, ring A is a 5-membered heteroaryl containing 3 heteroatoms independently selected from N, O, and S.

[0152] In certain embodiments, ring A is [ka] (wherein m is 0 or 1.) is.

[0153] In certain embodiments, ring A is [ka] is.

[0154] In certain embodiments, ring A is [ka] is.

[0155] In certain embodiments, ring A is [ka] is.

[0156] In certain embodiments, ring A is [ka] wherein q is 0, 1, 2, 3, or 4. is.

[0157] In certain embodiments, ring A is [ka] is.

[0158] In certain embodiments, ring A is [ka] is.

[0159] In certain embodiments, ring A is [ka] is.

[0160] In certain embodiments, ring A is a 5-membered heteroaryl containing 3 heteroatoms independently selected from N and O.

[0161] In certain embodiments, ring A is [ka] is.

[0162] In certain embodiments, ring A is a 5-6 membered heteroaryl containing 1 or 4 heteroatoms independently selected from N, O and S.

[0163] In certain embodiments, ring A is [ka] wherein m is 0, 1, 2, 3, or 4. If m>0, then R 3 It is understood that may replace the NH group of ring A.

[0164] In certain embodiments, each R 3 are independently halogen, -CN, -OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR8 ), -C(O)R 8 , -C(O)N(R 8 )2, -SR 8 , -S(O)2R 8 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 6 is replaced by .

[0165] In certain embodiments, each R 3 are independently halogen, -CN, -OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, -SR 8 , -S(O)2R 8 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 It is aryl, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl.

[0166] In certain embodiments, each R 3 are independently halogen, -CN, -OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, -SR 8 , -S(O)2R 8 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is selected from the group consisting of one or more R 6 is replaced by .

[0167] In certain embodiments, each R 3 are independently halogen, -CN, OR 8 , -NH2, NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclyl, wherein the alkyl, cycloalkyl, heterocyclyl, or heteroaryl optionally has one or more R 6 In certain embodiments, each R 3 are independently halogen, -CN, OR 8 , -NH2, NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, C1-C6 alkyl, C3-C8 cycloalkyl, or heteroaryl. In some embodiments, each R 3 are independently halogen, -CN, OR 8 , -NH2, NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , C1-C6 alkyl, or C3-C8 cycloalkyl. In certain embodiments, each R 3 are independently halogen, -CN, OR 8 , -NH2, NH(R 6 ), -N(R 6 )(R7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2 or C1-C6 alkyl. In some embodiments, each R 3 are independently halogen, -CN, OR 8 , -NH2, NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ) or -C(O)R 8 , -C(O)N(R 8 )2. In some embodiments, each R 3 are independently halogen, -CN, OR 8 , -NH2, NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 or -C(O)OR 8 In some embodiments, each R 3 are independently halogen, -CN, OR 8 , -NH2, NH(R 6 ), -N(R 6 )(R 7 ) or -NHC(O)R 8 In some embodiments, each R 3 are independently halogen, -CN, OR 8 , -NH2 or N(H)R 6 In some embodiments, each R 3 are independently halogen, -CN, OR 8 or -NH. In certain embodiments, each R 3 are independently halogen, -CN or OR 8 In some embodiments, each R 3 is independently halogen or —CN. In certain embodiments, each R 3 is halogen. In certain embodiments, each R 3 is —CN. In some embodiments, each R 3 is OR 8In some embodiments, each R 3 is —NH. In some embodiments, each R 3 is N(H)R 6 In some embodiments, each R 3 -N(R 6 )(R 7 In some embodiments, each R 3 is independently -NHC(O)R 8 In some embodiments, each R 3 -C(O)OR 8 In some embodiments, each R 3 HA-C(O)R 8 In some embodiments, each R 3 are independently -C(O)N(R 8 )2. In some embodiments, each R 3 is C1-C6 alkyl. In some embodiments, each R 3 is C-C cycloalkyl. In certain embodiments, each R 3 is heteroaryl. In certain embodiments, each R 3 is optionally 1 or more R 6 In certain embodiments, each R 3 is optionally 1 or more R 6 In certain embodiments, each R 3 is optionally 1 or more R 6 and heteroaryl substituted with

[0168] In some embodiments, R 3 is not a halogen or two geminal R 3 do not form an oxo together with the carbon atom to which they are attached.

[0169] In some embodiments, R 3 is not a halogen.

[0170] In some embodiments, two geminal R 3do not form an oxo together with the carbon atom to which they are attached.

[0171] In certain embodiments, each R 3 are independently -CN, -OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, -SR 8 , -S(O)2R 8 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally has one or more R 6 or two R 3 together with the atom to which they are attached, form a C3-C8 cycloalkyl, a C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 7 is replaced by .

[0172] In some embodiments, R 3 Ha-SR 8 or -S(O)2R 8 isn't it.

[0173] In certain embodiments, each R 3 are independently halogen, -CN, -OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, -SR 8, -S(O)2R 8 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 6 or replaced by 2 R's 3 together with the atom to which they are attached, form a C3-C8 cycloalkyl, a C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 7 or replaced by 2 Germinal R 3 together with the carbon atom to which they are attached form oxo.

[0174] In some embodiments, two R 3 together with the atom to which they are attached, form a C3-C8 cycloalkyl, a C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 7 is replaced by .

[0175] In some embodiments, two R 3 together with the atom to which they are attached, form C3-C8 cycloalkyl, C6-C 10 It forms an aryl, a 5- to 10-membered heteroaryl, or a 3- to 10-membered heterocyclyl.

[0176] In some embodiments, two R 3 together with the atom to which they are attached, form a C3-C8 cycloalkyl, a C6-C 10aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl is selected from the group consisting of one or more R 7 is replaced by .

[0177] In some embodiments, two R 3 together with the atoms to which they are attached, optionally one or more R 7 Form a C3-C8 cycloalkyl substituted with

[0178] In some embodiments, two R 3 together with the atoms to which they are attached form a C3-C8 cycloalkyl.

[0179] In some embodiments, two R 3 together with the atoms to which they are attached, form one or more R 7 Form a C3-C8 cycloalkyl substituted with

[0180] In some embodiments, two R 3 together with the atoms to which they are attached, optionally one or more R 7 C6-C substituted with 10 Forms an aryl.

[0181] In some embodiments, two R 3 together with the atoms to which they are attached, form C6-C 10 Forms an aryl.

[0182] In some embodiments, two R 3 together with the atoms to which they are attached, form one or more R 7 C6-C substituted with 10 Forms an aryl.

[0183] In some embodiments, two R 3 together with the atoms to which they are attached, optionally one or more R 7Form a 5- to 10-membered heteroaryl substituted with

[0184] In some embodiments, two R 3 together with the atom(s) to which they are attached form a 5- to 10-membered heteroaryl.

[0185] In some embodiments, two R 3 together with the atoms to which they are attached, form one or more R 7 Form a 5- to 10-membered heteroaryl substituted with

[0186] In some embodiments, two R 3 together with the atoms to which they are attached, optionally one or more R 7 Form a 3- to 10-membered heterocyclyl substituted with

[0187] In some embodiments, two R 3 together with the atoms to which they are attached form a 3- to 10-membered heterocyclyl.

[0188] In some embodiments, two R 3 together with the atoms to which they are attached, form one or more R 7 Form a 3- to 10-membered heterocyclyl substituted with

[0189] In some embodiments, two R 3 together with the intervening atoms form a C3-C8 cycloalkyl, aryl, heterocyclyl, or heteroaryl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally contains one or more R 7 In some embodiments, two R 3 together with the intervening atoms form a C-C cycloalkyl, aryl, or heterocyclyl. 3 together with the intervening atoms form a C-C cycloalkyl or aryl. In certain embodiments, two R3 together with the intervening atoms form a C3-C8 cycloalkyl. In certain embodiments, two R 3 together with the intervening atoms form an aryl. In certain embodiments, two R 3 together with the intervening atoms form a heterocyclyl. 3 together with the intervening atoms form a heteroaryl. In certain embodiments, two R 3 may, together with any intervening atoms, optionally be one or more R 7 In some embodiments, two R 3 may, together with any intervening atoms, optionally be one or more R 7 In some embodiments, two R 3 may, together with any intervening atoms, optionally be one or more R 7 In some embodiments, two R 3 may, together with any intervening atoms, optionally be one or more R 7 Form a heteroaryl substituted with

[0190] In some embodiments, two geminal R 3 together with the carbon atom to which they are attached form oxo.

[0191] In some embodiments, two R 3 is united with the intervening atoms, [ka] wherein q is 0, 1, 2, 3, or 4. Form.

[0192] In some embodiments, R 4 is H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10It is aryl, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl.

[0193] In some embodiments, R 4 is C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is aryl, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl.

[0194] In some embodiments, R 4 is H.

[0195] In some embodiments, R 4 is C6-C 10 It is aryl.

[0196] In some embodiments, R 4 is a 5- to 10-membered heteroaryl.

[0197] In some embodiments, R 4 is a 3- to 10-membered heterocyclyl.

[0198] In some embodiments, R 4 is C1-C6 alkyl. In some embodiments, R 4 is methyl (C1). In some embodiments, R 4 is ethyl (C2). In some embodiments, R 4 is n-propyl (C3). In some embodiments, R 4 is isopropyl (C3). In some embodiments, R 4 is n-butyl (C4). In some embodiments, R 4 is tert-butyl (C4). In some embodiments, R 4 is sec-butyl (C4). In some embodiments, R 4 is isobutyl (C4). In some embodiments, R 4 is n-pentyl (C5). In some embodiments, R 4is 3-pentanyl (C5). In some embodiments, R 4 is amyl (C5). In some embodiments, R 4 is neopentyl (C5). In some embodiments, R 4 is 3-methyl-2-butanyl (C5). In some embodiments, R 4 is tertiary amyl (C5). In some embodiments, R 4 is n-hexyl (C6).

[0199] In some embodiments, R 4 is H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C3 cycloalkyl, heterocyclyl, heteroaryl, or aryl. 4 is H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C3 cycloalkyl, heterocyclyl, or heteroaryl. 4 is H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C3 cycloalkyl, or heterocyclyl. In some embodiments, R 4 is H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, or C3-C3 cycloalkyl. 4 is H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, or C2-C6 alkynyl. In some embodiments, R 4 is H, C1-C6 alkyl, C1-C6 alkoxy, or C2-C6 alkenyl. In some embodiments, R 4 is H, C1-C6 alkyl, or C1-C6 alkoxy. In some embodiments, R 4 is H or C1-C6 alkyl. In some embodiments, R 4 is H. In some embodiments, R 4 is C1-C6 alkoxy. In some embodiments, R 4is C-C alkenyl. In some embodiments, R 4 is C2-C6 alkynyl. In some embodiments, R 4 is C-C cycloalkyl. In some embodiments, R 4 is heterocyclyl. In certain embodiments, R 4 is heteroaryl. In certain embodiments, R 4 is aryl.

[0200] In certain embodiments, each R 5 is independently -OH, halogen, -C(O)OH, C-C alkyl, C-C alkoxy, C-C alkenyl, C-C alkynyl, wherein the alkyl, alkoxy, alkenyl, or alkynyl is optionally substituted with halogen, -OH, or -NH. 5 is halogen, —C(O)OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, wherein said alkyl, alkoxy, alkenyl or alkynyl is optionally substituted with halogen, OH or NH2.

[0201] In certain embodiments, each R 5 is independently -OH, halogen, -C(O)OH, C-C alkyl, C-C alkoxy, C-C alkenyl, or C-C alkynyl. 5 are independently halogen, —C(O)OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, or C2-C6 alkynyl.

[0202] In certain embodiments, each R 5 are independently —OH.

[0203] In certain embodiments, each R 5 is independently halogen, —C(O)OH, C1-C6 alkyl, C1-C6 alkoxy, or C2-C6 alkenyl. 5is independently halogen, —C(O)OH, C1-C6 alkyl, or C1-C6 alkoxy. In some embodiments, each R 5 is independently halogen, —C(O)OH, or C1-C6 alkyl. In some embodiments, each R 5 is independently halogen or —C(O)OH. In certain embodiments, each R 5 is halogen. In certain embodiments, each R 5 is C1-C6 alkyl. In some embodiments, each R 5 is C1-C6 alkoxy. In certain embodiments, each R 5 is C2-C6 alkenyl. In certain embodiments, each R 5 is C2-C6 alkynyl optionally substituted with halogen, -OH, or -NH2. In certain embodiments, each R 5 is C1-C6 alkyl. In some embodiments, each R 5 is C-C alkoxy optionally substituted with halogen, —OH, or —NH. In certain embodiments, each R 5 is C-C alkenyl optionally substituted with halogen, —OH, or —NH. In certain embodiments, each R 5 is a C2-C6 alkynyl optionally substituted with halogen, -OH or -NH2.

[0204] In some embodiments, R 5 is not C1-C6 alkyl or C1-C6 alkoxy.

[0205] In certain embodiments, each R 5 are independently -OH, halogen, -C(O)OH, C2-C6 alkenyl, or C2-C6 alkynyl, wherein said alkenyl or alkynyl is optionally substituted with halogen, OH, or NH2.

[0206] In certain embodiments, each R 6 are independently halogen, OH, oxo, -CO(OR 8 ), -(CH2) n-NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , substituted with C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, heteroaryl, heterocyclyl or alkylaryl.

[0207] In certain embodiments, each R 6 are independently halogen, -OH, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally halogen, —OH, —NH, —NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl).

[0208] In certain embodiments, each R 6 are independently halogen, -OH, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is aryl, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl.

[0209] In certain embodiments, each R 6are independently halogen, -OH, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is halogen, —OH, —NH, —NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl).

[0210] In certain embodiments, each R 6 are independently optionally halogen, -OH, -NH, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n-NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 C6-C substituted with aryl 10 It is aryl.

[0211] In certain embodiments, each R 6 is independently C6-C 10 It is aryl.

[0212] In certain embodiments, each R 6 are independently halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2)n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 C6-C substituted with aryl 10 It is aryl.

[0213] In certain embodiments, each R 6 are independently halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 and C5-10 membered heteroaryl optionally substituted with aryl).

[0214] In certain embodiments, each R 6 are independently 5-10 membered heteroaryl.

[0215] In certain embodiments, each R 6 are independently halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 and C5-10 membered heteroaryl substituted with (aryl).

[0216] In certain embodiments, each R 6 are independently halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8, -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 and C3-10 membered heterocyclyl optionally substituted with aryl.

[0217] In certain embodiments, each R 6 are independently 3- to 10-membered heterocyclyl.

[0218] In certain embodiments, each R 6 are independently halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10and C3-10 membered heterocyclyl substituted with (aryl).

[0219] In certain embodiments, each R 6 are independently halogen, -OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. 6 are independently halogen, -OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, or heteroaryl. 6 are independently halogen, -OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, or heterocyclyl. 6 are independently halogen, -OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, or C3-C8 cycloalkyl. 6 are independently halogen, -OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, or C2-C6 alkynyl. 6 are independently halogen, -OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, or C2-C6 alkenyl. 6 are independently halogen, -OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, or C1-C6 alkoxy. In certain embodiments, each R 6 are independently halogen, -OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , —CN, or C1-C6 alkyl. In certain embodiments, each R 6 are independently halogen, -OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 or -CN. In certain embodiments, each R 6 are independently halogen, -OH, oxo, -CO(OR 8 ) or -(CH2) n -NHC(O)-(CH2) p -OR 8 In some embodiments, each R 6 are independently halogen, -OH, oxo or -CO(OR 8 In some embodiments, each R 6 is independently halogen, —OH, or oxo. In certain embodiments, each R 6 is independently halogen or —OH. In certain embodiments, each R 6is a halogen.

[0220] In certain embodiments, each R 6 is OH. In some embodiments, each R 6 is oxo. In certain embodiments, each R 6 -CO(OR 8 In some embodiments, each R 6 Ha-(CH2) n -NHC(O)-(CH2) p -OR 8 In some embodiments, each R 6 is CN. In some embodiments, each R 6 is C1-C6 alkyl. In some embodiments, each R 6 is C1-C6 alkoxy. In certain embodiments, each R 6 is C2-C6 alkenyl. In certain embodiments, each R 6 is C2-C6 alkynyl. In certain embodiments, each R 6 is C-C cycloalkyl. In certain embodiments, each R 6 is heterocyclyl. In certain embodiments, each R 6 is heteroaryl. In certain embodiments, each R 6 is aryl.

[0221] In certain embodiments, each R 6 is optionally halogen, OH, NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 and C1-C6 alkyl substituted with aryl.

[0222] In certain embodiments, each R 6 is optionally halogen, OH, NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl substituted with C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or alkylaryl. 6 is optionally halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8, -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or C1-C6 alkoxy substituted with alkylaryl. 6 is optionally halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C-C alkyl, C-C alkoxy, C-C cycloalkyl, heteroaryl, heterocyclyl, or alkylaryl. 6 is optionally halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2)n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C-C alkyl, C-C alkynyl substituted with C-C alkoxy, C-C cycloalkyl, heteroaryl, heterocyclyl, or alkylaryl. 6 is optionally halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or C3-C8 cycloalkyl substituted with alkylaryl. 6 is optionally halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or heterocyclyl substituted with alkylaryl. 6 is optionally halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8, -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or heteroaryl substituted with alkylaryl. 6 is optionally halogen, -OH, -NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8 , C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or aryl substituted with alkylaryl.

[0223] In some embodiments, two R 6 together with the atom to which they are attached, form C3-C8 cycloalkyl, C6-C 10 It forms an aryl, a 5- to 10-membered heteroaryl, or a 3- to 10-membered heterocyclyl.

[0224] In some embodiments, two R 6 together with the atoms to which they are attached, form C6-C 10 Forms an aryl.

[0225] In some embodiments, two R 6 together with the atom(s) to which they are attached form a 5- to 10-membered heteroaryl.

[0226] In some embodiments, two R 6 together with the atoms to which they are attached form a 3- to 10-membered heterocyclyl.

[0227] In some embodiments, two R 6 together with the intervening atoms form a C-C cycloalkyl, aryl, heterocyclyl, or heteroaryl. In some embodiments, two R 6 together with the intervening atoms form a C3-C8 cycloalkyl. In certain embodiments, two R 6 together with the intervening atoms form an aryl. In certain embodiments, two R 6 together with the intervening atoms form a heterocyclyl. 6 together with the intervening atoms form a heteroaryl.

[0228] In some embodiments, two geminal R 6 together with the carbon atom to which they are attached form oxo.

[0229] In certain embodiments, each R 7 are independently halogen, -OH, -C(O)OR 8 , C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is aryl, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl.

[0230] In certain embodiments, each R 7 is independently C6-C 10 It is aryl.

[0231] In certain embodiments, each R 7 are independently 5-10 membered heteroaryl.

[0232] In certain embodiments, each R 7 are independently 3- to 10-membered heterocyclyl.

[0233] In certain embodiments, each R 7 are independently halogen, -OH, -C(O)OR 8 , C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In certain embodiments, each R 7 is halogen. In certain embodiments, each R 7 is —OH. In some embodiments, each R 7 -C(O)OR 8 In some embodiments, each R 7 is C1-C6 alkyl. In some embodiments, each R 7 is C1-C6 alkoxy. In certain embodiments, each R 7 is C2-C6 alkenyl. In certain embodiments, each R 7 is C2-C6 alkynyl. In certain embodiments, each R 7 is C-C cycloalkyl. In certain embodiments, each R 7 is heterocyclyl. In certain embodiments, each R 7 is heteroaryl. In certain embodiments, each R 7 is aryl.

[0234] In some embodiments, two R 7 together with the atom to which they are attached, form C3-C8 cycloalkyl, C6-C 10 It forms an aryl, a 5- to 10-membered heteroaryl, or a 3- to 10-membered heterocyclyl.

[0235] In some embodiments, two R 7together with the atoms to which they are attached, form C6-C 10 Forms an aryl.

[0236] In some embodiments, two R 7 together with the atom(s) to which they are attached form a 5- to 10-membered heteroaryl.

[0237] In some embodiments, two R 7 together with the atoms to which they are attached form a 3- to 10-membered heterocyclyl.

[0238] In some embodiments, two R 7 together with the intervening atoms form a C-C cycloalkyl, aryl, heterocyclyl, or heteroaryl. In some embodiments, two R 7 together with the intervening atoms form a C3-C8 cycloalkyl. In certain embodiments, two R 7 together with the intervening atoms form an aryl. In certain embodiments, two R 7 together with the intervening atoms form a heterocyclyl. 7 together with the intervening atoms form a heteroaryl.

[0239] In some embodiments, two geminal R 7 together with the carbon atom to which they are attached form oxo.

[0240] In some embodiments, R 8 is H, -OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl optionally comprises one or more R 9 is replaced by .

[0241] In some embodiments, R 8 is H, -OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is aryl, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl.

[0242] In some embodiments, R 8 is H, -OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is selected from the group consisting of one or more R 9 is replaced by .

[0243] In some embodiments, R 8 is optionally 1 or more R 9 C6-C substituted with 10 It is aryl.

[0244] In some embodiments, R 8 is C6-C 10 It is aryl.

[0245] In some embodiments, R 8 is an R of 1 or more 9 C6-C substituted with 10 It is aryl.

[0246] In some embodiments, R 8 is optionally 1 or more R 9 is a 5- to 10-membered heteroaryl substituted with

[0247] In some embodiments, R 8 is a 5- to 10-membered heteroaryl.

[0248] In some embodiments, R8 is an R of 1 or more 9 is a 5- to 10-membered heteroaryl substituted with

[0249] In some embodiments, R 8 is optionally 1 or more R 9 is a 3- to 10-membered heterocyclyl substituted with

[0250] In some embodiments, R 8 is a 3- to 10-membered heterocyclyl.

[0251] In some embodiments, R 8 is an R of 1 or more 9 is a 3- to 10-membered heterocyclyl substituted with

[0252] In some embodiments, R 8 is H, —OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl optionally is selected from the group consisting of one or more R 9 is replaced by .

[0253] In some embodiments, R 8 is H. In some embodiments, R 8 is —OH. In some embodiments, R 8 is C1-C6 alkyl. In some embodiments, R 8 is C1-C6 alkoxy. In some embodiments, R 8 is C-C alkenyl. In some embodiments, R 8 is C2-C6 alkynyl. In some embodiments, R 8 is C-C cycloalkyl. In some embodiments, R 8 is heteroaryl. In certain embodiments, R 8 is aryl. In some embodiments, R 8is optionally 1 or more R 9 In some embodiments, R 8 is C1-C6 alkoxy. In some embodiments, R 8 is optionally 1 or more R 9 In certain embodiments, R 8 is optionally 1 or more R 9 In certain embodiments, R 8 is optionally 1 or more R 9 In certain embodiments, R 8 is optionally 1 or more R 9 In certain embodiments, R 8 is optionally 1 or more R 9 is an aryl substituted with

[0254] In some embodiments, R 9 Ha-(CH2) n -NHC(O)-(CH2) p -OR 10 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally halogen, —OH, —NH, —NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10, -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl).

[0255] In some embodiments, R 9 Ha-(CH2) n -NHC(O)-(CH2) p -OR 10 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is aryl, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl.

[0256] In some embodiments, R 9 Ha-(CH2) n -NHC(O)-(CH2) p -OR 10 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is halogen, —OH, —NH, —NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10, -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl).

[0257] In some embodiments, R 9 is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 C6-C substituted with aryl 10 It is aryl.

[0258] In some embodiments, R 9 is C6-C 10 It is aryl.

[0259] In some embodiments, R 9 are halogens, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n-NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 C6-C substituted with aryl 10 It is aryl.

[0260] In some embodiments, R 9 is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl).

[0261] In some embodiments, R 9is a 5- to 10-membered heteroaryl.

[0262] In some embodiments, R 9 are halogens, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl).

[0263] In some embodiments, R 9 is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl).

[0264] In some embodiments, R 9 is a 3- to 10-membered heterocyclyl.

[0265] In some embodiments, R 9 are halogens, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, or -(C1-C6 alkyl)-(C6-C 10 aryl).

[0266] In some embodiments, R 9 Ha-(CH2) n -NHC(O)-(CH2) p -OR 10, -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C3 cycloalkyl, heterocyclyl, heteroaryl or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , substituted with C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl or alkylaryl.

[0267] In some embodiments, R 9 Ha-(CH2) n -NHC(O)-(CH2) p -OR 10 In some embodiments, R 9 is CN. In some embodiments, R 9 is C1-C6 alkyl. In some embodiments, R 9 is C1-C6 alkoxy. In some embodiments, R 9 is C-C alkenyl. In some embodiments, R 9 is C2-C6 alkynyl. In some embodiments, R 9 is C-C cycloalkyl. In some embodiments, R 9 is heterocyclyl. In certain embodiments, R 9 is heteroaryl. In certain embodiments, R9 is aryl.

[0268] In some embodiments, R 9 is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl substituted with C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or alkylaryl. 9 is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkoxy substituted with C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or alkylaryl. 9 is optionally halogen, -OH, -NH2, -NHC(O)OR10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C-C alkyl, C-C cycloalkyl, heteroaryl, heterocyclyl, or alkylaryl. 9 is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C-C alkyl, C-C cycloalkyl, heteroaryl, heterocyclyl, or C-C alkynyl substituted with alkylaryl. 9 is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10, -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or C3-C8 cycloalkyl substituted with alkylaryl. 9 is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or heterocyclyl substituted with alkylaryl. 9 is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10, -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or heteroaryl substituted with alkylaryl. 9 is optionally halogen, -OH, -NH2, -NHC(O)OR 10 , -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or aryl substituted with alkylaryl.

[0269] In some embodiments, R 10 is C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally contains one or more halogen atoms, —OH, —CO(OH), —(CH) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10It is substituted with aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

[0270] In some embodiments, R 10 is C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is aryl, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl.

[0271] In some embodiments, R 10 is C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl is selected from the group consisting of one or more halogen, —OH, —CO(OH), —(CH) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is substituted with aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

[0272] In some embodiments, R 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 C6-C substituted with aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl 10 It is aryl.

[0273] In some embodiments, R10 is C6-C 10 It is aryl.

[0274] In some embodiments, R 10 is one or more halogens, -OH, -CO(OH), -(CH2) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 C6-C substituted with aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl 10 It is aryl.

[0275] In some embodiments, R 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is a 5- to 10-membered heteroaryl substituted with aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

[0276] In some embodiments, R 10 is a 5- to 10-membered heteroaryl.

[0277] In some embodiments, R 10 is one or more halogens, -OH, -CO(OH), -(CH2) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is a 5- to 10-membered heteroaryl substituted with aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

[0278] In some embodiments, R 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is a 3- to 10-membered heterocyclyl substituted with aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

[0279] In some embodiments, R 10 is a 3- to 10-membered heterocyclyl.

[0280] In some embodiments, R 10 is one or more halogens, -OH, -CO(OH), -(CH2) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C 10 It is a 3- to 10-membered heterocyclyl substituted with aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

[0281] In some embodiments, R 10 is C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein said alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally contains one or more halogen, —OH, —CO(OH), —(CH2) n -NHC(O)-(CH2) p -OR 8, -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl or aryl.

[0282] In some embodiments, R 10 is C1-C6 alkyl. In some embodiments, R 10 is C1-C6 alkoxy. In some embodiments, R 10 is C-C alkenyl. In some embodiments, R 10 is C2-C6 alkynyl. In some embodiments, R 10 is C-C cycloalkyl. In some embodiments, R 10 is heterocyclyl. In certain embodiments, R 10 is heteroaryl. In certain embodiments, R 10 is aryl.

[0283] In some embodiments, R 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or C1-C6 alkyl substituted with aryl. 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or C1-C6 alkoxy substituted with aryl. 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2)p -OR 8 , CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or C2-C6 alkenyl substituted with aryl. 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or C2-C6 alkynyl substituted with aryl. 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted with heterocyclyl, heteroaryl, or aryl. 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2) p -OR 8 , —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or heterocyclyl substituted with aryl. 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2) p -OR 8, —CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or heteroaryl substituted with aryl. 10 optionally one or more halogens, -OH, -CO(OH), -(CH) n -NHC(O)-(CH2) p -OR 8 , -CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or aryl substituted with aryl.

[0284] In certain embodiments, q is an integer selected from 0 to 4. In certain embodiments, q is an integer selected from 0 to 3. In certain embodiments, q is an integer selected from 0 to 2. In certain embodiments, q is an integer selected from 0 and 1. In certain embodiments, q is an integer selected from 1 to 4. In certain embodiments, q is an integer selected from 1 to 3. In certain embodiments, q is an integer selected from 1 and 2. In certain embodiments, q is an integer selected from 2 to 4. In certain embodiments, q is an integer selected from 2 and 3.

[0285] In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4.

[0286] In certain embodiments, m is an integer selected from 0 to 4. In certain embodiments, m is an integer selected from 0 to 3. In certain embodiments, m is an integer selected from 0 to 2. In certain embodiments, m is an integer selected from 0 and 1. In certain embodiments, m is an integer selected from 1 to 4. In certain embodiments, m is an integer selected from 1 to 3. In certain embodiments, m is an integer selected from 1 and 2. In certain embodiments, m is an integer selected from 2 to 4. In certain embodiments, m is an integer selected from 2 and 3.

[0287] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.

[0288] In certain embodiments, n is an integer selected from 0 to 6. In certain embodiments, n is an integer selected from 0 to 5. In certain embodiments, n is an integer selected from 0 to 4. In certain embodiments, n is an integer selected from 0 to 3. In certain embodiments, n is an integer selected from 0 to 2. In certain embodiments, n is an integer selected from 0 and 1. In certain embodiments, n is an integer selected from 1 to 6. In certain embodiments, n is an integer selected from 1 to 5. In certain embodiments, n is an integer selected from 1 to 4. In certain embodiments, n is an integer selected from 1 to 3. In certain embodiments, n is an integer selected from 1 and 2. In certain embodiments, n is an integer selected from 2 to 6. In certain embodiments, n is an integer selected from 2 to 5. In certain embodiments, n is an integer selected from 2 to 4. In certain embodiments, n is an integer selected from 2 and 3. In certain embodiments, n is an integer selected from 3 to 6. In certain embodiments, n is an integer selected from 3 to 5. In certain embodiments, n is an integer selected from 3 and 4. In certain embodiments, n is an integer selected from 4 to 6. In certain embodiments, n is an integer selected from 4 and 5.

[0289] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6.

[0290] In certain embodiments, p is an integer selected from 0 to 6. In certain embodiments, p is an integer selected from 0 to 5. In certain embodiments, n is an integer selected from 0 to 4. In certain embodiments, p is an integer selected from 0 to 3. In certain embodiments, p is an integer selected from 0 to 2. In certain embodiments, p is an integer selected from 0 and 1. In certain embodiments, p is an integer selected from 1 to 6. In certain embodiments, p is an integer selected from 1 to 5. In certain embodiments, p is an integer selected from 1 to 4. In certain embodiments, p is an integer selected from 1 to 3. In certain embodiments, p is an integer selected from 1 and 2. In certain embodiments, p is an integer selected from 2 to 6. In certain embodiments, p is an integer selected from 2 to 5. In certain embodiments, p is an integer selected from 2 to 4. In certain embodiments, p is an integer selected from 2 and 3. In certain embodiments, p is an integer selected from 3 to 6. In certain embodiments, p is an integer selected from 3 to 5. In certain embodiments, p is an integer selected from 3 and 4. In certain embodiments, p is an integer selected from 4 to 6. In certain embodiments, p is an integer selected from 4 and 5.

[0291] In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5. In some embodiments, p is 6.

[0292] In some embodiments, ring A is heteroaryl and R 1 Ga-SR 4 If so, R 4 is -CH3.

[0293] In certain embodiments, ring A is a 6-membered heteroaryl and R 1 Ga-SR 4 If so, R 4is -CH3.

[0294] In certain embodiments, if ring A is pyridinyl, the pyridinyl is selected from the group consisting of at least one R 3 is substituted with R 3 is not a halogen or two geminal R 3 do not form an oxo together with the carbon atom to which they are attached.

[0295] In certain embodiments, if ring A is pyridinyl, the pyridinyl is selected from the group consisting of at least one R 3 and each R 3 are independently -CN, -OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, -SR 8 , -S(O)2R 8 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally has one or more R 6 or two R 3 together with the atom to which they are attached, form a C3-C8 cycloalkyl, a C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 7 is replaced by .

[0296] In certain embodiments, ring A is at least one R 3 If pyrimidinyl is substituted with R 3 Ha-SR 8 or -S(O)2R 8 isn't it.

[0297] In certain embodiments, ring A is at least one R 3 If pyrimidinyl is substituted with, then each R 3 are independently halogen, -CN, -OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, -SR 8 , -S(O)2R 8 , C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 6 or replaced by 2 R's 3 together with the atom to which they are attached, form a C3-C8 cycloalkyl, a C6-C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 7 or replaced by 2 Germinal R 3 together with the carbon atom to which they are attached form oxo.

[0298] In certain embodiments, ring A is [ka] If so, R 3 is at least one R 6 is a 5-membered heteroaryl substituted with

[0299] In certain embodiments, ring A is [ka] and R 1 is phenyl, then the phenyl must have at least one R 5 is replaced by .

[0300] In certain embodiments, ring A is [ka] and if m is 1 or 2, then R 1 is at least one R 5 is phenyl substituted with R 5 is not C1-C6 alkyl or C1-C6 alkoxy.

[0301] In certain embodiments, ring A is [ka] and if m is 1 or 2, then R 1 is at least one R 5 and each R 5 are independently -OH, halogen, -C(O)OH, C2-C6 alkenyl, or C2-C6 alkynyl, wherein said alkenyl or alkynyl is optionally substituted with halogen, OH, or NH2.

[0302] In certain embodiments, ring A is [ka] and R 1 is a 6-membered heteroaryl, then R 2 is not methyl.

[0303] In certain embodiments, ring A is [ka] and R 1 is a 6-membered heteroaryl, then R 2is H or C2-C6 alkyl.

[0304] In certain embodiments, the compound is not N-(5-(3-chlorophenyl)-1,3,4-thiadiazol-2-yl)-3-methylisoxazole-5-carboxamide.

[0305] In certain embodiments, the compound is not N-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl)-3-methoxyisoxazole-5-carboxamide.

[0306] In certain embodiments, the compound of Formula (I) is a compound selected from the compounds provided in Table 1.

[0307] In certain embodiments, the compound of Formula (I) is a compound selected from the compounds provided in Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0308] In certain embodiments, the compound of Formula (I) is a compound selected from the compounds provided in Table 1, or a pharmaceutically acceptable salt thereof.

[0309] In certain embodiments, the compound of Formula (I) is a compound selected from the compounds provided in Table 1, or a hydrate thereof.

[0310] In certain embodiments, the compound of Formula (I) is a compound selected from the compounds provided in Table 1, or a solvate thereof.

[0311] In certain embodiments, the compound of Formula (I) is a compound selected from the compounds provided in Table 1 or a prodrug thereof.

[0312] In certain embodiments, the compound of Formula (I) is a compound selected from the compounds provided in Table 1 or a stereoisomer thereof.

[0313] In certain embodiments, the compound of Formula (I) is a compound selected from the compounds provided in Table 1, or a labeled isotope thereof.

[0314] In certain embodiments, the compound of Formula (I) is a compound selected from the compounds provided in Table 1, or a tautomer thereof.

[0315] Arbitrarily assigned stereochemistry is designated with an asterisk (*). [Table 1] [Table 2] [Table 3] [Table 4] [Table 5] [Table 6] [Table 7] [Table 8] [Table 9] [Table 10] [Table 11] [Table 12] [Table 13] [Table 14]

Table 15

Table 17

Table 18

Table 19

Table 30

[0316] In certain embodiments, the compound of Formula (I) is a compound selected from Table 2.

[0317] In certain embodiments, the compound of Formula (I) is a compound selected from Table 2 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0318] In certain embodiments, the compound of Formula (I) is a compound selected from Table 2, or a pharmaceutically acceptable salt thereof.

[0319] In certain embodiments, the compound of Formula (I) is a compound selected from Table 2 or a hydrate thereof.

[0320] In certain embodiments, the compound of Formula (I) is a compound selected from Table 2 or a solvate thereof.

[0321] In certain embodiments, the compound of Formula (I) is a compound selected from Table 2 or a prodrug thereof.

[0322] In certain embodiments, the compound of Formula (I) is a compound selected from Table 2 or a stereoisomer thereof.

[0323] In certain embodiments, the compound of Formula (I) is a compound selected from Table 2 or a labeled isotope thereof.

[0324] In certain embodiments, the compound of Formula (I) is a compound selected from Table 2 or a tautomer thereof. [Table 40]

[0325] In certain embodiments, the compound of Formula (I) is compound 7, 22, 55, 64, 90, 93, 94, 169, 205, or 206, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0326] In some embodiments, the compound is a pharmaceutically acceptable salt, hi some embodiments, the compound is a hydrochloride salt.

[0327] It should be understood that all isomeric forms, including mixtures thereof, are included within the scope of the present invention. If the compound contains a double bond, the substituent may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis or trans configuration. All tautomeric forms are also intended to be included.

[0328] The compounds of the present invention, as well as their pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, and prodrugs, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.

[0329] The compounds of the present invention contain asymmetric or chiral centers and can therefore exist in various stereoisomeric forms. All stereoisomeric forms of the compounds of the present invention and mixtures thereof, including racemic mixtures, are intended to form part of the present invention. Furthermore, the present invention encompasses all geometric and positional isomers. For example, if a compound of the present invention contains a double bond or a fused ring, both cis- and trans-forms and mixtures are encompassed within the scope of the present invention. Each compound disclosed herein includes all enantiomers that conform to the compound's general structure. The compounds may be in racemic or enantiomerically pure form, or any other form in terms of stereochemistry. Assay results may reflect data corrected for racemic, enantiomerically pure, or any other form in terms of stereochemistry.

[0330] Diastereomeric mixtures can be separated into individual diastereomers based on their physical chemical differences by methods well known to those skilled in the art, such as, for example, chromatography and / or fractional crystallization. Enantiomers can also be resolved by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), resolving the diastereomers, and converting the individual diastereomers to the corresponding pure enantiomers (e.g., by hydrolysis). Additionally, some of the compounds of the present invention may be atropisomers (e.g., substituted biaryls) and are considered part of the present invention. Enantiomers can also be separated using chiral HPLC columns.

[0331] It is possible that the compounds of the present invention may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.

[0332] All stereoisomers (e.g., geometric isomers, optical isomers, etc., such as those that may exist due to asymmetric carbon atoms in various substituents (which may also exist in the absence of asymmetric carbon atoms), rotamer, atropisomeric, and diastereomeric forms) of the present compounds (including salts, solvates, esters, and prodrugs of the compounds, and salts, solvates, and esters of the prodrugs) are contemplated within the scope of the present invention, as are positional isomers (e.g., 4-pyridyl and 3-pyridyl). (For example, if a compound of Formula (I) contains a double bond or a fused ring, both cis- and trans-forms and mixtures thereof are encompassed within the scope of the present invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are encompassed within the scope of the present invention.) Individual stereoisomers of the compounds of the present invention can be, for example, substantially free of other isomers or can exist, for example, as racemates or as all other or selected stereoisomers. Chiral centers of the present invention can be selected from the group consisting of methyl, ... Recommendations. Use of the terms "salts," "solvates," "esters," "prodrugs," and the like applies equally to salts, solvates, esters, and prodrugs of the enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates, or prodrugs of the compounds of the invention.

[0333] Compounds of formula (I) can form salts which are also within the scope of the present invention, and references to compounds of the formula herein are understood to include references to salts thereof, unless otherwise specified.

[0334] The present invention relates to compounds that are cGAS modulators. In some embodiments, the compounds of the present invention are cGAS inhibitors. In other embodiments, the cGAS is isoform 1. In other embodiments, the cGAS is isoform 2.

[0335] In certain embodiments, the compounds of Formula (I) are selective cGAS inhibitors.

[0336] The present invention relates to the compounds described herein and their pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers, and to pharmaceutical compositions comprising one or more compounds described herein or their pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, labeled isotopes, or tautomers.

[0337] Synthesis method In certain aspects, the present invention provides methods of making the compounds of the present invention.

[0338] In certain embodiments, the present invention provides a method of preparing a compound comprising one or more of the steps described herein.

[0339] In certain aspects, the present invention provides compounds obtainable by or obtained or directly from the methods for making compounds described herein.

[0340] In certain embodiments, the present invention provides intermediates described herein that are suitable for use in the methods of making compounds described herein.

[0341] The compounds of the invention may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the schemes shown below.

[0342] Compounds of formula (I) can be prepared by methods known in the art of organic synthesis, as illustrated in part in the following synthetic schemes. It is understood that in the schemes below, protecting groups for sensitive or reactive groups are employed where necessary according to general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," Third Edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods readily apparent to those skilled in the art. Selection procedures and reaction conditions and sequences within the skill of the art will recognize the presence of stereocenters, if any, in compounds of formula (I). Accordingly, the present invention encompasses both possible stereoisomers (unless otherwise specified in the synthesis), including not only racemates but also individual enantiomers and / or diastereomers. When a compound is described as a single enantiomer or diastereomer, it can be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, intermediate, or starting material can be carried out by any suitable method known to those skilled in the art. See, for example, "Stereochemistry of Organic Compounds" by EL Eliel, SH Wilen, and LN Mander (Wiley-Interscience, 1994).

[0343] The compounds described herein may be prepared from commercially available starting materials or synthesized using known organic, inorganic and / or enzymatic methods.

[0344] Compound production The compounds of the present invention can be prepared by several methods well known to those skilled in the art of organic synthesis. By way of example, the compounds of the present invention can be synthesized using the methods described below, along with synthetic methods known in the art of synthetic organic chemistry, or variations thereon that will be recognized by those skilled in the art. Preferred methods include, but are not limited to, the methods described below. The compounds of the present invention can be synthesized according to the steps outlined in General Methods A-G, including different orders for assembling intermediates or compounds. Starting materials are commercially available or prepared by methods known from the published literature or as described below.

[0345] General law A According to this method, compounds of formula (I) are prepared in a one-step process via amide coupling between an amine of formula (II) and an aniline and a carboxylic acid of formula (III), a metal carboxylate of formula (IV) or an ester of formula (V), wherein the amine or aniline of formula (II), the carboxylic acid of formula (III), the metal carboxylate of formula (IV) or the ester of formula (V) are either commercially available or known in the chemical literature, unless otherwise specified. [ka]

[0346] General law B According to this method, compounds of formula (I) are prepared in a one-step process via a transition metal catalyzed cross-coupling between an Ar-Br containing compound of formula (VI) and a boronic acid or boronic ester compound of formula (VII) or an organostannane compound of formula (VIII), where the Ar-Br containing compound of formula (VI) is prepared using general method A, and the boronic acid or boronic ester compound of formula (VII) or the organostannane compound of formula (VIII) is either commercially available or known in the chemical literature. [ka]

[0347] General law C According to this method, compounds of formula (I) have been prepared in a one-step process via deprotection of a compound containing a protecting group (PG) of formula (IX) or formula (X), where the PG-containing compound of formula (IX) or formula (X) has been prepared using general method A or B. [ka]

[0348] Biological assays Once compounds designed, selected, and / or optimized by the above methods are produced, they can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity. For example, molecules can be characterized using conventional assays, including but not limited to the assays described below, to determine whether they have the predicted activity, binding activity, and / or binding specificity.

[0349] Furthermore, high-throughput screening can be used to speed up the analysis using such assays. As a result, it is possible to rapidly screen for the activity of the molecules described herein using techniques known in the art. General methods for performing high-throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker; and U.S. Patent 5,763,263. High-throughput assays can use one or more different assay techniques, including, but not limited to, the following:

[0350] Various in vitro or in vivo biological assays may be suitable for detecting the effects of the compounds of the present invention, including, but not limited to, enzyme activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and assays described herein.

[0351] In certain embodiments, compounds of the invention may be tested for human-cGAS (h-cGAS) inhibitory activity using the methods described in Lama et al., "Development of human cGAS-specific small molecule inhibitors for repression of double stranded DNA (dsDNA)-triggered interferon expression," Nature Communications 10, Article number: 2261 (2019), which is incorporated herein by reference.

[0352] Usage In some embodiments, the invention provides a method of modulating cGAS activity (e.g., in vitro or in vivo), comprising contacting a cell with an effective amount of a compound of the invention, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0353] In some embodiments, the invention provides a method of modulating cGAS activity (e.g., in vitro or in vivo), comprising contacting a cell with a compound of the invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0354] In certain embodiments, the present invention provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0355] In certain aspects, the present invention provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, or a pharmaceutical composition of the present invention.

[0356] In certain embodiments, the present invention provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a compound of the present invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0357] In certain aspects, the present invention provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a compound of the present invention or a pharmaceutical composition of the present invention, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0358] In certain embodiments, the disease or disorder is associated with associated cGAS activity. In certain embodiments, the disease or disorder is a disease or disorder in which cGAS activity is implicated.

[0359] In certain embodiments, the present invention provides a compound of the present invention, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, for use in modulating cGAS activity (e.g., in vitro or in vivo).

[0360] In certain aspects, the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, for use in the treatment or prevention of a disease or disorder disclosed herein.

[0361] In certain aspects, the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, for use in treating a disease or disorder disclosed herein.

[0362] In certain embodiments, the invention provides the use of a compound of the invention, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, in the manufacture of a medicament for modulating cGAS activity (e.g., in vitro or in vivo).

[0363] In certain aspects, the present invention provides the use of a compound of the invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof in the manufacture of a medicament for the treatment or prevention of a disease or disorder disclosed herein.

[0364] In certain aspects, the present invention provides the use of a compound of the present invention or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof in the manufacture of a medicament for the treatment of a disease or disorder disclosed herein.

[0365] The present invention provides compounds that function as modulators of cGAS activity.

[0366] The present invention provides compounds that function as modulators of cGAS activity.

[0367] In some embodiments, the modulation is inhibition.

[0368] In certain embodiments, the present invention provides a method for treating a disease or disorder associated with the regulation of cGAS, comprising administering to a patient in need of treatment for a disease or disorder associated with the regulation of cGAS an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0369] In certain embodiments, the present invention provides a method of inhibiting cGAS, the method involving administering to a patient in need thereof an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0370] In certain embodiments, the present invention provides a method for treating, preventing, inhibiting, or eliminating a disease or disorder in a patient associated with cGAS inhibition, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof. In certain embodiments, the disease can be, but is not limited to, cancer or metastasis.

[0371] In one aspect, the present invention provides use of a cGAS inhibitor for the manufacture of a medicament for use in treating, preventing, inhibiting, or eliminating a disease or condition mediated by cGAS, wherein the medicament comprises a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0372] In certain embodiments, the present invention provides a method for manufacturing a medicament for the treatment, prevention, inhibition, or elimination of a disease or condition mediated by cGAS, wherein the medicament comprises a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0373] In certain aspects, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof for use in the manufacture of a medicament for the treatment of a disease associated with cGAS inhibition.

[0374] In certain aspects, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof in the treatment of a disease associated with cGAS inhibition.

[0375] In certain embodiments, the present invention provides a method of treating cancer, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0376] In certain embodiments, the present invention provides a method for treating or preventing cancer, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0377] In some embodiments, the present invention provides the use of a cGAS inhibitor for the manufacture of a medicament for use in treating, preventing, inhibiting, or eliminating a disease or disorder associated with cancer.

[0378] In certain embodiments, the disease or disorder is cancer.

[0379] In one aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, or a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier, for use in the treatment of a disease or disorder including, but not limited to, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), scleroderma, psoriasis, Aicardi-Goutieres syndrome, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, diabetes, cardiovascular, and neurodegenerative diseases.

[0380] In some embodiments, the compounds of the present invention are used to treat cancer, including but not limited to, bladder cancer, bone cancer, brain cancer, breast cancer, heart cancer, neck cancer, colon cancer, colorectal cancer, esophageal cancer, fibrosarcoma, gastric cancer, gastrointestinal cancer, head, spine and neck cancer, Kaposi's sarcoma, kidney cancer, pancreatic cancer, penile cancer, testicular germ cell cancer, thymoma carcinoma, thymic carcinoma, lung cancer, ovarian cancer, or prostate cancer.

[0381] In certain embodiments, the disease or condition is an inflammatory, allergic, or autoimmune disease such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), psoriasis, insulin-dependent diabetes mellitus (IDDM), scleroderma, Aicardi-Goutieres syndrome, dermatomyositis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and Sjogren's syndrome (SS).

[0382] In certain embodiments, the compounds of the present invention may be used to treat inflammation of any tissue or organ, including musculoskeletal inflammation, vascular inflammation, neuroinflammation, gastrointestinal inflammation, ocular inflammation, reproductive system inflammation, and other inflammations, as exemplified below.

[0383] In some embodiments, musculoskeletal inflammation refers to any inflammatory condition of musculoskeletal system, especially those that affect skeletal joints, including the joints of hand, wrist, elbow, shoulder, jaw, spine, neck, hip, knee, ankle and foot, and the condition that affects the tissue that connects muscle and bone, such as tendon.The example of musculoskeletal inflammation that can be treated with the compound of the present invention includes arthritis (for example, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, acute and chronic infectious arthritis, arthritis associated with gout and pseudogout and juvenile idiopathic arthritis), tendonitis, synovitis, tenosynovitis, bursitis, fibromyalgia, epicondylitis, myositis and osteitis (for example, including Paget's disease, osteitis pubis and osteitis fibrosa cystica).Ocular inflammation refers to the inflammation of any structure of the eye, including eyelid. Examples of ocular inflammation that may be treated with the compounds of the present invention include blepharitis, cutis laxa, conjunctivitis, dacryoadenitis, keratitis, keratoconjunctivitis sicca (dry eye), scleritis, lash growths, and uveitis. Examples of nervous system inflammation that may be treated with the compounds of the present invention include encephalitis, Guillain-Barre syndrome, meningitis, neuromyotonia, narcolepsy, multiple sclerosis, myelitis, and schizophrenia.

[0384] Examples of inflammation of the vasculature or lymphatic system that may be treated with the compounds of the invention include atherosclerosis, arthritis, phlebitis, vasculitis and lymphangitis.

[0385] Examples of inflammatory conditions of the digestive system that may be treated with the compounds of the invention include cholangitis, cholecystitis, enteritis, enterocolitis, gastritis, gastroenteritis, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), ileitis, and proctitis.

[0386] Examples of inflammatory conditions of the reproductive system that may be treated with the compounds of the invention include cervicitis, chorioamnionitis, endometritis, epididymitis, omphalitis, oophoritis, orchitis, salpingitis, tubo-ovarian abscess, urethritis, vaginitis, vulvitis and vulvodynia.

[0387] In some embodiments, the compounds of the present invention can be used to treat autoimmune conditions with an inflammatory component.Such conditions include systemic lupus erythematosus, cutaneous lupus erythematosus, acute disseminated alopecia universalis, Behcet's disease, Chagas' disease, chronic fatigue syndrome, dysautonomia, encephalomyelitis, ankylosing spondylitis, aplastic anemia, hidradenitis suppurativa, autoimmune hepatitis, autoimmune oophoritis, celiac disease, Crohn's disease, type 1 diabetes, giant cell arteritis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, Henoch-Scholein purpura, Kawasaki disease, microscopic colitis, Includes microscopic polyarteritis, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, opsoclonus-myoclonus syndrome, optic neuritis, Ord's thyroiditis, pemphigus, polyarteritis nodosa, polymyalgia, rheumatoid arthritis, Reiter's syndrome, Sjögren's syndrome, Aicardi-Goutières syndrome, temporal arteritis, Wegener's granulomatosis, warm autoimmune hemolytic anemia, interstitial cystitis, Lyme disease, morphea, psoriasis, sarcoidosis, scleroderma, ulcerative colitis, and leukoplakia.

[0388] In certain embodiments, the compounds of the invention are administered to treat T cell-mediated hypersensitivity disorders that have an inflammatory component. Such conditions include contact sensitivity, contact dermatitis (including that caused by poison ivy), hives, skin allergies, respiratory allergies (hay fever, allergic rhinitis), and gluten-sensitive enteropathy (celiac disease).

[0389] In certain embodiments, other inflammatory conditions that may be treated with the compounds of the invention include, for example, appendicitis, dermatitis, dermatomyositis, endocarditis, fibromyalgia, gingivitis, glossitis, hepatitis, hidradenitis suppurativa, iritis, laryngitis, mastitis, myocarditis, nephritis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, pneumonia, prostatitis, pyelonephritis, and stomatitis, transplant rejection (involving organs such as kidney, liver, heart, lung, pancreas (e.g., islet cells), bone marrow, cornea, small intestine, skin allografts, skin allografts, and heart valve xenografts, serum sickness, and graft-versus-host disease), acute pancreatitis, chronic pancreatitis, acute respiratory distress syndrome, Sézary syndrome, congenital adrenal hyperplasia, nonsuppurative thyroiditis, and conditions associated with cancer. These conditions include: hypercalcemia associated with flu-like substances, pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme, exfoliative dermatitis, seborrheic dermatitis, seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity reactions, allergic conjunctivitis, keratitis, herpes zoster ophthalmicus, iritis and iridocyclitis, chorioretinitis, optic neuritis, symptomatic sarcoidosis, fulminant or disseminated pulmonary tuberculosis chemotherapy, adult idiopathic thrombocytopenic purpura, adult secondary thrombocytopenia, acquired (autoimmune) hemolytic anemia, adult leukemia and lymphoma, childhood acute leukemia, regional enterocolitis, autoimmune vasculitis, multiple sclerosis, chronic obstructive pulmonary disease, solid organ transplant rejection, and sepsis. Preferred treatments include transplant rejection, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, type 1 diabetes, asthma, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, chronic lung disease and inflammation associated with infectious conditions (e.g., sepsis).

[0390] In certain embodiments, the compounds of the present invention and pharmaceutically acceptable salts thereof can also be used in combination with one or more other agents in the prevention or treatment of allergic inflammatory autoimmune diseases, where such other agents can include antigen immunotherapeutics; antihistamines; steroids; NSAIDs; bronchodilators (e.g., beta 2 agonists, adrenergic agonists, anticholinergics, theophylline); methotrexate; leukotriene modulators; monoclonal antibody agents such as anti-lgE, anti-TNF, anti-IL-5, anti-IL-6, anti-IL-12, anti-IL-1, and similar agents; receptor therapeutics such as etanercept; and antigen non-specific immunotherapeutics such as interferons or other cytokines / chemokines, cytokine / chemokine receptor modulators, cytokine agonists or antagonists, and TLR antagonists.

[0391] In one embodiment, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further comprise an excipient, diluent, or surfactant.

[0392] In certain embodiments, the present invention provides methods for treating a disease or disorder associated with the regulation of cGAS, including cancer or a cell proliferative disorder, comprising administering to a patient having at least one of said diseases or disorders a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

[0393] In certain embodiments, therapeutic uses of compounds or compositions of the invention that inhibit cGAS provide for the treatment of patients or subjects with cancer or cell proliferative disorders.

[0394] The disclosed compounds of the invention can be administered in an amount effective to treat or prevent a disorder and / or prevent its development in a subject.

[0395] Administration of the disclosed compounds can be achieved via any method of administering a therapeutic agent, including systemic or local administration, such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal, or topical administration methods.

[0396] Depending on the intended method of administration, the disclosed compositions may be in solid, semi-solid, or liquid dosage forms, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, and the like, and may be in unit dosage amounts, consistent with conventional pharmaceutical practice. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

[0397] Illustrative pharmaceutical compositions include a compound of the invention and a) a diluent, e.g., purified water, triglyceride oil such as hydrogenated or partially hydrogenated vegetable oil or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oil such as EPA or DHA or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose, and / or glycine; b) a lubricant, e.g., silica, talc, stearic acid, magnesium or calcium salts thereof, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate. , sodium acetate, sodium chloride and / or polyethylene glycol; also for tablets; c) binders, for example, aluminum magnesium silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, waxes and / or polyvinylpyrrolidone, if desired; d) disintegrants, for example, starch, agar, methylcellulose, bentonite, xanthan gum, alginic acid or its sodium salt or effervescent mixtures; e) absorbents, dyes, flavors and sweeteners; f) Tween g) an emulsifier or dispersing agent such as 80, Labrasol, HPMC, DOSS, Caproyl 909, Labrafac, Labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifier; and / or g) a pharmaceutically acceptable carrier such as an agent that enhances absorption of the compound, such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, or PEG200.

[0398] Liquid, particularly injectable compositions can be prepared, for example, by dissolving, dispersing, etc. For example, a disclosed compound can be dissolved or mixed in a pharmaceutically acceptable solvent, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, etc., to thereby form an injectable isotonic solution or suspension. Proteins, such as albumin, chylomicron particles, or serum proteins, can be used to solubilize the disclosed compounds.

[0399] The disclosed compounds may also be formulated as suppositories, which may be made from fatty emulsions or suspensions, using polyalkylene glycols, such as propylene glycol, as the carrier.

[0400] The disclosed compounds can also be administered in the form of liposome delivery system, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.Liposomes can be formed from various phospholipids, including cholesterol, stearylamine or phosphatidylcholine.In some embodiments, as described in U.S. Patent No. 5,262,564, the entirety of which is incorporated herein by reference, a thin layer of lipid components is hydrated with an aqueous drug solution to form a lipid layer that encapsulates the drug.

[0401] The disclosed compounds can also be delivered by using monoclonal antibodies as individual carriers to which the disclosed compounds are bound. The disclosed compounds can also be bound to soluble polymers, such as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymers, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspamidephenol, or polyethylene oxide polylysine substituted with palmitoyl residues. Furthermore, the disclosed compounds can also be bound to classes of biodegradable polymers useful for achieving controlled drug release, such as polylactic acid, polyepsilon caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and crosslinked or amphiphilic block copolymers of hydrogels. In some embodiments, the disclosed compounds are not covalently bound to polymers, such as polycarboxylic acid polymers or polyacrylates.

[0402] Parenteral injectable administration is generally used for subcutaneous, intramuscular or intravenous injection and infusion. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in solution prior to injection.

[0403] In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further comprise an additive, diluent or surfactant. In some embodiments, the pharmaceutical composition may further comprise an additional pharmaceutically active agent.

[0404] The compositions can be prepared by conventional mixing, granulating, or coating methods, respectively, and the pharmaceutical compositions can contain about 0.1% to about 99%, about 5% to about 90%, or about 1% to about 20% of the disclosed compounds by weight or volume.

[0405] The dosing regimen using the disclosed compounds is selected depending on a variety of factors, including the type, species, age, weight, sex, and medical condition of the patient; the severity of the condition being treated; the route of administration; the patient's renal or hepatic function; and the particular disclosed compound being used. A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

[0406] Effective dosages of the disclosed compounds, when used for the indicated effects, range from about 0.5 mg to about 5,000 mg of the disclosed compounds, as needed for treatment of the condition. Compositions for in vivo or in vitro use can contain about 0.5 mg, 5 mg, 20 mg, 50 mg, 75 mg, 100 mg, 150 mg, 250 mg, 500 mg, 750 mg, 1,000 mg, 1,250 mg, 2,500 mg, 3,500 mg, or 5,000 mg of the disclosed compounds or ranges from one amount to another in the dosage list. In some embodiments, the composition is in a secant form.

[0407] Exemplary Embodiments Embodiment 1. In one aspect, the present invention provides a compound of formula (I): [ka] [During the ceremony, Ring A is heteroaryl or heterocyclyl; R 1 is H, -SR 4 , -S(O)R 4 , -S(O)2R 4 , -N(R 4 )2, —CN, C1-C6 alkyl, aryl, or heteroaryl, wherein the alkyl, aryl, or heteroaryl optionally has one or more R 5 with the proviso that when A is 1-isoquinolinyl, R 1 but not pyridinyl; R 2 is H or C1-C6 alkyl; Each R 3 are independently halogen, -CN, OR 8 , -NH2, NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclyl, wherein the alkyl, cycloalkyl, heterocyclyl, or heteroaryl optionally is one or more R 6 is replaced by; or 2 R's 3 together with the intervening atoms form a C3-C8 cycloalkyl, aryl, heterocyclyl, or heteroaryl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally contains one or more R 7 is replaced by; or 2 Germinal R 3combine with the carbon atom to which they are attached to form oxo; R 4 is H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C3 cycloalkyl, heterocyclyl, heteroaryl, or aryl; Each R 5 is halogen, —C(O)OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, wherein said alkyl, alkoxy, alkenyl or alkynyl is optionally substituted with halogen, OH, NH2; Each R 6 are independently halogen, OH, oxo, -CO(OR 8 ), -(CH2) n -NHC(O)-(CH2) p -OR 8 , CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally halogen, OH, NH2, -NHC(O)OR 8 , -(CH2) n -NHC(O)R 8 , -(CH2) n -NHC(O)-(CH2) p -OR 8 , -(CH2) n -NHR 8 , -(CH2) n -NHS(O)R 8 , -(CH2) n -NHS(O)2R 8 , -(CH2) n -C(O)R 8 , -(CH2) n -C(O)OR 8 , -(CH2) n -OR 8 , -(CH2) n O(CH2) n C(O)NHR 8, substituted with C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, or alkylaryl; or 2 R's 6 together with the intervening atoms form a C3-C8 cycloalkyl, aryl, heterocyclyl, or heteroaryl; or 2 R's 6 combine with the carbon atom to which they are attached to form oxo; Each R 7 are independently halogen, -OH, -C(O)OR 8 , C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl or aryl or 2 R's 7 together with the intervening atoms form a C3-C8 cycloalkyl, aryl, heterocyclyl, or heteroaryl; or 2 R's 7 combine with the carbon atom to which they are attached to form oxo; R 8 is H, —OH, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl optionally is selected from the group consisting of one or more R 9 is replaced by; R 9 Ha-(CH2) n -NHC(O)-(CH2) p -OR 10 , CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C3 cycloalkyl, heterocyclyl, heteroaryl or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally halogen, OH, NH2, -NHC(O)OR 10, -(CH2) n -NHC(O)R 10 , -(CH2) n -NHC(O)-(CH2) p -OR 10 , -(CH2) n -NHR 10 , -(CH2) n -NHS(O)R 10 , -(CH2) n -NHS(O)2R 10 , -(CH2) n -C(O)R 10 , -(CH2) n -C(O)OR 10 , C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl or alkylaryl; R 10 is C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, alkylaryl, or alkylheteroaryl optionally contains one or more halogen, OH, —CO(OH), —(CH2) n -NHC(O)-(CH2) p -OR 8 , CN, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, heterocyclyl, heteroaryl or aryl; m is an integer from 0 to 4; n is an integer from 0 to 6; and and p is an integer of 0 to 6. or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers and tautomers thereof.

[0408] Embodiment 2. In one embodiment, the present invention provides a compound having formula (Ia): [ka] or a pharmaceutically acceptable salt, isomer, solvate, prodrug or tautomer thereof.

[0409] Embodiment 3. In one embodiment, the present invention provides a compound of formula (Ia) represented by formula (Ia-1): [ka] or a pharmaceutically acceptable salt, isomer, solvate, prodrug or tautomer thereof.

[0410] Embodiment 4. In one embodiment, the present invention provides a compound of formula (Ia) represented by formula (Ia-1-i): [ka] or a pharmaceutically acceptable salt, isomer, solvate, prodrug or tautomer thereof.

[0411] Embodiment 5. In one embodiment, the present invention provides a compound of formula (Ia) represented by formula (Ia-1-ii): [ka] or a pharmaceutically acceptable salt, isomer, solvate, prodrug or tautomer thereof.

[0412] Embodiment 6. In one embodiment, the present invention provides a compound represented by the formula (Ia) of formula (Ia-2): [ka] or a pharmaceutically acceptable salt, isomer, solvate, prodrug or tautomer thereof.

[0413] Embodiment 7. In one aspect, the present invention provides a compound represented by the formula (Ia) having the formula (Ia-2-i): [ka] or a pharmaceutically acceptable salt, isomer, solvate, prodrug or tautomer thereof.

[0414] Embodiment 8. In one embodiment, the present invention provides a compound represented by the formula (Ia) of formula (Ia-2-ii): [ka] or a pharmaceutically acceptable salt, isomer, solvate, prodrug or tautomer thereof.

[0415] Embodiment 9. In one aspect, the present invention provides a compound represented by the formula (Ia) of the formula (Ia-5) to the formula (Ia-13): [ka] or a pharmaceutically acceptable salt, isomer, solvate, prodrug or tautomer thereof.

[0416] Embodiment 10. In one embodiment, the present invention provides a compound comprising R 1 is hydrogen, —SCH3, —SCH2CH3, —CH3, —CHF2, —CF3, —CH2CH3, —(CH2)2CH3, —(CH2)4CH3, —CN, —CH2CH2OCH3, —NH2, —NH(CH3), —N(CH3)2, —CH(CH2CH3), —CH(C6H6)(CH2CH3), 3-chlorophenyl, 3-fluorophenyl, 3-methoxyphenyl, 2-fluoropyridinyl.

[0417] Embodiment 11. In one embodiment, the present invention provides a compound comprising R 1 is -SCH3.

[0418] Embodiment 12. In some embodiments, the invention provides a compound of any of the previous embodiments, wherein R2 is H.

[0419] Embodiment 13. In some embodiments, the invention provides a compound of any of the previous embodiments, wherein R2 is methyl.

[0420] Embodiment 14. In some embodiments, the invention provides a compound of any of the previous embodiments, wherein A is a 5- or 6-membered heterocyclyl or heteroaryl.

[0421] Embodiment 15. In some embodiments, the invention provides a compound of any of the previous embodiments, wherein A is 6-membered heterocyclyl.

[0422] Embodiment 16. In one embodiment, the present invention provides a compound in which A is [ka] The compound of any of the previous embodiments is provided, wherein

[0423] Embodiment 17. In one embodiment, the present invention provides a compound in which A is [ka] (wherein q is 0 to 4.)

[0023] The compound of any of the preceding embodiments is provided wherein R is an integer selected from

[0424] Embodiment 18. In some embodiments, the invention provides a compound of any of the previous embodiments, wherein A is a 5-membered heteroaryl.

[0425] Embodiment 19. In some embodiments, the invention provides a compound of any of the previous embodiments, wherein A is a 5-membered heteroaryl containing at least two heteroatoms independently selected from N, O, and S.

[0426] Embodiment 20. In some embodiments, the invention provides a compound of embodiment 19, wherein A is a 5-membered heteroaryl containing two heteroatoms independently selected from N, O, and S.

[0427] Embodiment 21. In one embodiment, the present invention provides a compound in which A is [ka] 20. The compound of claim 19, wherein

[0428] Embodiment 22. In one embodiment, the present invention provides a compound in which A is [ka] (wherein q is an integer selected from 0 to 4). 20. The compound of claim 19, wherein

[0429] Embodiment 23. In some embodiments, the invention provides a compound of Embodiment 19, wherein A is a 5-membered heteroaryl containing 3 heteroatoms independently selected from N, O, and S.

[0430] Embodiment 24. In one embodiment, the present invention provides a compound in which A is [ka] 24. The compound of claim 23, wherein

[0431] Embodiment 25. In one embodiment, the present invention provides a compound in which A is [ka] (wherein q is an integer selected from 0 to 4). 25. The compound of claim 24, wherein

[0432] Embodiment 26. In some embodiments, the invention provides a compound of Embodiment 19, wherein A is a 5-membered heteroaryl containing 3 heteroatoms independently selected from N and O.

[0433] Embodiment 27. In one embodiment, the present invention provides a compound in which A is [ka] 26. The compound of claim 25, wherein

[0434] Embodiment 28. In some embodiments, the invention provides a compound of embodiment 18, wherein A is a 5-6 membered heteroaryl containing 1 or 4 heteroatoms independently selected from N, O, and S.

[0435] Embodiment 29. In one embodiment, the present invention provides a compound in which A is [ka] 29. The compound of claim 28, wherein

[0436] Embodiment 30. In one embodiment, the present invention provides a method for treating a pulmonary arthritis, comprising administering to a patient ... a method for treating a pulmonary arthritis, and a method for treating a pulmonary arthritis. 3 are independently halogen, -CN, OR 8 , -NH2, -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 )2, C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclyl, wherein the alkyl, cycloalkyl, heterocyclyl, or heteroaryl optionally is one or more R 6

[0023] Provided is a compound according to any of the preceding embodiments, wherein the compound is substituted with:

[0437] Embodiment 31. In one embodiment, the present invention provides a compound comprising two R 3 together with the intervening atoms form a C3-C8 cycloalkyl, aryl, heterocyclyl, or heteroaryl, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally contains one or more R 7 The compound of embodiment 30 is provided, wherein the compound is substituted with

[0438] Embodiment 32. In one embodiment, the present invention provides a compound having two geminal R 3are taken together with the carbon atom to which they are attached to form oxo.

[0439] Embodiment 33. In one embodiment, the present invention provides a compound comprising two R 3 But, united with the intervening atoms, [ka] (wherein q is an integer selected from 0 to 4). The compound of embodiment 31 is provided, wherein

[0440] Embodiment 34. In one embodiment, the present invention provides a compound comprising R 4 is C1-C6 alkyl.

[0441] Embodiment 35. In one embodiment, the present invention provides a compound comprising R 4

[0023] Provided is a compound of any of the preceding embodiments, wherein is methyl or ethyl.

[0442] Embodiment 36. In some embodiments, the present invention provides a compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

[0443] Embodiment 37. In one embodiment, the present invention provides a compound of any of the previous embodiments, or a pharmaceutically acceptable salt or stereoisomer thereof.

[0444] Embodiment 38. In one embodiment, the present invention provides a compound of any of the previous embodiments, or a pharmaceutically acceptable salt thereof.

[0445] Embodiment 39. In one embodiment, the present invention provides an isotopic derivative of a compound of any of the previous embodiments.

[0446] Embodiment 40. In one embodiment, the present invention provides a pharmaceutical composition comprising a compound of any of the previous embodiments and one or more pharmaceutically acceptable carriers.

[0447] Embodiment 41. In some embodiments, the present invention provides a method for treating or preventing a cGAS-associated disease or disorder, comprising administering to a subject at least one therapeutically effective amount of a compound of any of the preceding embodiments.

[0448] Embodiment 42. In some embodiments, the present invention provides a method of inhibiting cGAS, comprising administering to a subject at least one therapeutically effective amount of a compound of any of the previous embodiments.

[0449] Embodiment 43. In some embodiments, the present invention provides a compound of any of the previous embodiments for use in treating or preventing a cGAS-related disease or disorder.

[0450] Embodiment 44. In some embodiments, the invention provides the use of a compound of any of the preceding embodiments in the manufacture of a medicament for the treatment or prevention of a cGAS-related disease or disorder.

[0451] Embodiment 45. In an embodiment, the invention provides the method, compound, or use of any of the preceding embodiments, wherein the subject is a human.

[0452] Embodiment 46. In some embodiments, the invention provides the method, compound, or use of any of the preceding embodiments, wherein the cGAS-related disease or disorder is inflammation, an autoimmune disease, cancer, infection, a disease or disorder of the central nervous system, a metabolic disease, a cardiovascular disease, a respiratory disease, a kidney disease, a liver disease, an eye disease, a skin disease, a lymphatic disease, a rheumatic disease, a psychiatric disease, graft-versus-host disease, allodynia, or a cGAS-related disease in a subject determined to have a germline or somatic non-silent mutation in cGAS.

[0453] Embodiment 47. In some embodiments, the invention provides the method, compound, or use of any of the preceding embodiments, wherein the disease or disorder of the central nervous system is Parkinson's disease, Alzheimer's disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, or multiple sclerosis.

[0454] Embodiment 48. In an embodiment, the invention provides the method, compound, or use of any of the preceding embodiments, wherein the kidney disease is acute kidney disease, chronic kidney disease, or a rare kidney disease.

[0455] Embodiment 49. In some embodiments, the invention provides the method, compound, or use of any of the preceding embodiments, wherein the skin disease is psoriasis, hidradenitis suppurativa (HS), or atopic dermatitis.

[0456] Embodiment 50. In some embodiments, the invention provides the method, compound, or use of any of the previous embodiments, wherein the rheumatic disease is dermatomyositis, Still's disease, or juvenile idiopathic arthritis.

[0457] Embodiment 51. In some embodiments, the invention provides the method, compound, or use of any of the preceding embodiments, wherein the cGAS-associated disease in the subject determined to have a germline or somatic non-silent mutation in cGAS is cryopyrin-associated autoinflammatory syndrome.

[0458] Embodiment 52. In one embodiment, the invention provides the method, compound, or use of any of the preceding embodiments, wherein the cryopyrin-associated autoinflammatory syndrome is familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or neonatal-onset multisystem inflammatory disease. [Example]

[0459] The present invention is further illustrated by the following examples and synthetic schemes, which should not be construed as limiting the scope or spirit of the invention to the specific methods described therein. It is understood that the examples are provided for the purpose of illustrating certain embodiments, and that no limitation of the scope of the invention is intended thereby. It is further understood that reliance may be placed on various other embodiments, modifications, and equivalents thereof, which may themselves suggest themselves to those skilled in the art, without departing from the spirit of the invention and / or the scope of the appended claims.

[0460] Nuclear magnetic resonance (NMR) spectra were recorded at 400 MHz and 300.3 K unless otherwise stated; chemical shifts (δ) are reported in parts per million (ppm). Spectra were recorded using a Bruker Avance 400 instrument with 8, 16, or 32 scans. DMSO-d6 = deuterated dimethyl sulfoxide. Methanol-d4 = deuterated methanol. CHCl3-d = deuterated chloroform.

[0461] LC-MS chromatograms and spectra were recorded using a Shimadzu LCMS-2020. The injection volume was 0.7–8.0 μl, and the flow rate was typically 0.8 or 1.2 ml / min. The detection method was diode array (DAD) or evaporative light scattering (ELSD) with positive ion electrospray ionization. The MS range was 100–1000 Da. The solvent was a gradient of water and acetonitrile, both containing modifiers such as trifluoroacetic acid (TFA) or ammonium carbonate (typically 0.01–0.04%).

[0462] The following examples illustrate the synthesis of certain exemplary compounds and the experimental results obtained. Unless otherwise noted, all numbers expressing numerical values ​​for ingredients, reaction conditions, concentrations, properties, stability, and the like used in the specification and claims are understood to be modified in all instances by the term "about." At the very least, each numerical parameter should be construed in light of at least the number of significant digits recited and by applying ordinary rounding techniques. Thus, unless otherwise indicated, the numerical parameters set forth in the specification and appended claims are approximations that may vary depending on the properties sought to be obtained. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the embodiments are approximations, the numerical values ​​set forth in the specific examples are reported as precisely as possible. However, all numerical values ​​inherently contain certain errors resulting from experimentation, test measurements, statistical analysis, and the like. The following description is merely illustrative and should not be construed as limiting the foregoing disclosure in any respect. Those of ordinary skill in the art will readily recognize appropriate variations from the present methods, both with respect to reactants and reaction and purification conditions and techniques. Unless otherwise specified, starting materials or intermediates are commercially available or known from the chemical literature.

[0463] Purification / isolation methods include preparative high performance liquid chromatography (Prep HPLC).

[0464] Example 1: Methyl 5-((5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)carbamoyl)isoxazole-3-carboxylate (Compound 1) [ka] To a solution of 3-methoxycarbonylisoxazole-5-carboxylic acid (1.00 equiv., 100 mg, 0.584 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (1.20 equiv., 267 mg, 0.701 mmol) in N,N-dimethylformamide (DMF) (1 mL) was added diisopropylethylamine (DIPEA) (1.50 equiv., 0.15 mL, 0.877 mmol) and the mixture was stirred at rt for 5 min, after which 5-(2-chlorophenyl)-1,3,4-thiadiazol-2-amine (1.20 equiv., 148 mg, 0.701 mmol) was added and the mixture was stirred at room temperature (rt). After 16 hours, water (5 mL) was added and the solid was collected, washed with water (3 × 3 mL), then diethyl ether (EtO) (3 × 3 mL), then ethanol (EtOH) (3 × 3 mL), and dried to give methyl 5-((5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)carbamoyl)isoxazole-3-carboxylate (98 mg, 43% yield) as a cream-colored solid. LCMS (ES, m / z) = 365.28 [M+1]+. 1 H NMR (400 MHz, DMSO-d6) δ 14.09 (s, 1H), 8.15 (dd, J = 7.6, 2.0Hz, 1H), 7.86 (s, 1H), 7.71 (d, J = 7.8Hz, 1H), 7.65 - 7.41 (m, 2H)

[0465] Example 2: 5-((5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)carbamoyl)isoxazole-3-carboxylic acid (Compound 2) [ka] Methyl 5-[[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]carbamoyl]isoxazole-3-carboxylate (1.00 equiv., 90 mg, 0.247 mmol) was suspended in a mixture of tetrahydrofuran (THF) (4 mL) and HO (2 mL). LiOH monohydrate (2.50 equiv., 26 mg, 0.617 mmol) was added and stirred at rt. After 3 h, LCMS indicated complete hydrolysis. 6 N HCl was added to a pH of approximately 1, and the resulting solid was collected by filtration, washed with HO (3 × 3 mL), and dried to give 5-[[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]carbamoyl]isoxazole-3-carboxylic acid (62 mg, 71% yield) as a light yellow solid. LCMS (ES, m / z) = 351.14 [M+1]+. 1 H NMR (400 MHz, DMSO-d6) δ 14.76 - 13.58 (m, 2H), 8.16 (dd, J = 7.6, 2.0Hz, 1H), 7.82 (s, 1H), 7.72 (dd, J = 7.9, 1.5Hz, 1H), 7.58 (dtd, J = 17.9, 7.4, 1.7Hz, 2H)

[0466] Example 3: N 5 -(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)-N 3 -Methoxyisoxazole-3,5-dicarboxamide (Compound 91) [ka] 5-[[5-(2-Chlorophenyl)-1,3,4-thiadiazol-2-yl]carbamoyl]isoxazole-3-carboxylic acid (1.0 equiv., 30 mg, 0.086 mmol) and O-methylhydroxylamine hydrochloride (1.2 equiv., 8.8 mg, 0.10 mmol) were combined in ethyl acetate (EtOAc) (0.5 mL). Propylphosphonic acid (T3P) (50% in EtOAc) (2.00 equiv., 0.10 mL, 0.171 mmol) was added, followed by diisopropylethylamine (DIPEA) (3.00 equiv., 0.045 mL, 0.257 mmol), and the mixture was placed in a 55 °C heating block. After 90 min, LCMS indicated high conversion. Water (5 mL) was added and the solid was collected, washed with water (2 x 3 mL), then diethyl ether (EtO) (3 x 2 mL), then ethanol (EtOH) (3 x 2 mL), dried and purified with N 5 -[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]-N 3 -Methoxy-isoxazole-3,5-dicarboxamide (11 mg, 32% yield) was obtained as a tan solid. LCMS (ES, m / z) = 380.22 [M+1]+. 1 H NMR (400 MHz, DMSO-d6) δ 14.01 (s, 1H), 12.42 (s, 1H), 8.15 (dd, J = 7.6, 2.0Hz, 1H), 7.78 (s, 1H), 7.72 (dd, J = 7.8, 1.5Hz, 1H), 7.63 - 7.50 (m, 2H), 3.74 (s, 3H)

[0467] Example 4: (Compound 7) [ka] Step 1: To a solution of potassium tert-butoxide (KOtBu) in tetrahydrofuran (THF) (1M) (4.6 L, 46 mol, 3 eq) and N,N-dimethylformamide (DMF) (5 L) was added 8-nitroquinoline (250.00 g, 1.435 mol, 1.00 eq). A solution of ethyl chloroacetate (211.10 g, 1.722 mol, 1.20 eq) in DMF (5 L) was added dropwise to the above solution at 0 °C. The mixture was stirred at 0 °C for 1 hour. The reaction was quenched at 0 °C with saturated ammonium chloride (2 L) and diluted with ethyl acetate (EtOAc) (1 L). The resulting solution was extracted with ethyl acetate (5 × 500 mL), and the organic layers were combined. The solution was washed with saturated sodium chloride (3 × 500 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The solid was mixed with 1500 ml (ethyl acetate and petroleum ether 1:9). The solution was filtered, and the filter cake was recrystallized twice from ethyl acetate / petroleum ether / dichloromethane (4:4:1) to give ethyl 2-(8-nitroquinolin-7-yl)acetate (130 g, 34% yield) as an off-white solid. LCMS (ES, m / z) = 261 [M+1]+

[0468] Step 2: To a stirring solution of ethyl 2-(8-nitroquinolin-7-yl)acetate (100 g, 384.247 mmol, 1.00 equiv) in triethylamine (1000 mL) was added dropwise at 0° C. under nitrogen. The mixture was then stirred at 50° C. for 3 days under nitrogen. The resulting mixture was concentrated under reduced pressure to give the crude product, ethyl [1,2]oxazolo[4,3-h]quinoline-3-carboxylate (369 g), as an off-white solid. LCMS (ES, m / z) = 243 [M+1]+

[0469] Step 3: To a stirring solution of ethyl [1,2]oxazolo[4,3-h]quinoline-3-carboxylate (240 g, 991 mmol, 1.00 equiv., crude product containing the NEt3-HCl salt) in ethanol (2.4 L) and water (1.2 L) was added sodium hydroxide (60 g, 1500 mmol, 1.51 equiv.) at room temperature. The mixture was stirred at room temperature for 30 min. The resulting mixture was filtered, and the filter cake was washed with ethanol (3 × 200 mL) to afford the product as the sodium salt, [1,2]oxazolo[4,3-h]quinoline-3-carboxylate (105.8 g, 44.76%, from 4 batches) as an off-white solid. LCMS (ES, m / z) = 215 [M+1]+. 1 H NMR (400 MHz, DMSO-d6) δ 8.90 (d, J = 4.0 Hz, 1H), 8.35 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.76-7.73 (m, 1H), 7.43 (d, J = 9.2 Hz, 1H)

[0470] Step 4: Sodium isoxazolo[4,3-h]quinoline-3-carboxylate (1.00 equiv., 80 mg, 0.339 mmol) and 5-(2-chlorophenyl)-1,3,4-thiadiazol-2-amine (1.21 equiv., 87 mg, 0.410 mmol) were combined in ethyl acetate (EtOAc) (0.5 mL). Propylphosphonic acid (T3P) (50% solution in EtOAc) (2.00 equiv., 0.40 mL, 0.678 mmol) was added, followed by diisopropylethylamine (3.00 equiv., 0.18 mL, 1.02 mmol), and the mixture was placed in a 55 °C heating block. After 5 h, LCMS showed high conversion. Water (5 mL) was added, and the solid was collected, washed with water (2 × 3 mL), then diethyl ether (EtO) (3 × 2 mL), then ethanol (EtOH) (3 × 2 mL), and dried to give N-[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]isoxazolo[4,3-h]quinoline-3-carboxamide (88 mg, 62% yield) as a yellow solid. LCMS (ES, m / z) = 408.24 [M+1]+.1 H NMR (400 MHz, DMSO-d6) δ 14.55 (s, 1H), 8.98 (d, J = 4.5Hz, 1H), 8.44 (dd, J = 8.2, 1.7Hz, 1H), 8.20 - 7.99 (m, 2H), 7.83 (dd, J = 8.1, 4.5Hz, 1H), 7.76 - 7.67 (m, 2H), 7.65 - 7.51 (m, 2H)

[0471] Example 5: N-(5-methyl-1,3,4-thiadiazol-2-yl)isoxazolo[4,3-h]quinoline-3-carboxamide (Compound 93) [ka] Sodium isoxazolo[4,3-h]quinoline-3-carboxylate (1.00 equiv., 11.00 g, 46.6 mmol) was suspended in N,N-dimethylformamide (DMF) (200 mL). 5-Methyl-1,3,4-thiadiazol-2-amine (1.20 equiv., 6.42 g, 55.8 mmol) was added, followed by 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (1.20 equiv., 21.27 g, 55.9 mmol). The reaction mixture was stirred at rt for 5 days. The mixture did not become homogeneous. LCMS indicated nearly complete conversion. Water (approximately 200 mL) was added, stirred for 1 h at rt, and the solid was collected by filtration and washed with water (3 x 100 mL). The solid was air-dried at rt overnight and then vacuum-line dried overnight. The solid was pulverized using a mortar and pestle and dried again for 24 h to give N-(5-methyl-1,3,4-thiadiazol-2-yl)isoxazolo[4,3-h]quinoline-3-carboxamide (11.00 g, 74% yield) as a tan powder. LCMS (ES, m / z) = 312.09 [M+1]+. 1H NMR (400 MHz, DMSO-d6) δ 14.51 (s, 1H), 8.96 (dd, J = 4.5, 1.7Hz, 1H), 8.40 (dd, J = 8.2, 1.7 Hz, 1H), 8.01 (d, J = 9.2Hz, 1H), 7.80 (dd, J = 8.1, 4.5Hz, 1H), 7.67 (d, J = 9.2Hz, 1H), 2.63 (s, 3H)

[0472] Example 6: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)isoxazolo[4,3-h]quinoline-3-carboxamide (Compound 94) [ka] 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (1.20 equiv., 171 mg, 0.450 mmol) was dissolved in N,N-dimethylformamide (DMF) (1 mL) and sodium isoxazolo[4,3-h]quinoline-3-carboxylate (1.00 equiv., 90 mg, 0.374 mmol), followed by the sequential addition of diisopropylethylamine (DIPEA) (4.02 equiv., 0.26 mL, 1.50 mmol). After stirring for 2 min, 5-(methylsulfanyl)-1,3,4-thiadiazol-2-amine (1.21 equiv., 70 mg, 0.452 mmol) was added, and the reaction was stirred for 90 min at RT. Water was slowly added, and a solid precipitated. The mixture was allowed to stir for 30 minutes. The solution was then filtered, and the solid was washed with water and saved. To the filtrate, ethyl acetate (EtOAc) was added, and the phases were separated. Both phases contained the final product. Formic acid (FA) was added to the aqueous phase until an acidic pH was achieved, and the aqueous phase was extracted with EtOAc (2x). All EtOAc extracts were combined, dried over MgSO4, filtered, and evaporated under reduced pressure. The crude product was purified by C18 reverse-phase chromatography (0-100% MeCN / 0.1% aqueous formic acid) to afford N-(5-methylsulfanyl-1,3,4-thiadiazol-2-yl)isoxazolo[4,3-h]quinoline-3-carboxamide (45 mg, 35% yield) as a beige solid. LCMS (ES, m / z) = 344.10 [M+1]+. 1 H NMR (400 MHz, DMSO-d6) δ 8.98 (dd, J = 4.5, 1.7 Hz, 1H), 8.44 (dd, J = 8.1, 1.6 Hz, 1H), 8.00 (d, J = 9.1 Hz, 1H), 7.83 (dd, J = 8.1, 4.5 Hz, 1H), 7.72 (d, J = 9.2 Hz, 1H), 2.76 (s, 3H) [NH amide signal not observed]

[0473] Example 7: N-[5-(pyrazin-2-yl)-1,3,4-thiadiazol-2-yl]-2,1-benzoxazole-3-carboxamide (Compound 130) [ka] Step 1: 5-(pyrazin-2-yl)-1,3,4-thiadiazol-2-amine was prepared from pyrazine-2-carbonitrile instead of thiazole-4-carbonitrile according to the method of Example 36, Step 1. LCMS (ES, m / z): 180.0 [M+H] +

[0474] Step 2: To a solution of benzo[c]isoxazole-3-carboxylic acid (501 mg, 3.071 mmol, 1.00 equiv.) in dimethylformamide (8 mL), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (1522 mg, 4.003 mmol, 1.30 equiv.) and N-methylmorpholine (NMM) (1080 mg, 10.678 mmol, 3.48 equiv.) were added at room temperature. The resulting mixture was stirred for 30 minutes at room temperature. To the above mixture, 5-(pyrazin-2-yl)-1,3,4-thiadiazol-2-amine (550 mg, 3.069 mmol, 1 equiv.) was added at room temperature. The resulting mixture was stirred for an additional 2 hours at room temperature. The precipitated solid was collected by filtration and washed with acetonitrile (5×2 mL), giving N-[5-(pyrazin-2-yl)-1,3,4-thiadiazol-2-yl]-2,1-benzoxazole-3-carboxamide (27 mg, 2.65%) as a white solid. LCMS (ES, m / z): 325.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 9.44 (s, 1H), 8.83 (s, 2H), 8.12 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 9.2 Hz, 1H), 7.67 - 7.48 (m, 1H), 7.40 (dd, J = 8.8, 6.4Hz, 1H)

[0475] Example 8: 4-([1,1'-biphenyl]-2-yl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-2-oxo-2H-pyran-6-carboxamide (Compound 182) [ka] Step 1: Under an argon atmosphere, a flask was charged with 2-biphenylboronic acid (1.1 equiv., 115 mg, 582 μmol), 4-bromo-6-methyl-2H-pyran-2-one (1.00 equiv., 100 mg, 529 μmol), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) (5 mol%, 19.4 mg, 26.5 μmol), tripotassium phosphate (3.00 equiv., 337 mg, 1.59 mmol), degassed 1,4-dioxane (5.0 mL), and degassed water (1.0 mL). The reaction mixture was stirred at 80 °C for 5 h. The crude reaction mixture was loaded onto silica gel, and the solvent was removed by rotary evaporation. Subsequent purification by flash silica gel chromatography (0→30% ethyl acetate (EtOAc) in hexanes) afforded 4-([1,1′-biphenyl]-2-yl)-6-methyl-2H-pyran-2-one (131 mg, 94% yield) as an off-white solid. LCMS (ES, m / z) = 263.1 [M+H] + . 1 H NMR (CHCl3-d, 300 MHz): δ H 7.51-7.40 (4H, m), 7.38-7.32 (3H, m), 7.26-7.24 (1H, m), 6.14 (1H, s), 5.57 (1H, s), 2.06 (3H, s)

[0476] Step 2: Under an argon atmosphere, a suspension of 4-([1,1'-biphenyl]-2-yl)-6-methyl-2H-pyran-2-one (1.00 equiv., 131 mg, 499 μmol) and selenium dioxide (10.00 equiv., 554 mg, 4.99 mmol) in anhydrous 1,4-dioxane (5.0 mL) was stirred at 100° C. for 22 hours. The reaction mixture was filtered, and the filter cake was rinsed with dichloromethane (DCM). The filtrate was concentrated by rotary evaporation to give a mixture of 4-([1,1'-biphenyl]-2-yl)-2-oxo-2H-pyran-6-carbaldehyde (131 mg, 95% yield) and 4-([1,1'-biphenyl]-2-yl)-6-(hydroxymethyl)-2H-pyran-2-one as a light yellow solid, which was used without further purification. LCMS (ES, m / z) = 277.0 [M+H] +

[0477] Step 3: To a solution of 4-([1,1'-biphenyl]-2-yl)-2-oxo-2H-pyran-6-carbaldehyde (1.00 equiv., 131 mg, 474 μmol) in a solvent mixture of t-butanol (3.35 mL), water (1.67 mL), tetrahydrofuran (THF) (3.35 mL), and 2-methyl-2-butene (1.12 mL) was added monosodium phosphate (6.00 equiv., 341 mg, 2.84 mmol) followed by sodium chlorite (3.00 equiv., 129 mg, 1.42 mmol) in one portion at 0°C. The reaction mixture was stirred at rt for 2.5 h. The reaction mixture was diluted with water (25 mL) and diluted with 2 M HCl. (水性) The mixture was acidified to pH 1 with HCl. The aqueous phase was extracted with ethyl acetate (EtOAc) (3×15 mL), and the combined organic extracts were dried over MgSO and concentrated to give crude 4-([1,1′-biphenyl]-2-yl)-2-oxo-2H-pyran-6-carboxylic acid (152 mg, 100% yield) as a yellow solid, which was used without further purification. LCMS (ES, m / z) = 291.0 [MH] -

[0478] Step 4: To a solution of 4-([1,1'-biphenyl]-2-yl)-2-oxo-2H-pyran-6-carboxylic acid (1.00 equiv., 50.0 mg, 164 μmol), 2-amino-5-(methylthio)-1,3,4-thiadiazole (1.20 equiv., 29.6 mg, 197 μmol), and N,N-diisopropylethylamine (3.00 equiv., 86.7 μL, 493 μmol) in anhydrous N,N-dimethylformamide (DMF) (1.6 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (1.20 equiv., 74.9 mg, 197 μmol) in one portion under an argon atmosphere. The reaction mixture was stirred at RT for 15 min. The crude material was purified by reverse-phase chromatography (30-70% MeCN in 0.1% formic acid) to give the desired product. The material was repurified by flash silica gel chromatography (0-50% MeCN in 0.1% formic acid in hexanes) to give 4-([1,1'-biphenyl]-2-yl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-2-oxo-2H-pyran-6-carboxamide (12.6 mg, 18% yield) as a yellow solid. LCMS (ES, m / z) = 422.0 [M+H] + . 1 H NMR (DMSO-d6, 300 MHz): δ H 2.72 (3H, s), 6.48 (1H, d, J = 1.5 Hz), 6.93 (1H, d, J = 1.5 Hz), 7.42-7.30 (5H, m), 7.66-7.51 (4H, m)

[0479] Example 9: 5-((3,4-rac-trans-dihydroxypiperidin-1-yl)methyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide (Compound 183) [ka] Step 1: A suspension of ethyl 5-(bromomethyl)benzo[c]isoxazole-3-carboxylate (1.0 equiv., 75.0 mg, 264 μmol), trans-3,4-dihydroxypiperidine hydrochloride (1.1 equiv., 46.0 mg, 290 μmol), and potassium carbonate (1.1 equiv., 40.5 mg, 290 μmol) in anhydrous N,N-dimethylformamide (DMF) (2 mL) was stirred at rt for 16 h. The crude material was purified by reverse-phase chromatography (2-30% MeCN in 0.1% formic acid) to afford ethyl 5-((trans-3,4-dihydroxypiperidin-1-yl)methyl)benzo[c]isoxazole-3-carboxylate (73.4 mg, 87% yield) as a yellow oil. LCMS (ES, m / z) = 321.2 [M+H] + . 1 H NMR (CHCl3-d, 300 MHz): δ H 7.92 (1H, s), 7.73 (1H, d, J = 8.9 Hz), 7.50 (1H, d, J = 9.2 Hz), 6.75 (2H, br. s), 4.55 (1H, q, J = 7.1 Hz), 3.99-3.88 (2H, m), 3.76 (1H, s), 3.63 (1H, s), 3.21 (1H, d, J = 11.7 Hz), 3.12-3.04 (1H, m), 2.68-2.56 (2H, m), 2.17-2.10 (1H, m), 1.79-1.72 (1H, m), 1.49 (3H, t, J = 7.1 Hz)

[0480] Step 2: A solution of ethyl 5-((trans-3,4-dihydroxypiperidin-1-yl)methyl)benzo[c]isoxazole-3-carboxylate (1.0 equiv., 73.4 mg, 229 μmol) and lithium hydroxide monohydrate (1.2 equiv., 11.8 mg, 275 μmol) in water (2 mL) and tetrahydrofuran (THF) (2 mL) was stirred at rt for 6 h. The volatile solvents were removed by rotary evaporation, and the aqueous phase was acidified with 2 M HCl at pH 6. The aqueous phase was lyophilized to afford 5-((trans-3,4-dihydroxypiperidin-1-yl)methyl)benzo[c]isoxazole-3-carboxylic acid (67.0 mg, 100% yield) as an off-white solid. The crude product containing lithium chloride was used without further purification. LCMS (ES, m / z) = 293.1 [M+H] +

[0481] Step 3: A solution of 5-((trans-3,4-dihydroxypiperidin-1-yl)methyl)benzo[c]isoxazole-3-carboxylic acid (1.0 equiv., 67.0 mg, 229 μmol), 2-amino-5-(methylthio)-1,3,4-thiadiazole (1.2 equiv., 41.3 mg, 275 μmol), and N,N-diisopropylethylamine (3.0 equiv., 121 μL, 688 μmol) in anhydrous N,N-dimethylformamide (DMF) (2 mL) was treated with 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (1.5 equiv., 131 mg, 344 μmol) under an Ar atmosphere. The reaction mixture was stirred at rt for 30 min. The reaction mixture was directly purified by reverse-phase chromatography (5-40% MeCN in 0.1% formic acid), followed by further PREP HPLC purification (pH 10 buffer / MeOH) to afford 5-((trans-3,4-dihydroxypiperidin-1-yl)methyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide (4.60 mg, 4.8% yield) as a light yellow solid. LCMS (ES, m / z) = 422.1 [M+H] + . 1H NMR (DMSO-d6, 400 MHz): δ H 8.86 (1H, br. s), 8.34 (1H, s), 7.68 (1H, d, J = 8.9 Hz), 7.45 (1H, d, J = 8.9 Hz), 4.83 (1H, br. s), 3.69 (1H, br. s), 3.31-3.29 (4H, m), 2.96 (2H, br. s), 2.65 (3H, s), 1.89 (1H, br. s), 1.49 (1H, br. s)

[0482] Example 10: 3-(Isoquinolin-1-yl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)isoxazole-5-carboxamide (Compound 150) [ka] Step 1: A suspension of hydroxylamine hydrochloride (3.20 equiv., 354 mg, 5.09 mmol) and potassium acetate (KOAc) (4.00 equiv., 631 mg, 6.36 mmol) in 80% aqueous ethanol (6.4 mL) was stirred at rt for 30 min. Isoquinoline-1-carbaldehyde (1.00 equiv., 250 mg, 1.59 mmol) was added, and the reaction mixture was refluxed for 1 h. The reaction mixture was cooled to rt, the solvent was evaporated under reduced pressure, and the residue was dissolved in water (25 mL) and extracted with dichloromethane (DCM) (3 × 15 mL) followed by ethyl acetate (EtOAc) (3 × 15 mL). The combined organic extracts were dried over Na2SO4, and the solvent was removed by rotary evaporation to give isoquinoline-1-carbaldehyde oxime (274 mg, 100% yield) as a pink solid, which was used without further purification. LCMS (ES, m / z) = 173.1 [M+H] + . 1 H NMR (CHCl3-d, 300 MHz): δ H11.05 (1H, br s), 8.98 (1H, d, J = 8.5 Hz), 8.58 (1H, s), 8.47 (1H, d, J = 5.6 Hz), 7.76 (1H, d, J = 8.1 Hz), 7.62 (1H, td, J = 7.6, 1.3 Hz), 7.50-7.55 (2H, m)

[0483] Step 2: A solution of isoquinoline-1-carbaldehyde oxime (1.00 equiv., 100 mg, 581 μmol) in anhydrous tetrahydrofuran (THF) (11.6 mL) was treated with N-chlorosuccinimide (NCS) (1.11 equiv., 86.1 mg, 645 μmol) and pyridine (Py) (0.50 equiv., 23.5 μL, 290 μmol). The reaction mixture was heated at 55°C for 30 minutes. The reaction mixture was cooled to 0°C and treated with ethyl propiolate (3.00 equiv., 177 μL, 1.74 mmol) (dropwise) and triethylamine (NEt) (1.00 equiv., 81.4 μL, 581 μmol) (dropwise) while maintaining the temperature at 5°C. The reaction mixture was stirred for 15 minutes. The reaction mixture was filtered, and the solid was washed with tetrahydrofuran (10 mL). The filtrate was concentrated under reduced pressure, and the residue was purified by flash silica gel chromatography (0-30% ethyl acetate (EtOAc) / hexanes) to afford ethyl 3-(isoquinolin-1-yl)isoxazole-5-carboxylate (109 mg, 70% yield) as a yellow solid. LCMS (ES, m / z) = 269.1 [M+H] + . 1 H NMR (CHCl3-d, 400 MHz): δ H 9.13 (1H, d, J = 8.3 Hz), 8.65 (1H, d, J = 5.6 Hz), 7.92 (1H, d, J = 8.0 Hz), 7.74-7.80 (3H, m), 7.71 (1H, s), 4.50 (2H, q, J = 7.1 Hz), 1.49 (3H, t, J = 7.1 Hz)

[0484] Step 3: A solution of ethyl 3-(isoquinolin-1-yl)isoxazole-5-carboxylate (1.00 equiv., 100 mg, 373 μmol) and lithium hydroxide monohydrate (1.10 equiv., 17.6 mg, 410 μmol) in water (3.7 mL) and tetrahydrofuran (THF) (3.7 mL) was stirred at rt for 2 h. The reaction mixture was cooled to 0° C., acidified to pH 4 with 2 M HCl, and diluted with water (25 mL). The aqueous phase was lyophilized to give 3-(isoquinolin-1-yl)isoxazole-5-carboxylic acid (90.0 mg, 100% yield) as an off-white solid, which was used without further purification. LCMS (ES, m / z) = 241.1 [M+H] +

[0485] Step 4: To a solution of 3-(isoquinolin-1-yl)isoxazole-5-carboxylic acid (1.00 equiv., 87.3 mg, 363 μmol), 2-amino-5-(methylthio)-1,3,4-thiadiazole (1.20 equiv., 65.5 mg, 436 μmol), N,N-diisopropylethylamine (3.00 equiv., 191 μL, 1.09 mmol), and anhydrous N,N-dimethylformamide (DMF) (3.6 mL), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (1.50 equiv., 207 mg, 545 μmol) was added in one portion, and the reaction mixture was stirred at rt for 30 min. The reaction mixture was treated with water (25 mL); a colloid was observed. The aqueous phase was extracted with dichloromethane (DCM) (3 x 15 mL). The combined organic extracts were concentrated by rotary evaporation, and the resulting yellow solid was then triturated with DCM overnight to give 3-(isoquinolin-1-yl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)isoxazole-5-carboxamide (95.0 mg, 68% yield) as an off-white solid. LCMS (ES, m / z) = 370.0 [M+H] + . 1 H NMR (DMSO-d6, 300 MHz): δ H8.95 (1H, dd, J = 8.4, 1.3 Hz), 8.73 (1H, d, J = 5.6 Hz), 8.13-8.16 (2H, m), 8.07 (1H, d, J = 5.6 Hz), 7.81-7.93 (2H, m), 2.76 (3H, s)

[0486] Example 11: 5-(benzo[d][1,3]dioxol-5-ylmethyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide (Compound 185) [ka] Step 1: A flame-dried flask was charged with 2-(5-methyl-2-nitrophenyl)acetic acid (3.00 g, 15.4 mmol), ethanol (EtOH) (25.0 mL), sulfuric acid (82 μL, 1.54 mmol), and toluene (85.0 mL). A condenser was attached to the flask, and the solution was refluxed for 14 hours. The solvent was removed under reduced pressure, and sulfuric acid (25.0 mL) was added. After the addition, the reaction was heated to 90°C and stirred for 90 minutes. The solution was then poured into ice (300 g), and the mixture was extracted with ether (2 × 100 mL) and ethyl acetate (100 ml). The combined organic layers were dried over MgSO4 and concentrated under reduced pressure. The crude product was dissolved in MeOH (30 mL), and sulfuric acid (800 μL, 12.3 mmol) was added. The reaction mixture was stirred under reflux for 14 hours. The reaction mixture was evaporated to dryness and purified by flash chromatography through Si gel (0-40% ethyl acetate / hexanes) to give methyl 5-methylbenzo[c]isoxazole-3-carboxylate (606 mg, 21%) as an off-white solid. LCMS (ES, m / z) = 192.1 [M+1] + . 1 H NMR (400 MHz, DMSO-d): δ H 7.75-7.73 (m, 1H), 7.60-7.58 (m, 1H), 7.38-7.36 (m, 1H), 4.00 (s, 3H), 2.39 (m, 3H)

[0487] Step 2: To a solution of methyl 5-methylbenzo[c]isoxazole-3-carboxylate (989 mg, 4.66 mmol) in carbon tetrachloride (CCl) (16.2 mL), N-bromosuccinimide (NBS) (829 mg, 4.66 mmol) and 2,2'-azobis(2-methylpropionitrile) (AIBN) (76.5 mg, 466 μmol) were added at room temperature. The resulting mixture was stirred for 16 hours at 80 °C. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with hexane / ethyl acetate (EtOAc) (4:1) to afford methyl 5-(bromomethyl)benzo[c]isoxazole-3-carboxylate (760 mg, 60%) as a light yellow solid. LCMS (ES, m / z) = 271.9 [M+1] + . 1 H NMR (400 MHz, methanol-d4) δ 7.98-7.96 (m, 1H), 7.76 (d, J = 8.4, 1H), 7.54 (d, J = 8.4 Hz, 1H), 4.86 (s, 2H), 4.10 (s, 3H)

[0488] Step 3: Methyl 5-(bromomethyl)benzo[c]isoxazole-3-carboxylate (200 mg, 741 μmol) and 3,4-methylenedioxyphenylboronic acid, pinacol ester (184 mg, 741 μmol) were dissolved in dioxane (6.00 mL)-HO (2.00 mL), and cesium carbonate (724 mg, 2.22 mmol) was added. The suspension was degassed and purged with nitrogen (3x). 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) (10.8 mg, 14.8 μmol) was added, and the suspension was degassed with nitrogen (3x). The reaction mixture was heated to 80 °C and monitored by LC-MS. After overnight, the black reaction mixture was filtered through Celite and washed with ethyl acetate / methanol. The filtrate was acidified with resin (Amberlist IR-120), filtered, and concentrated. The crude product was purified by normal phase chromatography eluting with 100% dichloromethane (DCM) to 10% MeOH over 25 minutes to give 5-(benzo[d][1,3]dioxol-5-ylmethyl)benzo[c]isoxazole-3-carboxylic acid (115 mg, 52%). LCMS (ES, m / z) = 298.0 [M+1] + . 1 H NMR (400 MHz, methanol-d4): δ H 7.68 (1H, s), 7.59 (1H, d, J = 9.3 Hz), 7.28 (1H, d, J = 9.3 Hz), 6.69-6.74 (3H, m), 5.88 (2H, s), 3.93 (2H, s)

[0489] Step 4: N,N-Diisopropylethylamine (160 μL, 920 μmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (160 mg, 422 μmol) were added sequentially to a solution of 5-(benzo[d][1,3]dioxol-5-ylmethyl)benzo[c]isoxazole-3-carboxylic acid (114 mg, 383 μmol) in N,N-dimethylformamide (DMF) (4 mL) at 0° C. and stirred for 10 min. To the resulting solution was added 2-amino-5-(methylthio)-1,3,4-thiadiazole (56.5 mg, 383 μmol) and stirred at 0° C. for 1 h, then at rt for 15 h. Upon completion, the reaction was diluted with water and extracted with ethyl acetate (3x). The combined organic layers were washed with brine and concentrated. The crude product was subjected to column chromatography through silica gel, eluting with 0-10% MeOH in dichloromethane / methanol (DCM / MeOH) to afford the desired product, 5-(benzo[d][1,3]dioxol-5-ylmethyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide, as a yellow solid (67 mg, 41% yield). LCMS (ES, m / z) = 427.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d): δ H 7.83 (1H, s), 7.74 (1H, d, J = 9.3 Hz), 7.38 (1H, d, J = 9.3 Hz), 6.83-6.86 (2H, m), 6.76 (1H, d, J = 8.0 Hz), 5.96 (2H, s), 3.95 (2H, s), 2.74 (3H, s)

[0490] Example 12: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-[1,2,3]triazolo[1,5-a]quinoline-3-carboxamide (Compound 190) [ka] Step 1: 2-Azidobenzaldehyde (200 mg, 1.36 mmol) was dissolved in dimethyl sulfoxide (DMSO) (2.0 mL), and methyl acetoacetate, 99% (147 μL, 1.36 mmol) was added, followed by 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (41 μL, 272 μmol). The resulting reaction mixture was stirred for 24 h at 120 °C. The reaction mixture was cooled to rt, water was added, and the mixture was extracted with ethyl acetate (EtOAc). The organics were washed with brine, dried over sodium sulfate, and concentrated. The crude product was subjected to column silica gel chromatography (0–30% EtOAc / hexanes) to afford methyl [1,2,3]triazolo[1,5-a]quinoline-3-carboxylate (160 mg, 26%) as an off-white solid. LCMS (ES, m / z) = 228.1 [M+1] + . 1 H NMR (400 MHz, CHCl3-d): δ H 8.87 (1H, d, J = 8.4 Hz), 8.12 (1H, d, J = 9.3 Hz), 7.94 (1H, d, J = 8.0 Hz), 7.80-7.87 (2H, m), 7.69 (1H, t, J = 7.6 Hz), 4.08 (3H, s)

[0491] Step 2: Methyl [1,2,3]triazolo[1,5-a]quinoline-3-carboxylate (110 mg, 483 μmol) was dissolved in a mixture of tetrahydrofuran (THF) (6.6 mL) and HO (3.3 mL). The reaction mixture was cooled to 0° C., followed by the addition of lithium hydroxide monohydrate (61 mg, 1.45 mmol). The reaction mixture was stirred at 0° C.-10° C. for 90 minutes. The reaction mixture was neutralized using acidic resin (Amberlist IR-120) and filtered to remove the resin. The filtrate was concentrated, and the resulting solid was used in the next step without further purification. LCMS (ES, m / z) = 214.1 [M+1] +

[0492] Step 3: N,N-Diisopropylethylamine (DIPEA) (196 μL, 1.13 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (196 mg, 516 μmol) were added sequentially to a solution of [1,2,3]triazolo[1,5-a]quinoline-3-carboxylic acid (100 mg, 469 μmol) in N,N-dimethylformamide (DMF) (4.1 mL) at 0° C. and stirred for 15 minutes. To the resulting solution was added 2-amino-5-(methylthio)-1,3,4-thiadiazole (69 mg, 469 μmol), and stirring was continued at 0° C. for 1 hour, then at rt for 15 hours. After 15 hours, the conversion of the acid was incomplete, and additional N,N-diisopropylethylamine (DIPEA) (98 μL, 563 μmol), HATU (98 mg, 258 μmol), and 2-amino-5-(methylthio)-1,3,4-thiadiazole (34.5 mg, 234 μmol) were added and stirred for 3 hours. Upon completion, the reaction was diluted with water. The precipitate that formed was collected by filtration and rinsed with ethyl acetate (EtOAc), MeOH, and acetonitrile (MeCN) to give 35 mg of product (99% purity, LC-MS 254 nm). Meanwhile, the filtrate was extracted with ethyl acetate (3×). The combined organic layers were washed with brine and concentrated to give a crude solid, which was rinsed with EtOAc, MeOH, and MeCN to give an additional 24 mg of product. In addition, N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-[1,2,3]triazolo[1,5-a]quinoline-3-carboxamide (59.0 mg, 37%) was obtained as an off-white solid. LCMS (ES, m / z) = 343.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d): δ H 13.35 (1H, s), 8.78 (1H, d, J = 8.4 Hz), 8.17-8.23 (3H, m), 7.98 (1H, t, J = 7.8 Hz), 7.82 (1H, t, J = 7.6 Hz), 2.75 (3H, s)

[0493] Example 13: N6 ,N 6 -Dimethyl-N 3 -(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3,6-dicarboxamide (Compound 192) [ka] Step 1: Following the method of Step 1 of Example 11, ethyl 6-bromobenzo[c]isoxazole-3-carboxylate (5.20 g, 51%) was obtained as a white solid. LCMS (ES, m / z) = 272.0 [M+1] + . 1 H NMR (400 MHz, CHCl3-d): δ H 7.94 (1H, s), 7.82 (1H, d, J = 9.2 Hz), 7.29 (1H, d, J = 9.2 Hz), 4.55 (2H, q, J = 7.1 Hz), 1.49 (3H, t, J = 7.1 Hz)

[0494] Step 2: A dry vial was charged with ethyl 6-bromobenzo[c]isoxazole-3-carboxylate (100 mg, 370 μmol), palladium(II) acetate (Pd(OAc)2) (6.65 mg, 29.6 μmol), xantphos (17.1 mg, 29.6 μmol), 4-dimethylaminopyridine (DMAP) (13.8 mg, 111 μmol), and dioxane (3.2 mL). The flask was evacuated and backfilled with nitrogen three times. Triethylamine (516 μL, 3.70 mmol) and dimethylamine hydrochloride (45.3 mg, 555 μmol) were added, then the flask was evacuated once more and a CO2 balloon was installed and gas was bubbled through for 1 minute. The vial was sealed and heated at 80 °C under a CO2 atmosphere for 17 h. After overnight, the reaction mixture was filtered through Celite, washed with ethyl acetate (EtOAc) and methanol (MeOH), and the filtrate was concentrated. The crude product was purified by silica gel column chromatography (0-100% EtOAc / hexanes) to give ethyl 6-(dimethylcarbamoyl)benzo[c]isoxazole-3-carboxylate (47.0 mg, 48%) as an off-white solid. LCMS (ES, m / z) = 263.1 [M+1] + . 1 H NMR (400 MHz, CHCl3-d): δ H 7.99 (1H, dd, J = 8.9, 1.1 Hz), 7.73 (1H, s), 7.28 (1H, d, J = 1.3 Hz), 4.56 (2H, q, J = 7.1 Hz), 3.16 (3H, s), 3.04 (3H, s), 1.50 (3H, t, J = 7.1 Hz)

[0495] Step 3: To a solution of ethyl 6-(dimethylcarbamoyl)benzo[c]isoxazole-3-carboxylate (47.0 mg, 179 μmol) in tetrahydrofuran (THF) (2.4 mL) and HO (1.2 mL) at 0° C., lithium hydroxide (LiOH) monohydrate (22.6 mg, 538 μmol) was added, and the resulting mixture was stirred for 1 h at 0–10° C. The reaction mixture was acidified by the addition of resin (Amberlist IR-120, strongly acidic) and subsequently filtered to remove the resin. The resin was further rinsed with ethyl acetate / methanol (EtOAc / MeOH), and the filtrate was concentrated to give 6-(dimethylcarbamoyl)benzo[c]isoxazole-3-carboxylic acid (42 mg, 100% yield) as a yellow solid, which was used directly in the next step without further purification. LCMS (ES, m / z) = 235.1 [M+1] +

[0496] Step 4: N,N-Diisopropylethylamine (78.1 μL, 448 μmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (81.8 mg, 215 μmol) were added sequentially to a solution of 6-(dimethylcarbamoyl)benzo[c]isoxazole-3-carboxylic acid (42.0 mg, 179 μmol) in N,N-dimethylformamide (DMF) (1.55 mL) at 0° C. and stirred for 10 minutes. To the resulting solution, 2-amino-5-(methylthio)-1,3,4-thiadiazole (26.4 mg, 179 μmol) was added and stirred at 0° C. for 10 minutes, then at room temperature for 3 hours. Upon completion, the reaction was diluted with water and lyophilized. The solid thus obtained was treated with EtOH / water to precipitate, which was collected by filtration. The EtOH / water filtrate contained some product, which was recovered by C18 reverse phase chromatography (10-100% MeCN / water). The product from the precipitate and reverse phase was combined and lyophilized. This product was further washed with ether and purified by N 6 ,N 6 -Dimethyl-N 3-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3,6-dicarboxamide (17.0 mg, 26% yield) was obtained as a light yellow solid. LCMS (ES, m / z) = 364.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d): δ H 8.13 (1H, d, J = 8.9 Hz), 7.86 (1H, s), 7.30 (1H, d, J = 9.0 Hz), 3.01 (3H, s), 2.94 (3H, s), 2.73 (3H, s)

[0497] Example 14: 6-(hydroxymethyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide (Compound 194) [ka] Step 1: Anhydrous dioxane (10.0 mL) and ethyl 6-bromobenzo[c]isoxazole-3-carboxylate (400 mg, 1.48 mmol) were added to (tributylstannyl)methanol (740 mg, 2.07 mmol) and tetrakis(triphenylphosphine)palladium (Pd(PPh3)4) (342 mg, 296 μmol) at room temperature under nitrogen. The mixture was stirred at 80 °C for 24 h. After cooling to room temperature, potassium fluoride (KF) (258 mg, 4.44 mmol) and water / methanol (MeOH) (1:1, 10 mL) were added and stirred overnight. The reaction mixture was filtered through Celite, and the filtrate was concentrated and purified by silica gel flash chromatography (0–10% MeOH / dichloromethane (DCM)) to give methyl 6-(hydroxymethyl)benzo[c]isoxazole-3-carboxylate (150 mg, 24%). LCMS (ES, m / z) = 208.1 [M+1] +

[0498] Step 2: To a solution of methyl 6-(hydroxymethyl)benzo[c]isoxazole-3-carboxylate (150 mg, 339 μmol) in tetrahydrofuran (THF) (4.6 mL)-HO (2.3 mL) at 0° C., lithium hydroxide (LiOH) monohydrate (43 mg, 1.02 mmol) was added, and the resulting mixture was stirred for 1 h at 0° C. Resin (Amberlist IR-120, strongly acidic) was added, followed by filtration to remove the resin. The resin was further rinsed with ethyl acetate (EtOAc) / MeOH, and the filtrate was concentrated to give 6-(hydroxymethyl)benzo[c]isoxazole-3-carboxylic acid (65 mg, 100% yield), which was used directly in the next step without further purification. LCMS (ES, m / z) = 194.0 [M+1] +

[0499] Step 3: N,N-Diisopropylethylamine (147 μL, 841 μmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (154 mg, 404 μmol) were added sequentially to a solution of 6-(hydroxymethyl)benzo[c]isoxazole-3-carboxylic acid (65.0 mg, 337 μmol) in N,N-dimethylformamide (DMF) (2.91 mL) at 0° C. and stirred for 10 minutes. To the resulting solution, 2-amino-5-(methylthio)-1,3,4-thiadiazole (49.5 mg, 337 μmol) was added and stirred at 0° C. for 10 minutes, then at rt for 90 minutes. Upon completion, the reaction mixture was diluted with water and extracted with ethyl acetate (3×). The combined organic layers were washed with brine and concentrated. The crude product was purified by flash chromatography over silica gel (0-10% MeOH / dichloromethane (DCM)) to give 6-(hydroxymethyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide (28.0 mg, 26% yield) as a light yellow solid. LCMS (ES, m / z) = 323.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d): δ H8.01 (1H, d, J = 8.9 Hz), 7.62 (1H, s), 7.23 (1H, d, J = 9.0 Hz), 5.53 (1H, s), 4.58 (2H, s), 2.72 (3H, s)

[0500] Example 15: 3-methyl-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-2-oxo-4-phenyl-2H-pyran-6-carboxamide (Compound 203) [ka] Step 1: To a solution of 2-oxo-4-phenyl-2H-pyran-6-carboxylic acid (350.00 mg, 1.619 mmol, 1.00 equiv) in methanol (MeOH) (4.00 mL) was added a solution of HCl (4 M) in 1,4-dioxane (1.50 mL). The resulting mixture was stirred for 3 hours at room temperature, and the resulting solution was concentrated under reduced pressure. The residue was diluted with water (30 mL). The mixture was basified to pH 9 with saturated sodium bicarbonate (aqueous). The resulting mixture was extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (2 × 10 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to give methyl 2-oxo-4-phenyl-2H-pyran-6-carboxylate (280 mg, 75% yield) as a brown solid. LCMS (ES, m / z) = 231 [M+H] +

[0501] Step 2: To a solution of methyl 2-oxo-4-phenyl-2H-pyran-6-carboxylate (400.00 mg, 1.737 mmol, 1.00 equiv.) in trifluoroacetic acid (TFA) (6.00 mL), N-bromosuccinimide (NBS) (371.09 mg, 2.084 mmol, 1.20 equiv.) was added at room temperature. The resulting solution was stirred at 70° C. for 3 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (5:4 petroleum ether / ethyl acetate (EtOAc)) to afford methyl 3-bromo-2-oxo-4-phenyl-2H-pyran-6-carboxylate (500 mg, 93% yield) as a yellow oil. LCMS (ES, m / z) = 309 [M+H]+

[0502] Step 3: Under nitrogen, to a mixture of methyl 3-bromo-2-oxo-4-phenyl-2H-pyran-6-carboxylate (300 mg, 0.971 mmol, 1.00 equiv.), bis(tri-t-butylphosphine)palladium (Pd(t-BuP)) (49.60 mg, 0.097 mmol, 0.10 equiv.), and tri-tert-butylphosphonium tetrafluoroborate (t-BuP)HBF) (28.14 mg, 0.097 mmol, 0.10 equiv.) in tetrahydrofuran (THF) (5.00 mL) was added (μ-1,4-diazabicyclo[2.2.2]octane-κN). 1 :κN 4 )(Hexamethyl)dialuminum (DABAL-Me3) (497.57 mg, 1.942 mmol, 2.00 equiv.) was added dropwise at room temperature. The resulting solution was stirred at 70 °C for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (5:4 petroleum ether / ethyl acetate (EtOAc)) to give methyl 3-methyl-2-oxo-4-phenyl-2H-pyran-6-carboxylate (100 mg, 42% yield) as a yellow oil. LCMS (ES, m / z) = 245 [M+H]+

[0503] Step 4: A solution of methyl 3-methyl-2-oxo-4-phenyl-2H-pyran-6-carboxylate (100 mg, 0.409 mmol, 1.00 equiv) in HCl (6 M) (1.00 mL) was stirred for 4 hours at 100° C. The resulting mixture was concentrated under reduced pressure, and then the residue was diluted with water (10 mL). The mixture was basified to pH 8 with saturated sodium bicarbonate (aqueous). The aqueous layer was extracted with ethyl acetate (2 × 10 mL). The aqueous layer was acidified with HCl (aqueous, 1 M) to pH 3. The resulting mixture was extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with brine (2 × 5 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to give 3-methyl-2-oxo-4-phenyl-2H-pyran-6-carboxylic acid (50 mg, 53% yield) as a yellow oil. LCMS (ES, m / z) = 231 [M+H]+

[0504] Step 5: To a solution of 3-methyl-2-oxo-4-phenyl-2H-pyran-6-carboxylic acid (50.0 mg, 0.217 mmol, 1.00 equiv.) in dichloromethane (0.50 mL), 5-(methylthio)-1,3,4-thiadiazol-2-amine (38.4 mg, 0.260 mmol, 1.20 equiv.), hydroxybenzotriazole (HOBt) (44.02 mg, 0.326 mmol, 1.50 equiv.), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (124.90 mg, 0.651 mmol, 3.00 equiv.) were added at room temperature. The resulting solution was stirred for 1 hour at room temperature. The resulting mixture was diluted with water (10 mL). The resulting mixture was extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine (2 × 5 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by prep-HPLC (conditions: column, XBridge Prep OBD C18 column, 30 × 150 mm, 5 μm; mobile phase: water (phase A: 10 mmol / L NH4HCO3) and acetonitrile (MeCN) (phase B), gradient: 20% phase B to 35% phase B in 7 min; detector, UV 254) to give 3-methyl-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-2-oxo-4-phenyl-2H-pyran-6-carboxamide (8.1 mg, 10% yield) as a yellow solid. LCMS (ES, m / z) = 360.15 [M+H]+. 1 H NMR (400 MHz, DMSO-d6) δ 7.61-7.49 (m, 5H), 7.30 (s, 1H), 2.69 (s, 3H), 2.07 (s, 3H)

[0505] Example 16: N-[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]-6-oxo-4-phenylpyran-2-carboxamide (Compound 205) [ka] Step 1: To a stirred mixture of 4-hydroxy-6-methyl-2H-pyran-2-one (300.0 g, 2.37 mol) and tetra-n-butylammonium bromide (TBAB) (1150.3 g, 3.56 mol) in toluene (1000 mL) was slowly added phosphorus pentoxide (PO) (847.54 g, 5.97 mmol) at room temperature. The mixture was heated at 100°C for 2 hours, then cooled to room temperature and quenched by the addition of 1.5 L of water. The layers were separated, and the aqueous phase was extracted with 3 x 500 mL of ethyl acetate. The combined organic layers were washed with 2 x 200 mL of brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to give 413 g of crude product, which was suspended in 2 L of N,N-dimethylformamide (DMF) / water (9:1) and stirred at room temperature for 1 hour. The solid was collected by filtration to give 4-bromo-6-methyl-2H-pyran-2-one (310 g, 68% yield) as a reddish-brown solid. LCMS (ES, m / z) = 189 / 191 [M+H]

[0506] Step 2: To a stirred mixture of 4-bromo-6-methyl-2H-pyran-2-one (50.0 g, 264.54 mmol) and N-bromosuccinimide (NBS) (56.50 g, 317.44 mmol) in dichloroethane (DCE) (500 mL) was added azobisisobutyronitrile (AIBN) (4.34 g, 26.454 mmol) slowly at room temperature. The mixture was stirred for 2 hours at 80° C. and then concentrated under reduced pressure. The residue was dissolved in acetonitrile (MeCN) (500 mL). N-methylmorpholine-N-oxide (NMO) (61.98 g, 529.07 mmol) was added slowly at room temperature. The resulting mixture was stirred for 1.5 hours at 80° C. and then quenched by the addition of 1 L of water at room temperature. The solid was filtered off, and the filtrate was extracted with 3×500 mL of ethyl acetate. The aqueous layer was acidified with concentrated hydrochloric acid (12N) to pH 3 and extracted with 3 x 500 mL of ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate and then concentrated under reduced pressure to give 4-bromo-2-oxo-2H-pyran-6-carboxylic acid (4.5 g, 7.9% yield) as a yellow solid as a 3:1 mixture of 4-bromo-2-oxo-2H-pyran-6-carboxylic acid:pyrrolidine-2,5-dione from N-bromosuccinimide (NBS). This was used directly in the next step without further purification. LCMS (ES, m / z) = 217 / 219 [M - 1] - . 1 H NMR (300 MHz, DMSO-d6) δ 7.26 (d, J = 1.8 Hz, 1H), 7.13 (d, J = 1.8 Hz, 1H)

[0507] Step 3: To a solution of 4-bromo-6-oxopyran-2-carboxylic acid (200 mg, 0.913 mmol, 1 equiv.) in dioxane / HO (2 mL), phenylboronic acid (167 mg, 1.370 mmol, 1.50 equiv.), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl) (134 mg, 0.183 mmol, 0.20 equiv.), and KCO (252 mg, 1.823 mmol, 2.00 equiv.) were added at room temperature. The resulting mixture was stirred for 2 hours at 80 °C under a nitrogen atmosphere. The resulting mixture was diluted with water (20 mL). The resulting mixture was extracted with ethyl acetate (EtOAc) (3 × 50 mL). The combined organic layers were washed with brine (2 × 5 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 petroleum ether / EtOAc) to give 6-oxo-4-phenylpyran-2-carboxylic acid (80 mg, 38% yield) as an off-white solid. LCMS (ES, m / z): 217 [M+H] +

[0508] Step 4: To a solution of 6-oxo-4-phenylpyran-2-carboxylic acid (50 mg, 0.231 mmol, 1 equiv.) in dichloromethane (DCM) (1 mL), hydroxybenzotriazole (HOBt) (47 mg, 0.348 mmol, 1.50 equiv.) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (133 mg, 0.694 mmol, 3.00 equiv.) were added at room temperature. The resulting mixture was stirred for 0.5 hours at room temperature. To the stirring mixture, 5-(2-chlorophenyl)-1,3,4-thiadiazol-2-amine (54 mg, 0.255 mmol, 1.10 equiv.) was added at room temperature. The resulting mixture was stirred for 1 hour at room temperature. The precipitated solid was collected by filtration and washed with acetonitrile (3 × 10 mL). The crude product was purified by prep-HPLC using the following conditions: XBridge Shield RP18 OBD column, 30 × 150 mm, 5 μm; mobile phase A: water (10 mmol / L NH₄HCO₃), mobile phase B: MeCN; flow rate: 60 mL / min; gradient: 28% B to 43% B for 8 min, 43% B; wavelength: 254 nm to give N-[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]-6-oxo-4-phenylpyran-2-carboxamide (6 mg, 6% yield) as a green solid. LCMS (ES, m / z) = 410.05 [M+H]. + . 1 H NMR (400 MHz, DMSO-d6) δ 8.07 (dd, J = 6.0, 3.6 Hz, 1H), 7.90 (dd, J = 6.8, 3.2 Hz, 2H), 7.69-7.60 (m, 2H), 7.59-56 (m, 3H), 7.51-7.78 (m, 2H), 6.83 (s, 1H)

[0509] Example 17A: N-[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]-6-oxo-4-(phenylamino)pyran-2-carboxamide (Compound 206) [ka] Step 1: To a solution of 4-bromo-6-oxopyran-2-carboxylic acid (3 g, 13.7 mmol, 1 equiv.) in ethanol (EtOH) (40 mL), aniline (1275 mg, 13.69 mmol, 1.00 equiv.) was added and stirred at room temperature for 12 hours. The resulting mixture was diluted with water (200 mL). The resulting mixture was extracted with ethyl acetate (EtOAc) (3×200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC using the following conditions: Column: Xselect CSH C18 OBD column 30 x 150 mm 5 μm; Mobile phase A: MeCN, Mobile phase B: Water (0.05% trifluoroacetic acid (TFA)); Flow rate: 60 mL / min; Gradient: 20% B to 35% B for 8 min, 35% B; Wavelength: 254 / 220 nm; RT1 (min): 7.72; Number of runs: 0) to give 6-oxo-4-(phenylamino)pyran-2-carboxylic acid (800 mg, 25% yield) as a brown solid. LCMS (ES, m / z) = 232.05 [M+H] +

[0510] Step 2: To a solution of 6-oxo-4-(phenylamino)pyran-2-carboxylic acid (130 mg, 0.562 mmol, 1 equiv.) in N,N-dimethylformamide (DMF) (2 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (323 mg, 1.685 mmol, 3.00 equiv.), hydroxybenzotriazole (HOBt) (114 mg, 0.844 mmol, 1.50 equiv.), and 5-(2-chlorophenyl)-1,3,4-thiadiazol-2-amine (130 mg, 0.614 mmol, 1.09 equiv.) were added, and the mixture was stirred for 1 hour at room temperature. The reaction was quenched by the addition of water (2 mL) at room temperature. The precipitated solid was collected by filtration and washed with water (10 mL). The residue was washed with dimethyl sulfoxide:acetonitrile (DMSO:MeCN) (3:1) (3 × 4 mL) to give N-[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]-6-oxo-4-(phenylamino)pyran-2-carboxamide (39.6 mg, 17% yield) as a yellow solid. LCMS (ES, m / z) = 424.9 [M+H]+ . 1 H NMR (400 MHz, DMSO-d6) δ 13.57 (br, 1H), 9.68 (s, 1H), 8.14 (dd, J = 7.6, 2.0 Hz, 1H), 7.71 (dd, J = 8.0, 1.6 Hz, 1H), 7.60-7.56 (m, 2H), 7.50-7.43 (m, 2H), 7.34 - 7.28 (m, 2H), 7.25 (dd, J = 7.2, 1.2 Hz, 1H), 7.14 (d, J = 2.0 Hz, 1H), 5.52 (d, J = 2.0 Hz, 1H)

[0511] Example 17B: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-2-oxo-4-phenoxy-2H-pyran-6-carboxamide (Compound 202) [ka] Step 1: Phenol (1.61 equiv., 40 mg, 0.425 mmol) was dissolved in N,N-dimethylformamide (DMF) (1 mL), followed by the addition of 4-bromo-6-methyl-pyran-2-one (1.00 equiv., 50 mg, 0.265 mmol). The solution was stirred for 30 min, after which NaH (1.60 equiv., 17 mg, 0.423 mmol) was added. The mixture was then stirred at rt for 15 h. Dimethyl sulfoxide (DMSO) (0.5 mL) was added, and the reaction mixture was directly purified by C18 reverse-phase chromatography (0-100% MeCN / water) to afford 6-methyl-4-phenoxy-pyran-2-one (31 mg, 58% yield) as a yellow solid. LCMS (ES, m / z) = 202.93 [M+H] + . 1 H NMR (CDCl3, 300 MHz): δ 7.48 - 7.38 (m, 2H), 7.34 - 7.27 (m, 1H), 7.11 - 7.04 (m, 2H), 6.01 - 5.93 (m, 1H), 5.20 (d, J = 2.2 Hz, 1H), 2.30 - 2.22 (m, 3H)

[0512] Step 2: To a suspension of 6-methyl-4-phenoxy-pyran-2-one (1.00 equiv., 31 mg, 0.15 mmol) in CCl (0.2 mL), azobisisobutyronitrile (AIBN) (0.1 equiv., 2.5 mg, 0.015 mmol) was added, followed by N-bromosuccinimide (NBS) (1.2 equiv., 33 mg, 0.18 mmol), and the mixture was stirred at 80 °C. After 2 h, the volatiles were removed under reduced pressure, and the crude material was resuspended in MeCN (0.75 mL). N-methylmorpholine N-oxide (NMO) (4.0 equiv., 72 mg, 0.61 mmol) was then added and stirred for an additional 90 min at 80 °C. The mixture was then diluted with water and ethyl acetate, the phases were separated, and the ethyl acetate extract was set aside. The aqueous phase was then acidified with 1N HCl to pH=1 and extracted with ethyl acetate (×2). These ethyl acetate extracts were combined, dried (MgSO), filtered, and concentrated under reduced pressure to give crude 2-oxo-4-phenoxy-2H-pyran-6-carboxylic acid (31 mg, 87% yield), which was used directly in the next step. LCMS (ES, m / z) = 232.94 [M+H] +

[0513] Step 3: 5-(Methylsulfanyl)-1,3,4-thiadiazol-2-amine (1.01 equiv., 21 mg, 0.136 mmol) was dissolved in tetrahydrofuran (THF) (0.5 mL), and diisopropylethylamine (DIPEA) (3.01 equiv., 0.070 mL, 0.402 mmol) was added, followed by 6-oxo-4-phenoxy-pyran-2-carboxylic acid (1.00 equiv., 31 mg, 0.134 mmol). Propylphosphonic acid (T3P) (2.32 equiv., 0.18 mL, 0.309 mmol) was then added, and the reaction mixture was stirred at rt for 30 min. The volatiles were removed under reduced pressure, and the crude material was dissolved in a small amount of dimethyl sulfoxide (DMSO) and directly purified by C18 reverse-phase chromatography (0–100% MeCN / water) to afford N-(5-methylsulfanyl-1,3,4-thiadiazol-2-yl)-6-oxo-4-phenoxy-pyran-2-carboxamide (5.7 mg, 12% yield) as a brown solid. LCMS (ES, m / z) = 362.22 [M+1]+. 1 HNMR (400 MHz, CDCl3) δ 7.52 - 7.45 (m, 2H), 7.40 - 7.32 (m, 1H), 7.23 (d, J = 2.3 Hz, 1H), 7.14 - 7.06 (m, 2H), 5.57 (d, J = 2.3 Hz, 1H), 2.78 (s, 3H)

[0514] Example 18: N-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)-3-hydroxy-2-oxo-2H-pyran-6-carboxamide (Compound 64) [ka] 5-Hydroxy-6-oxo-pyran-2-carboxylic acid (1.00 equiv., 44 mg, 0.283 mmol) and 5-(2-chlorophenyl)-1,3,4-thiadiazol-2-amine (1.21 equiv., 73 mg, 0.343 mmol) were combined in ethyl acetate (EtOAc) (0.5 mL). Diisopropylethylamine (DIPEA) (3.00 equiv., 0.15 mL, 0.850 mmol) was added, followed by propylphosphonic acid (T3P) (50% in EtOAc) (2.00 equiv., 0.34 mL, 0.567 mmol), and the mixture was placed in a 55 °C heating block. After 16 hours, water (5 mL) was added, and the solid was collected, washed with water (2 × 3 mL), then diethyl ether (EtO) (3 × 3 mL), then ethanol (EtOH) (3 × 3 mL), and dried to give N-[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]-5-hydroxy-6-oxo-pyran-2-carboxamide (8.0 mg, 8% yield) as a brown solid. LCMS (ES, m / z) = 350.21 [M+1]+. 1 H NMR (400 MHz, DMSO-d6) δ 8.13 (dd, J = 7.7, 2.2 Hz, 1H), 7.70 (dd, J = 7.7, 1.6 Hz, 1H), 7.64 - 7.50 (m, 3H), 7.41 (d, J = 7.5 Hz, 1H), 6.80 (d, J = 7.5 Hz, 1H). (NH signal not observed.)

[0515] Example 19: [5-(2,1-benzoxazole-3-amido)-1,3,4-thiadiazol-2-yl]acetic acid (Compound 132) [ka] Step 1: To a stirring solution of 2,1-benzoxazole-3-carboxylic acid (200 mg, 1.23 mmol, 1 equiv.) and ethyl 2-(5-amino-1,3,4-thiadiazol-2-yl)acetate (301 mg, 1.61 mmol, 1.31 equiv.) in N,N-dimethylformamide (DMF) (2 mL) was added hydroxybenzotriazole (HOBt) (200 mg, 1.48 mmol, 1.21 equiv.) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (940 mg, 4.90 mmol, 4.00 equiv.). The resulting mixture was stirred for 1 hour at room temperature. The resulting mixture was diluted with water (10 mL). The resulting mixture was extracted with ethyl acetate (EtOAc) (3 × 20 mL). The combined organic layers were washed with water (2 × 5 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (3:1 petroleum ether / EtOAc) to give ethyl 2-[5-(2,1-benzoxazole-3-amido)-1,3,4-thiadiazol-2-yl]acetate (67 mg, 16% yield) as a light yellow solid. LCMS (ES, m / z) = 333.0 [M+H] +

[0516] Step 2: To a stirred solution of ethyl 2-[5-(2,1-benzoxazole-3-amido)-1,3,4-thiadiazol-2-yl]acetate (60 mg, 0.181 mmol, 1 equiv.) in ethanol (EtOH) (0.6 mL) and HO (0.2 mL) was added NaOH (8 mg, 0.200 mmol, 1.11 equiv.). The resulting mixture was stirred for 1 h at room temperature. The mixture was acidified with HCl (6 M) to pH = 4. The resulting mixture was extracted with ethyl acetate (EtOAc) (3 × 5 mL). The combined organic layers were washed with water (2 × 5 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The crude product (30 mg) was purified by Prep-HPLC (conditions: column: Xselect CSH C18 OBD column 30 × 150 mm 5 μm, n; mobile phase A: acetonitrile (MeCN), mobile phase B: water (0.05% trifluoroacetic acid (TFA)); flow rate: 60 mL / min; gradient: 15% B to 40% B for 8 min, 40% B to 40% B for 10 min, 40% B; wavelength: 254 / 220 nm; RT1 (min): 9.12) to give [5-(2,1-benzoxazole-3-amido)-1,3,4-thiadiazol-2-yl]acetic acid (2.6 mg, 5% yield) as a light yellow solid. LCMS (ES, m / z) = 305.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J = 8.0 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.55-7.48(m, 1H), 7.36-7.26 (m, 1H), 4.13 (s, 2H)

[0517] Example 20: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(3-phenylpyrrolidin-1-yl)-1,3,4-oxadiazole-2-carboxamide (Compound 73) [ka] Step 1: Ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate (1.00 equiv., 100 mg, 0.452 mmol) was dissolved in dioxane (2.5 mL). 3-Phenylpyrrolidine (1.50 equiv., 0.10 mL, 0.679 mmol) was added, followed by diisopropylethylamine (DIPEA) (2.00 equiv., 0.16 mL, 0.905 mmol), and the mixture was stirred at rt overnight. After 16 h, LCMS indicated high conversion. The mixture was diluted with ethyl acetate (EtOAc) (40 mL), washed with saturated NaHCO3 (10 mL), dried (Na2SO4), filtered, and concentrated to dryness. The crude material was purified by flash chromatography through Si gel (25 g Si, 0-100% ethyl acetate / hexanes) to give ethyl 5-(3-phenylpyrrolidin-1-yl)-1,3,4-oxadiazole-2-carboxylate (66 mg, 49% yield) as a clear oil. LCMS (ES, m / z) = 288.06 [M+1]+

[0518] Step 2: 5-(Methylsulfanyl)-1,3,4-thiadiazol-2-amine (1.40 equiv., 23 mg, 0.146 mmol) was dissolved in tetrahydrofuran (THF) (0.5 mL) in a flask under nitrogen. Lithium bis(trimethylsilyl)amide (LiHMDS) (1 M in THF) (1.50 equiv., 0.16 mL, 0.157 mmol) was then added and stirred for 5 min at rt. Then a solution of ethyl 5-(3-phenylpyrrolidin-1-yl)-1,3,4-oxadiazole-2-carboxylate (1.00 equiv., 30 mg, 0.104 mmol) in THF (1 mL) was added and the mixture was stirred at rt. After 3 h, LCMS showed complete conversion. Water (5 mL) was added, and the resulting solid was collected and washed with water (3 × 3 mL) and then diethyl ether (EtO) (3 × 3 mL) to give N-(5-methylsulfanyl-1,3,4-thiadiazol-2-yl)-5-(3-phenylpyrrolidin-1-yl)-1,3,4-oxadiazole-2-carboxamide (6.0 mg, 15% yield) as a cream-colored solid. LCMS (ES, m / z) = 389.25 [M+1]+. 1H NMR (400 MHz, DMSO-d6) δ 7.40–7.31 (m, 4H), 7.25 (tt, J = 5.5, 2.7Hz, 1H), 3.99–3.89 (m, 1H), 3.71 (t, J = 7.9Hz, 1H), 3.63–3.51 (m, 2H), 3.45 (t, J = 9.2Hz, 1H), 2.61 (s, 3H), 2.47–2.29 (m, 1H), 2.10 (p, J = 9.4Hz, 1H). [No amide NH signal observed]

[0519] Example 21: 1-(5-{[5-(methylsulfanyl)-1,3,4-thiadiazol-2-yl]carbamoyl}-1,3,4-oxadiazol-2-yl)piperidine-3-carboxylic acid (Compound 110) [ka] Steps 1 and 2: tert-Butyl 1-(5-((5-(methylthio)-1,3,4-thiadiazol-2-yl)carbamoyl)-1,3,4-oxadiazol-2-yl)piperidine-3-carboxylate was prepared according to Steps 1-2 of Example 23, starting with tert-butyl piperidine-3-carboxylate instead of piperidine. LCMS (ES, m / z) = 427.0 [M+H] +

[0520] Step 3: A solution of tert-butyl 1-(5-{[5-(methylsulfanyl)-1,3,4-thiadiazol-2-yl]carbamoyl}-1,3,4-oxadiazol-2-yl)piperidine-3-carboxylate (25 mg, 0.059 mmol, 1 equiv) in 1,4-dioxane (4 M) HCl (3 mL) was stirred for 5 h at room temperature. The resulting mixture was stirred for an additional 2 h at room temperature and concentrated under reduced pressure. The crude product was purified by Prep-HPLC (conditions: column, Xselect CSH C18 OBD column 30 × 150 mm 5 μm, n; mobile phase: acetonitrile (MeCN) and water (0.05% TFA), gradient: 15% water (0.05% TFA) and up to 45% water (0.05% TFA) in 8 min) to give 1-(5-{[5-(methylsulfanyl)-1,3,4-thiadiazol-2-yl]carbamoyl}-1,3,4-oxadiazol-2-yl)piperidine-3-carboxylic acid (3.5 mg, 15.94%) as a white solid. LCMS (ES, m / z) = 371.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 4.05-4.01 (m, 1H), 3.85-3.66 (m, 1H), 3.51 - 3.24 (m, 2H), 2.74 (s, 3H), 2.64-2.50 (m, 1H), 2.02 - 2.00 (m, 1H), 1.99-1.98 (m, 3H)

[0521] Example 22: tert-Butyl 3-{[5-(methylsulfanyl)-1,3,4-thiadiazol-2-yl]carbamoyl}-5H,6H,8H-[1,2,4]triazolo[4,3-a]pyrazine-7-carboxylate (Compound 98) [ka] A mixture of 7-tert-butyl 3-ethyl 5H,6H,8H-[1,2,4]triazolo[4,3-a]pyrazine-3,7-dicarboxylate (200 mg, 0.675 mmol, 1.00 equiv.) and 5-(methylsulfanyl)-1,3,4-thiadiazol-2-amine (130 mg, 0.883 mmol, 1.31 equiv.) in tetrahydrofuran (THF) (2 mL) was added dropwise to lithium bis(trimethylsilyl)amide (LiHMDS) (1.5 mL, 1.5 mmol, 2 equiv., 1 M in THF) at 0°C. The resulting mixture was stirred for 1 hour at room temperature under a nitrogen atmosphere. The reaction was quenched with water at 0°C. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC (conditions: column, Xselect CSH C18 OBD column 30 × 150 mm 5 μm, n; mobile phase: acetonitrile (MeCN) and water (0.05% trifluoroacetic acid (TFA)), gradient: 30% water (0.05% TFA) up to 50% water (0.05% TFA) in 10 min; detector, UV 254) to give tert-butyl 3-{[5-(methylsulfanyl)-1,3,4-thiadiazol-2-yl]carbamoyl}-5H,6H,8H-[1,2,4]triazolo[4,3-a]pyrazine-7-carboxylate (29.6 mg, 11% yield) as a white solid. LCMS (ES, m / z) = 398.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 13.60 (br, 1H), 4.80 (s, 2H), 4.35 (t, J = 5.6 Hz, 2H), 3.79 (t, J = 5.6 Hz, 2H), 2.75 (s, 3H), 1.45 (s, 9H)

[0522] Example 23: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(piperidin-1-yl)-1,3,4-oxadiazole-2-carboxamide (Compound 108) [ka] Step 1: To a solution of piperidine (128 mg, 1.503 mmol, 1.00 equiv) in dioxane (3 mL), ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate (240 mg, 1.160 mmol, 0.77 equiv) and diisopropylethylamine (DIPEA) (340 mg, 2.365 mmol, 1.57 equiv) were added. The resulting mixture was stirred for 2 hours at room temperature under a nitrogen atmosphere. The resulting mixture was diluted with water (50 mL). The resulting mixture was extracted with ethyl acetate (EtOAc) (3 × 50 mL). The combined organic layers were washed with water (1 × 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (12:1 petroleum ether / ethyl acetate) to give ethyl 5-(piperidin-1-yl)-1,3,4-oxadiazole-2-carboxylate (50 mg, 14% yield) as a white solid. LCMS (ES, m / z) = 226.0 [M+H] +

[0523] Step 2: The trifluoroacetic acid (TFA) salt of N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(piperidin-1-yl)-1,3,4-oxadiazole-2-carboxamide was prepared from ethyl 5-(piperidin-1-yl)-1,3,4-oxadiazole-2-carboxylate (1 equivalent) and 5-(methylsulfanyl)-1,3,4-thiadiazol-2-amine 2,2,2-trifluoroacetate (1.2 equivalents) according to Example 22. LCMS (ES, m / z) = 327.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 13.57 (br, 1H), 3.61-3.53 (m, 4H), 2.74 (s, 3H), 1.65-1.61 (m, 6H)

[0524] Example 24: N-[5-(methylsulfanyl)-1,3,4-thiadiazol-2-yl]-3-(thiophen-3-yl)-1,2-oxazole-5-carboxamide (Compound 139) [ka] Step 1: To a solution of 3-thiophenecarboxaldehyde (500 mg, 4.458 mmol, 1 equiv.) in methanol (14 mL) was added hydroxylamine hydrochloride (929 mg, 13.369 mmol, 3.00 equiv.). The resulting mixture was stirred overnight at room temperature. The mixture was then diluted with water (30 mL) and extracted with ethyl acetate (EtOAc) (3×50 mL). The combined organic layers were washed with brine (50 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to afford (E)-N-(thiophen-3-ylmethylidene)hydroxylamine (485 mg, 86% yield) as a brown solid. LCMS (ES, m / z) = 128.0 [M+H] +

[0525] Step 2: To a solution of (E)-N-(thiophen-3-ylmethylidene)hydroxylamine (804 mg, 6.323 mmol, 1 equiv.) in dimethylformamide (DMF) (12 mL) and dichloromethane (DCM) (4 mL) was added N-chlorosuccinimide (NCS) (1.01 g, 7.564 mmol, 1.20 equiv.) at room temperature. The resulting mixture was stirred for 30 minutes at room temperature. The mixture was then diluted with water (200 mL) and extracted with ethyl acetate (EtOAc) (3 × 200 mL). The combined organic layers were washed with water (3 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The crude product was used directly in the next step without further purification. LCMS (ES, m / z) = 162.0 [M+H] +

[0526] Step 3: To the above crude product prepared in Step 2, ethyl acetate (EtOAc) (18 mL), ethyl propiolate (1861 mg, 18.970 mmol, 3.00 equiv.), and saturated sodium bicarbonate (aqueous, 9 mL) were added at room temperature. The resulting mixture was stirred overnight at room temperature. The mixture was then diluted with water (20 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine (10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 petroleum ether / ethyl acetate) to afford ethyl 3-(thiophen-3-yl)-1,2-oxazole-5-carboxylate (490 mg, 25% yield) as a brown solid. LCMS (ES, m / z) = 224.00 [M+H] +

[0527] Step 4: To a mixture of ethyl 3-(thiophen-3-yl)-1,2-oxazole-5-carboxylate (444 mg, 1.99 mmol, 1 equiv.) and 5-(methylsulfanyl)-1,3,4-thiadiazol-2-amine (352 mg, 2.39 mmol, 1.20 equiv.) in tetrahydrofuran (4 mL), lithium bis(trimethylsilyl)amide (LiHMDS) (4 mL, 4.0 mmol, 2.00 equiv., 1 M in tetrahydrofuran (THF)) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 4 hours at room temperature. The resulting mixture was diluted with water (20 mL) and extracted with ethyl acetate (EtOAc) (3 × 30 mL). The combined organic layer was washed with brine (30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The crude product (200 mg) was purified by prep-HPLC (conditions: XBridge Prep OBD C18 column, 30 × 150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile (MeCN); flow rate: 60 mL / min; gradient: 15% B to 25% B for 8 min, 25% B; wavelength: 254 nm; RT1 (min): 7.5) to give N-[5-(methylsulfanyl)-1,3,4-thiadiazol-2-yl]-3-(thiophen-3-yl)-1,2-oxazole-5-carboxamide (16.3 mg, 2.5% yield) as a white solid. LCMS (ES, m / z) = 325.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.24 (s, 1H), 7.75 (d, J = 5.2 Hz, 1H), 7.61(s, 1H), 7.59 (d, J = 5.2 Hz, 1H), 2.69 (s, 3H)

[0528] Example 25: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(2-phenylpyrrolidin-1-yl)-1,2,4-oxadiazole-3-carboxamide (Compound 99) [ka] Step 1: To a stirred solution of 2-phenylpyrrolidine (500 mg, 3.396 mmol, 1 equiv.) in dichloromethane (DCM) (8 mL), triethylamine (TEA) (1.03 g, 10.189 mmol, 3.00 equiv.) and BrCN (431 mg, 4.069 mmol, 1.20 equiv.) were added at room temperature. The resulting mixture was stirred for 1 hour at room temperature. The resulting mixture was poured into water and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with water (20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 petroleum ether / ethyl acetate) to afford 2-phenylpyrrolidine-1-carbonitrile (450 mg, 77% yield) as a red oil. LCMS (ES, m / z) = 173 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 7.48 - 7.25 (m, 5H), 4.68 (t, J = 7.2 Hz, 1H), 3.72 - 3.64 (m, 1H), 3.56 - 3.49 (m, 1H), 2.33 - 2.24 (m, 1H), 2.01 - 1.87 (m, 2H), 1.79 - 1.68 (m, 1H)

[0529] Step 2: To a stirred solution of 2-phenylpyrrolidine-1-carbonitrile (100 mg, 0.581 mmol, 1 equiv.) and ethyl (Z)-2-amino-2-(hydroxyimino)acetate (92 mg, 0.696 mmol, 1.20 equiv.) in ethyl acetate (2 mL) was added a solution of ZnCl (0.5 M) in tetrahydrofuran (THF) (1.5 mL, 0.75 mmol, 1.28 equiv.) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 1 hour at 50° C. under a nitrogen atmosphere. To the above stirring mixture, ethanol (EtOH) (1 mL) and acetic acid (AcOH) (0.5 mL) were added at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 1 hour at 100° C. under a nitrogen atmosphere. The resulting mixture was poured into water and extracted with EA (3×50 mL). The combined organic layers were washed with water (10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 petroleum ether / ethyl acetate) to give ethyl 5-(2-phenylpyrrolidin-1-yl)-1,2,4-oxadiazole-3-carboxylate (120 mg, 72% yield) as a colorless oil. LCMS (ES, m / z) = 288 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 7.38 - 7.32 (m, 2H), 7.30 - 7.23 (m, 3H), 5.11 (dd, J = 8.0, 3.6 Hz, 1H), 4.97 (q, J = 7.1 Hz, 2H), 3.97 - 3.88 (m, 1H), 3.78 - 3.68 (m, 1H), 2.05 - 1.81 (m, 4H), 1.27 (t, J = 7.1 Hz, 3H)

[0530] Step 3: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(2-phenylpyrrolidin-1-yl)-1,2,4-oxadiazole-3-carboxamide was prepared from ethyl 5-(2-phenylpyrrolidin-1-yl)-1,2,4-oxadiazole-3-carboxylate (1 equivalent) and 5-(methylthio)-1,3,4-thiadiazol-2-amine (1.2 equivalents) according to Example 22. LCMS (ES, m / z) = 389.10 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 13.40 (br, 1H), 7.39 - 7.32 (m, 2H), 7.31 - 7.25 (m, 3H), 5.16 - 5.11 (m, 1H), 3.99 - 3.92 (m, 1H), 3.83 - 3.74 (m, 1H), 2.74 (s, 3H), 2.08 - 1.96 (m, 2H), 1.92 - 1.84 (m, 2H)

[0531] Example 26: N-[5-(methylsulfanyl)-1,3,4-thiadiazol-2-yl]-5-(oxylidin-2-yl)-1,2,4-oxadiazole-3-carboxamide (Compound 104) [ka] Step 1: To a stirring mixture of ethyl (Z)-2-amino-2-(hydroxyimino)acetate (300 mg, 2.27 mmol, 1.00 equiv.) in dichloromethane (DCM) (3 mL) and diisopropylethylamine (DIPEA) (470 mg, 3.64 mmol, 1.60 equiv.) was added pyridine-2-carbonyl chloride (640 mg, 4.52 mmol, 1.99 equiv.) at −15° C. The resulting mixture was stirred for an additional hour at room temperature. The mixture was then concentrated under reduced pressure to give crude ethyl (Z)-2-(hydroxyimino)-2-(picolinamido)acetate (1.4 g) as a brown solid, which was used directly in the next step without further purification. LCMS (ESI, m / z) = 238.0 [M+H] +

[0532] Step 2: To a stirring mixture of ethyl (Z)-2-(hydroxyimino)-2-(picolinamido)acetate (800 mg, 3.37 mmol, 1.00 equiv.) in dioxane (8 mL), tetra-n-butylammonium fluoride (TBAF) (6.7 mL, 25.6 mmol, 7.60 equiv.) was added. The resulting mixture was stirred at 80° C. for 2 hours. The resulting mixture was diluted with water (20 mL) and extracted with ethyl acetate (EtOAc) (3×20 mL). The combined organic layers were washed with water (2×3 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (1:1 petroleum ether / ethyl acetate) to afford ethyl 5-(pyridin-2-yl)-1,2,4-oxadiazole-3-carboxylate (270 mg, 36% yield) as a white solid. LCMS (ES, m / z) = 220.0 [M+H] +

[0533] Step 3: N-[5-(methylsulfanyl)-1,3,4-thiadiazol-2-yl]-5-(pyridin-2-yl)-1,2,4-oxadiazole-3-carboxamide was prepared from ethyl 5-(pyridin-2-yl)-1,2,4-oxadiazole-3-carboxylate (1 equivalent) and 5-(methylthio)-1,3,4-thiadiazol-2-amine (1.2 equivalents) according to Example 22. LCMS (ES, m / z) = 320.9 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.88 (d, J = 4.0 Hz, 1H), 8.35 (d, J = 8.0 Hz, 1H), 8.19-8.15 (m, 1H), 7.80-7.76 (m, 1H), 2.77 (s, 3H)

[0534] Example 27: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole-2-carboxamide (Compound 106) [ka] Step 1: To a solution of pyridine-2-carbohydrazide (600 mg, 4.38 mmol, 1.00 equiv.) in dichloromethane (DCM) (6 mL), ethyl chloroglyoxylate (657 mg, 4.81 mmol, 1.10 equiv.) and NEt3 (885 mg, 8.75 mmol, 2.00 equiv.) were added at room temperature. The resulting mixture was stirred for 1 hour at room temperature. The resulting mixture was concentrated under reduced pressure. The residue was diluted with acetonitrile (MeCN) (5 mL) and stirred for 30 minutes at room temperature. The solid was collected by filtration, washed with MeCN (3 mL), and dried under reduced pressure to give ethyl 2-oxo-2-(pyridin-2-ylformohydrazide)acetate (1.5 g, 94% yield) as a brown solid. LCMS (ES, m / z) = 238 [M+H] +

[0535] Step 2: To a solution of ethyl 2-oxo-2-(pyridin-2-ylformohydrazide)acetate (1.2 g, 5.06 mmol, 1 equiv.) in dichloroethane (DCE) (12 mL), methyl N-(triethylammoniumsulfonyl)carbamate (Burgess reagent) (5.06 g, 21.2 mmol, 4.2 equiv.) was added at room temperature. The resulting mixture was stirred for 3 hours at 50°C. The resulting solution was diluted with water (10 mL) and extracted with dichloromethane (DCM) (3 x 30 mL). The combined organic layer was washed with water (10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 petroleum ether / ethyl acetate) to give ethyl 5-(pyridin-2-yl)-1,3,4-oxadiazole-2-carboxylate (380 mg, 34% yield) as a white solid. LCMS (ES, m / z) = 220 [M+H] +

[0536] Step 3: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole-2-carboxamide was prepared from ethyl 5-(pyridin-2-yl)-1,3,4-oxadiazole-2-carboxylate (1 equivalent) and 5-(methylsulfanyl)-1,3,4-thiadiazol-2-amine (1.2 equivalents) according to Example 22. LCMS (ES, m / z) = 321.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.84 (d, J = 8.8 Hz, 1H), 8.32 (d, J = 8.8 Hz, 1H), 8.12 - 8.11 (m, 1H), 7.73 - 7.70 (m, 1H), 2.76 (s, 3H)

[0537] Example 28: (R)—N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(2-phenylpiperidin-1-yl)-1,3,4-oxadiazole-2-carboxamide (Compound 121*) and (S)—N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(2-phenylpiperidin-1-yl)-1,3,4-oxadiazole-2-carboxamide (Compound 122*) [ka] Steps 1-2: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(2-phenylpiperidin-1-yl)-1,3,4-oxadiazole-2-carboxamide was prepared according to Example 23 Steps 1-2 from 2-phenylpiperidine instead of piperidine.

[0538] Step 3: The R and S isomers of N-(5-(methylthio)-v1,3,4-thiadiazol-2-yl)-5-(2-phenylpiperidin-1-yl)-1,3,4-oxadiazole-2-carboxamide were separated by chiral HPLC under the following conditions: Column: CHIRAL ART Amylose-SA, 2*25 cm, 5 μm; Mobile phase A: Hex (0.2% FA) - HPLC, Mobile phase B: EtOH:dichloromethane (DCM) = 1:1 - HPLC; Flow rate: 20 mL / min; Gradient: 30% B to 30% B over 15 min; Wavelength: 220 / 254 nm; RT1 (min): 11.55; RT2 (min): 13.93; Sample solvent: MeOH:DCM = 1:1; Injection volume: 0.5 mL; Number of runs: 6.

[0539] (R)—N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(2-phenylpiperidin-1-yl)-1,3,4-oxadiazole-2-carboxamide (Compound 121*), RT2 (min): 13.93, LCMS (ES, m / z) = 403.1 [M+H] + , 1 HNMR (400 MHz, DMSO-d6) δ 13.75 (br, 1H), 7.43-7.41 (m, 2H), 7.34-7.28 (m, 3H), 5.52-5.39 (m, 1H), 4.10-4.07 (m, 1H), 3.27-3.23 (m, 1H), 2.74 (s, 3H), 2.41-2.33 (m, 1H), 2.07-2.01 (m, 1H), 1.68-1.63 (m, 3H), 1.42-1.33 (m, 1H)

[0540] (S)—N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(2-phenylpiperidin-1-yl)-1,3,4-oxadiazole-2-carboxamide (Compound 122*), RT1 (min): 11.55, LCMS (ES, m / z) = 403.1 [M+H] + , 1HNMR (400 MHz, DMSO-d6) δ 13.75 (br, 1H), 7.43-7.41 (m, 2H), 7.34-7.28 (m, 3H), 5.52-5.39 (m, 1H), 4.10-4.07 (m, 1H), 3.27-3.23 (m, 1H), 2.74 (s, 3H), 2.41-2.33 (m, 1H), 2.07-2.01 (m, 1H), 1.68-1.63 (m, 3H), 1.42-1.33 (m, 1H)

[0541] The stereochemistry of compounds 121* and 122* was arbitrarily assigned.

[0542] Example 29: N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]-2-(pyridin-2-ylmethyl)-1,2,3,4-tetrazole-5-carboxamide (Compound 133) [ka] Step 1: To a solution of ethyl 2H-1,2,3,4-tetrazole-5-carboxylate (500 mg, 3.52 mmol, 1.00 equiv.) in N,N-dimethylformamide (DMF) (5 mL), 2-(chloromethyl)pyridine hydrochloride (1.10 g, 6.79 mmol, 1.93 equiv.) and K2CO3 (1459 mg, 10.5 mmol, 3.00 equiv.) were added at room temperature. The resulting mixture was stirred for 5 hours at 50 °C. The resulting mixture was diluted with water (30 mL) and extracted with ethyl acetate (EtOAc) (3 × 50 mL). The combined organic layer was washed with water (2 × 10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 petroleum ether / ethyl acetate) to give ethyl 2-(pyridin-2-ylmethyl)-1,2,3,4-tetrazole-5-carboxylate (340 mg, 40% yield) as an off-white oil. LCMS (ES, m / z) = 234 [M+H] +

[0543] Step 2: N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]-2-(pyridin-2-ylmethyl)-1,2,3,4-tetrazole-5-carboxamide was prepared from ethyl 2-(pyridin-2-ylmethyl)-1,2,3,4-tetrazole-5-carboxylate (1 equivalent) and 5-(methylthio)-1,3,4-thiadiazol-2-amine (1.2 equivalents) according to Example 23, Step 2. LCMS (ES, m / z) = 335.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.70 (d, J = 2.4 Hz, 1H), 8.61 - 8.57 (m, 1H), 7.82 (dd, J = 8.0, 2.0 Hz, 1H), 7.43-7.40 (m, 1H), 6.03 (s, 2H), 2.63 (s, 3H)

[0544] Example 30: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-2-(pyridin-2-yl)-2H-tetrazole-5-carboxamide (Compound 136) [ka] Step 1: To a solution of ethyl 2H-1,2,3,4-tetrazole-5-carboxylate (300 mg, 2.11 mmol, 1.00 equiv.) in methanol (MeOH) (15 mL) and sodium methoxide (NaOMe) (125 mg, 2.31 mmol, 1.10 equiv.) was added methanol (MeOH) (15 mL) and sodium methoxide (NaOMe) (125 mg, 2.31 mmol, 1.10 equiv.) at room temperature. The resulting mixture was stirred overnight at room temperature under nitrogen. The reaction was quenched with saturated NH4Cl (aqueous) at 0 °C. The resulting mixture was extracted with ethyl acetate (EtOAc) (3 × 100 mL). The combined organic layers were washed with water (20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 petroleum ether / EtOAc) to give ethyl 2-(pyridin-2-yl)-1,2,3,4-tetrazole-5-carboxylate (70 mg, 15% yield) as a white solid. LCMS (ES, m / z) = 220.0 [M+H] +

[0545] Step 2: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-2-(pyridin-2-yl)-2H-tetrazole-5-carboxamide was prepared from ethyl 2-(pyridin-2-yl)-1,2,3,4-tetrazole-5-carboxylate (1 equivalent) and 5-(methylthio)-1,3,4-thiadiazol-2-amine (1.2 equivalents) according to Example 23, Step 2. LCMS (ES, m / z) = 321.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.76 (d, J = 4.0 Hz, 1H), 8.28 - 8.22 (m, 2H), 7.78 - 7.76 (m, 1H), 2.77 (s, 3H)

[0546] Example 31: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-2-(pyridin-3-yl)-2H-tetrazole-5-carboxamide (Compound 137) [ka] Step 1: To a stirred solution of ethyl 2H-tetrazole-5-carboxylate (300 mg, 2.11 mmol, 1.00 equiv.) and pyridin-3-ylboronic acid (390 mg, 3.17 mmol, 1.50 equiv.) in dichloroethane (DCE) (3 mL), pyridine (Py) (334 mg, 4.22 mmol, 2.00 equiv.) and Cu(OAc) (765 mg, 4.21 mmol, 2.00 equiv.) were added at room temperature. The resulting mixture was stirred for 2 days at 50 °C under an air atmosphere. The reaction was quenched with water (20 mL) at room temperature and extracted with ethyl acetate (EtOAc) (3 × 50 mL). The combined organic layer was washed with brine (3 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure, and the residue was then purified by C18 reverse flash chromatography to give ethyl 2-(pyridin-3-yl)-2H-tetrazole-5-carboxylate (45 mg, 9% yield) as a colorless oil. LCMS (ES, m / z) = 220.1 [M +H] +

[0547] Step 2: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-2-(pyridin-3-yl)-2H-tetrazole-5-carboxamide was prepared from ethyl 2-(pyridin-3-yl)-1,2,3,4-tetrazole-5-carboxylate (1 equivalent) and 5-(methylthio)-1,3,4-thiadiazol-2-amine (1.2 equivalents) according to Example 22. LCMS (ES, m / z) = 321.1 [M+H] + . 1 HNMR (400 MHz, DMSO-d6) δ 9.38 (s, 1H), 8.86 (d, J= 4.8 Hz, 1H), 8.57 (d, J=8.4 Hz, 1H), 7.74 (dd, J = 8.4, 4.8 Hz, 1H), 2.63 (s, 3H)

[0548] Example 33: 3-((5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)carbamoyl)benzo[c]isoxazole-7-carboxylic acid (Compound 178) [ka] Step 1: Ethyl 7-(dibromomethyl)benzo[c]isoxazole-3-carboxylate (400 mg, 1.10 mmol) was dissolved in ethanol (EtOH) (8.3 mL) / water (2.75 mL) and silver nitrate (416 mg, 2.42 mmol) was added thereto. The resulting solution was stirred at 75° C. for 2 hours. The solution was then filtered, and the filtrate was concentrated to give ethyl 7-formylbenzo[c]isoxazole-3-carboxylate (250 mg, 100% yield), which was used directly in the next step without further purification. LCMS (ES, m / z) = 220.1 [M+1] +

[0549] Step 2: To a stirring solution of ethyl 7-formylbenzo[c]isoxazole-3-carboxylate (130 mg, 0.591 mmol) in acetonitrile (5.9 mL) was added hydrogen peroxide (2.74 mmol). The reaction mixture was slowly heated at 50° C. for 3 days until all the aldehyde was consumed. The solvent was then removed under reduced pressure, and the residue was purified by C18 reverse-phase chromatography to give 3-(ethoxycarbonyl)benzo[c]isoxazole-7-carboxylic acid (70.0 mg, 50% yield) as a yellow solid. LCMS (ES, m / z) = 236.1 [M+1] +

[0550] Step 3: An oven-dried vial equipped with a stir bar was charged with a solution of 3-(ethoxycarbonyl)benzo[c]isoxazole-7-carboxylic acid (20.0 mg, 0.085 mmol), 5-(2-chlorophenyl)-1,3,4-thiadiazol-2-amine (36.0 mg, 0.17 mmol) in dry toluene (850 μL) under argon. Lithium bis(trimethylsilyl)amide (LiHMDS) (340 μL, 0.34 mmol) was added slowly with vigorous stirring at room temperature, and the reaction mixture was stirred at room temperature until complete conversion. The reaction mixture was quenched with NHCl and extracted with 2-methyltetrahydrofuran (2-MeTHF). The organic layer was washed with brine, dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography over silica gel followed by C18 reverse phase chromatography to give 3-((5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)carbamoyl)benzo[c]isoxazole-7-carboxylic acid (2.00 mg, 5.9% yield). LCMS (ES, m / z) = 401.1 [M+1] + . 1 H NMR (400 MHz, DMSO-d): δ H 8.56 (1H, s), 8.04 (2H, s), 7.59 (1H, s), 7.44-7.46 (2H, m), 7.27 (1H, s). [COOH and NH signals not observed]

[0551] Example 34: N-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyethoxy)isoxazole-5-carboxamide (Compound 175) [ka] Step 1: Potassium carbonate (1.20 equiv., 450 mg, 3.25 mmol) was added to a solution of methyl 3-hydroxyisoxazole-5-carboxylate (1.00 equiv., 400 mg, 2.71 mmol) in acetone (6 mL), followed by the addition of 2-bromoethyl methyl ether (1.00 equiv., 255 μL, 2.71 mmol). The reaction mixture was refluxed for 22 h. The acetone was then removed under reduced pressure, and the residue was dissolved in water and extracted with ethyl acetate (20 × 2 mL). The combined organic extracts were dried and concentrated to dryness. The residue was purified by flash chromatography over silica gel (0–10% ethyl acetate (EtOAc) / hexanes) to afford methyl 3-(2-methoxyethoxy)isoxazole-5-carboxylate (340 mg, 62% yield) as a white solid. LCMS (ESI, m / z) = 202.1 [M+1] + . 1 H NMR (400 MHz, CDCl3) δ 6.58 (s, 1H), 4.45 (t, J = 4.3Hz, 2H), 3.95 (s, 3H), 3.75 (t, J = 4.3Hz, 2H), 3.44 (s, 3H)

[0552] Step 2: Lithium bis(trimethylsilyl)amide (LiHMDS) was added to a suspension of methyl 3-(2-methoxyethoxy)isoxazole-5-carboxylate (1.00 equiv., 50 mg, 0.249 mmol) and 5-(2-chlorophenyl)-1,3,4-thiadiazol-2-amine (1.00 equiv., 55 mg, 0.249 mmol) in tetrahydrofuran (THF) (2 mL). The reaction mixture was refluxed for 5 h. The reaction mixture was then concentrated to dryness, and the residue was purified by flash chromatography on silica gel (0-10% MeOH / dichloromethane (DCM)). The appropriate fractions were combined and concentrated to dryness, then the residue was dissolved in CHCN / HO and lyophilized to give N-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyethoxy)isoxazole-5-carboxamide (20 mg, 21% yield) as a white solid. LCMS (ESI, m / z) = 381.1 [M+1] + .1 H NMR (400 MHz, DMSO-d6) δ 8.15 (d, J = 7.5Hz, 1H), 7.71 (d, J = 7.8Hz, 1H), 7.61 - 7.53 (m, 2H), 7.2 (s, 1H), 4.38 (t, J=4.1Hz, 2H), 3.69 (t, J=4.1Hz, 2H), 3.31 (s, 3H)

[0553] Example 35: 5-(5-chlorothiophen-2-yl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)isoxazole-3-carboxamide (Compound 95) [ka] To a solution of 5-(5-chlorothiophen-2-yl)-1,2-oxazole-3-carboxylic acid (200 mg, 0.871 mmol, 1.00 equiv.) in acetonitrile (MeCN) (2 mL), N-methylimidazole (NMI) (143 mg, 1.742 mmol, 2.00 equiv.) and chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (TCFH) (293 mg, 1.045 mmol, 1.20 equiv.) were added at room temperature. The resulting mixture was stirred for 10 minutes at room temperature. To the above mixture, 5-(methylsulfanyl)-1,3,4-thiadiazol-2-amine (141 mg, 0.958 mmol, 1.10 equiv.) was added. The resulting mixture was stirred for 2 hours at room temperature. The precipitated solid was collected by filtration and washed with acetonitrile (3 × 2 mL). The crude product (260 mg) was purified by Prep-HPLC (conditions: XBridge Prep OBD C18 column, 30 × 150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile (MeCN); flow rate: 60 mL / min; gradient: 15% B to 25% B for 8 min, 25% B; wavelength: 254 nm) to give 5-(5-chlorothiophen-2-yl)-N-[5-(methylsulfanyl)-1,3,4-thiadiazol-2-yl]-1,2-oxazole-3-carboxamide (154 mg, 49% yield) as an off-white solid. LCMS (ES, m / z) = 359.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 13.67 (br, 1H), 7.74 (d, J = 4.0Hz, 1H), 7.47 (s, 1H), 7.37 (d, J = 4.0 Hz, 1H), 2.76 (s, 3H)

[0554] Example 36: N-(2-chlorophenyl)-5-oxo-4H-[1,2,3]triazolo[1,5-a]pyrimidine-3-carboxamide (Compound 97) [ka] Step 1: To a solution of ethyl propiolate (10 g, 102 mmol, 1.00 equiv.) in tert-butanol (tBuOH) (200 mL) and water (20 mL), potassium fluoride (KF) (11.84 g, 203.8 mmol, 2.00 equiv.) and azidotrimethylsilane (TMSN3) (23.47 g, 203.7 mmol, 2.00 equiv.) were added. The mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with water (300 mL). The resulting solution was extracted with ethyl acetate (5 × 300 mL), and the organic layers were combined. The organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give ethyl (2E)-3-azidoprop-2-enoate (11.1 g, 77% yield) as a yellow oil. LCMS (ES, m / z) = 142 [M+H] +

[0555] Step 2: To a stirred solution of sodium methoxide (NaOMe) (30%) in methanol (MeOH) (165 mL) was added dropwise a solution of ethyl (2E)-3-azidoprop-2-enoate (11.1 g, 78.6 mmol, 1.00 equiv.) and ethyl cyanoacetate (9.79 g, 86.5 mmol, 1.10 equiv.) in methanol (110 mL) at room temperature. The reaction mixture was stirred at room temperature for 0.5 hours. The precipitated solid was then collected by filtration, washed with methanol (10 × 50 mL), and dried under reduced pressure to give methyl 5-oxo-4H-[1,2,3]triazolo[1,5-a]pyrimidine-3-carboxylate (2.0 g, 6.5% yield) as a light yellow solid. LCMS (ES, m / z) = 195 [M+H] +

[0556] Step 3: To a solution of methyl 5-oxo-4H-[1,2,3]triazolo[1,5-a]pyrimidine-3-carboxylate (30 g, 154 mmol, 1.00 equiv.) in methanol (MeOH) (500 mL) was added sodium hydroxide (NaOH) (aqueous, 150 mL, 10 M). The mixture was stirred at room temperature for 0.5 h. The precipitated solid was then collected by filtration and washed with methanol (5 × 50 mL) to give the crude product. The crude product was diluted with methanol and water (20 / 1) (600 mL) overnight. The solid was then collected by filtration, washed with methanol (10 × 20 mL), and dried under reduced pressure to give sodium 5-oxo-4,5-dihydro-[1,2,3]triazolo[1,5-a]pyrimidine-3-carboxylate (20.8 g, 75% yield) as a light yellow solid. LCMS (ES, m / z) = 181.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 7.90 (d, J = 5.6 Hz, 1H), 5.55 (d, J = 5.6 Hz, 1H)

[0557] Step 4: N-(2-chlorophenyl)-5-oxo-4H-[1,2,3]triazolo[1,5-a]pyrimidine-3-carboxamide was prepared from sodium 5-oxo-4,5-dihydro-[1,2,3]triazolo[1,5-a]pyrimidine-3-carboxylate (1.5 equivalents) and 2-chloroaniline (1 equivalent) according to Example 35. LCMS (ES, m / z) = 290.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 8.56 (d, J = 8.4, 1H), 7.99 (d, J = 5.6 Hz, 1H), 7.53 (d, J = 8.0, 1H), 7.40 - 7.31 (m, 1H), 7.13-7.09 (m, 1H), 5.63 (d, J = 6.0 Hz, 1H)

[0558] Example 37: N-(5-(thiazol-4-yl)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide (Compound 127) [ka] Step 1: To a stirred solution of thiazole-4-carbonitrile (400 mg, 3.632 mmol, 1 equiv.) in trifluoroacetic acid (TFA) (4 mL) was added hydrazinecarbothioamide (364 mg, 3.99 mmol, 1.10 equiv.) at room temperature. The resulting mixture was stirred for 2 hours at 80° C. The resulting solution was concentrated under reduced pressure, and the residue was then diluted with water (15 mL). The pH of the mixture was then adjusted to 10 with NaOH (2 M). The precipitated solid was collected by filtration to give 5-(thiazol-4-yl)-1,3,4-thiadiazol-2-amine (500 mg) as a yellow solid. LCMS (ES, m / z) = 185 [M+H] +

[0559] Step 2: N-(5-(thiazol-4-yl)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide was prepared from benzo[c]isoxazole-3-carboxylic acid (1.0 equiv.) and 5-(thiazol-4-yl)-1,3,4-thiadiazol-2-amine (1.0 equiv.) according to Example 35. LCMS (ES, m / z) = 330.1 [M+H] + . 1 HNMR(400 MHz, DMSO-d6) δ 14.71 (br, 1H), 9.35 (s, 1H), 8.55 (s, 1H), 8.14 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 9.2 Hz, 1H), 7.58-7.54 (m, 1H), 7.41-7.37 (m, 1H)

[0560] Example 38: N-(5-(pyrimidin-2-yl)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide (Compound 148) [ka] Step 1: To a solution of 5-bromo-1,3,4-thiadiazol-2-amine (2.00 g, 11.1 mmol, 1.0 equiv.) and 2,5-hexanedione (1.27 g, 11.1 mmol, 1 equiv.) in toluene (10 mL) was added p-toluenesulfonic acid monohydrate (TsOH) (0.57 g, 3.33 mmol, 0.3 equiv.). The mixture was stirred at 110 °C for 2 h. The resulting mixture was concentrated under reduced pressure, and the crude residue was purified by flash chromatography on silica gel (5:1 petroleum ether / ethyl acetate) to give 2-bromo-5-(2,5-dimethylpyrrol-1-yl)-1,3,4-thiadiazole (1.5 g, 37% yield) as a brown solid. LCMS (ES, m / z) = 258.0 [M+1] +

[0561] Step 2: To a solution of 2-bromo-5-(2,5-dimethylpyrrol-1-yl)-1,3,4-thiadiazole (200 mg, 0.775 mmol, 1 equiv.) in N,N-dimethylformamide (DMF) (1 mL) was added CsF (353 mg, 2.32 mmol, 3 equiv.), tetrakis(triphenylphosphine)palladium (Pd(PPh3)4) (89.5 mg, 0.078 mmol, 0.1 equiv.), CuI (14.8 mg, 0.078 mmol, 0.1 equiv.), and 2-(tributylstannyl)pyrimidine (286 mg, 0.775 mmol, 1 equiv.). The mixture was stirred at 80 °C under a nitrogen atmosphere. After 2 h, the reaction was quenched by the addition of water (10 mL) at room temperature. The aqueous layer was extracted with ethyl acetate (EtOAc) (3 x 10 mL) and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (5:1 petroleum ether / ethyl acetate) to give 2-[5-(2,5-dimethylpyrrol-1-yl)-1,3,4-thiadiazol-2-yl]pyrimidine (160 mg, 56% yield) as a brown liquid. LCMS (ES, m / z) = 258.1 [M+1] +

[0562] Step 3: To a solution of trifluoroacetic acid (TFA) (1.00 mL) and HO (1.00 mL) was added 2-[5-(2,5-dimethylpyrrol-1-yl)-1,3,4-thiadiazol-2-yl]pyrimidine (160 mg, 0.622 mmol, 1 equiv.). The mixture was stirred at rt for 2 h. The resulting mixture was then concentrated under reduced pressure. The mixture was basified to pH 10 with saturated NaHCO (aqueous). The resulting mixture was extracted with ethyl acetate (EtOAc) (3 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC (conditions: Xselect CSH C18 OBD column 30 × 150 mm 5 μm, n; mobile phase, acetonitrile (MeCN) and water (0.05% trifluoroacetic acid (TFA)), gradient: 3% water (0.05% TFA) up to 10% water (0.05% TFA) in 8 min; detector, UV 254 nm) to give 5-(pyrimidin-2-yl)-1,3,4-thiadiazol-2-amine (60 mg, 86% yield) as an off-white solid. LCMS (ES, m / z) = 180.1 [M+1] +

[0563] Step 4: The trifluoroacetic acid (TFA) salt of N-(5-(pyrimidin-2-yl)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide was prepared from 5-(pyrimidin-2-yl)-1,3,4-thiadiazol-2-amine (1 equivalent) and benzo[c]isoxazole-3-carboxylic acid (1.2 equivalents) according to Example 35. LCMS (ES, m / z) = 325.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ 9.02 (d, J = 4.9 Hz, 2H), 8.15 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.67-7.62 (m, 1H), 7.57-7.55 (m, 1H), 7.40-7.38 (m, 1H)

[0564] Example 39A: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(phenylamino)benzo[c]isoxazole-3-carboxamide (Compound 162) [ka] Step 1: Potassium t-butoxide (2.78 g, 24.8 mmol) was suspended in N,N-dimethylformamide (DMF) (20 mL) and cooled in an ice bath. A solution of 1-bromo-4-nitrobenzene (2.00 g, 9.90 mmol) and ethyl chloroacetate (1.06 mL, 9.90 mmol) in DMF (9.9 mL) was then added dropwise under argon. The resulting purple solution was stirred at 0 °C for 2.5 hours. Upon completion, 3 N HCl (9.6 mL, 28.7 mmol) was added dropwise. The resulting solution was diluted with water and extracted with ethyl acetate (EtOAc). The organic extracts were combined, washed with brine, dried over sodium sulfate, and concentrated to give ethyl 2-(5-bromo-2-nitrophenyl)acetate (1.90 g, 67% yield) as an oil. LCMS (ES, m / z) = 288.0 / 290.0[M+1] +

[0565] Step 2: 2-(5-Methyl-2-nitrophenyl)acetic acid (1.50 g, 5.21 mmol) was dissolved in N,N-dimethylformamide (DMF) (26 mL) and treated successively with triethylamine (3.63 mL, 26.0 mmol) and chlorotrimethylsilane (TMSCl) (3.30 mL, 26.0 mmol). The resulting mixture was stirred at rt for 5 days. The reaction mixture was then poured into ice-cold dilute HCl and extracted with ethyl acetate (EtOAc). The organic phase was collected, concentrated, and purified by flash chromatography through silica gel to give ethyl 5-bromobenzo[c]isoxazole-3-carboxylate (0.80 g, 57% yield). LCMS (ES, m / z) = 269.9 / 271.9 [M+1] +

[0566] Step 3: Ethyl 5-bromobenzo[c]isoxazole-3-carboxylate (60.0 mg, 0.222 mmol), aniline (24.8 mg, 0.267 mmol), and potassium phosphate tribasic (94.3 mg, 0.444 mmol) were mixed in toluene (2.2 mL). The mixture was degassed with argon, then chloro(crotyl)(2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl)palladium(II) (13.5 mg, 0.022 mmol) was added and heated at 110 °C until the starting material was completely consumed. Upon completion, the reaction mixture was cooled, diluted with ethyl acetate (EtOAc), washed with water, brine, dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography on silica gel (0-40% EtOAc / hexanes) to give ethyl 5-(phenylamino)benzo[c]isoxazole-3-carboxylate (30.0 mg, 48% yield). LCMS (ES, m / z) = 283.1 [M+1] +

[0567] Step 4: Ethyl 5-(phenylamino)benzo[c]isoxazole-3-carboxylate (50.0 mg, 0.177 mmol) was dissolved in tetrahydrofuran (THF) (886 μL) / HO (886 μL) and 1N lithium hydroxide (LiOH / THF) solution (213 μL, 0.213 mmol) was added. The solution was stirred at rt until complete conversion of the starting material. Amberlite-120[H] was then added to acidify the reaction mixture and then removed by filtration. The filtrate was concentrated to give 5-(phenylamino)benzo[c]isoxazole-3-carboxylic acid (48.0 mg, 100% yield), which was used directly in the next step without further purification. LCMS (ES, m / z) = 255.0 [M+1] +

[0568] Step 5: 5-(Phenylamino)benzo[c]isoxazole-3-carboxylic acid (50.0 mg, 0.197 mmol), 1-methylimidazole (54.9 μL, 0.688 mmol), 2-amino-5-(methylthio)-1,3,4-thiadiazole (43.4 mg, 0.295 mmol), and 1,8-diazabicyclo[5.4.0]undec-7-ene (29.9 mg, 0.197 mmol) were dissolved in anhydrous N,N-dimethylformamide (DMF) (1.97 mL). Chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (TCFH) (548 mg, 0.216 mmol) was added. The reaction mixture was stirred at rt until complete conversion. The reaction mixture was diluted with ethyl acetate (EtOAc), washed with water, brine, dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography over silica gel to give N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(phenylamino)benzo[c]isoxazole-3-carboxamide (60.0 mg, 80% yield) as an orange powder. LCMS (ES, m / z) = 384.1 [M+1] + . 1 H NMR (400 MHz, CHCl3-d): δ H 10.11 (1H, s), 7.67 (1H, d, J = 9.5 Hz), 7.40 (2H, t, J = 7.7 Hz), 7.35 (1H, s), 7.23 (2H, d, J = 7.9 Hz), 7.14 (2H, t, J = 8.2 Hz), 6.08 (1H, s), 2.79 (3H, s)

[0569] Example 39B: N-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyethyl)isoxazole-5-carboxamide (Compound 169) [ka] Step 1: To a solution of ethyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)isoxazole-5-carboxylate (1.11 g, 3.67 mmol) in tetrahydrofuran (THF) (12 mL) at 10° C., tetra-n-butylammonium fluoride (TBAF) (5.51 mL, 5.51 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The mixture was quenched with water and subsequently extracted with ethyl acetate (EtOAc). The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by flash chromatography over silica gel (0-40% EtOAc / hexanes) to afford ethyl 3-(2-hydroxyethyl)isoxazole-5-carboxylate (410 mg, 60% yield) as a colorless oil. LCMS (ES, m / z) = 186.1 [M+1] +

[0570] Step 2: Ethyl 3-(2-hydroxyethyl)isoxazole-5-carboxylate (100 mg, 0.540 mmol) was dissolved in tetrahydrofuran (THF) (5.4 mL). The solution was cooled in an ice-water bath, and sodium hydride (25.9 mg of a 60% oil dispersion, 0.648 mmol) was added. After stirring for 10 min, methyl iodide (50.4 μL, 0.810 mmol) was added. The resulting mixture was warmed to rt and continued stirring at rt overnight. NaH (2 equiv.) and CHCl (4 equiv.) were added, and stirring at rt was continued for an additional 1 h. Amberlite IR-120[H] was then added to acidify the reaction mixture. The resin was removed by filtration, and the filtrate was concentrated to give crude 3-(2-methoxyethyl)isoxazole-5-carboxylic acid (90 mg, 78% yield), which was used in the next step without further purification. LCMS (ES, m / z) = 172.1 [M+1] +

[0571] Step 3: N-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyethyl)isoxazole-5-carboxamide was prepared according to Step 5 of Example 39A using 3-(2-methoxyethyl)isoxazole-5-carboxylic acid. LCMS (ES, m / z) = 365.1 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.12 (1H, d, J = 7.4 Hz), 7.69 (1H, d, J = 7.8 Hz), 7.51-7.59 (2H, m), 7.43 (1H, s), 3.64 (2H, t, J = 6.1 Hz), 3.27 (3H, s), 2.96 (2H, t, J = 6.1 Hz). [NH signal not observed]

[0572] Example 40: N-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)-3-(methoxymethyl)isoxazole-5-carboxamide (Compound 170) [ka] Step 1: To a solution of methyl 3-methylisoxazole-5-carboxylate (1.00 g, 7.09 mmol) in carbon tetrachloride (35 mL), N-bromosuccinimide (NBS) (1.51 g, 8.50 mmol) and 2,2'-azobis(2-methylpropionitrile) (AIBN) (175 mg, 1.06 mmol) were added at room temperature. The resulting mixture was stirred at 90 °C. After 2 days, the reaction mixture was cooled to rt, filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (0-10% ethyl acetate (EtOAc) / hexanes) to afford methyl 3-(bromomethyl)isoxazole-5-carboxylate (0.51 g, 33% yield) as a white solid. LCMS (ES, m / z) = 219.9 / 221.9 [M+1] +

[0573] Step 2: Methyl 3-(bromomethyl)isoxazole-5-carboxylate (100 mg, 0.455 mmol) and 18-Crown-6 (36.0 mg, 0.136 mmol) were dissolved in tetrahydrofuran (THF) (1.5 mL). Sodium methoxide (NaOMe) (31.2 μL, 0.545 mmol) was then added, and the reaction mixture was warmed to rt and continued stirring overnight. NaOMe (1 equivalent) and 18-Crown-6 (1 equivalent) were added, and the reaction mixture was heated at 65° C. for 1 h. The reaction mixture was then cooled to rt and acidified with Amberlite IR-120 [H]. The resin was filtered off, and the filtrate was concentrated. The residue was dissolved in anhydrous THF and cooled in an ice-water bath. Sodium hydride (NaH) (36.4 mg, 0.909 mmol) was added. After stirring at 0 °C for 5 min, CHI (141 μL, 2.27 mmol) was added, and the mixture was stirred at rt overnight, then acidified with Amberlite IR-120 [H]. The resin was filtered off, the filtrate was concentrated, and the residue was purified by C18 reverse-phase chromatography to give 3-(methoxymethyl)isoxazole-5-carboxylic acid (35 mg, 49% yield). LCMS (ES, m / z) = 158.1 [M+1] +

[0574] Step 3: N-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)-3-(methoxymethyl)isoxazole-5-carboxamide was prepared according to Step 5 of Example 39A using 3-(methoxymethyl)isoxazole-5-carboxylic acid. LCMS (ES, m / z) = 351.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.13 (1H, d, J = 7.4 Hz), 7.69 (1H, d, J = 7.7 Hz), 7.49-7.58 (3H, m), 4.58 (2H, s), 3.33 (3H, s). [NH signal not observed]

[0575] Example 41: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-4,5-dihydroisoxazolo[4,5-h]quinoline-3-carboxamide (Compound 180) [ka] Step 1: Sodium hydride (544 mg, 13.6 mmol) was added portionwise to a solution of 7,8-dihydroquinolin-5(6H)-one (1.00 g, 6.79 mmol) in tetrahydrofuran (THF) (50 mL), and the resulting mixture was refluxed for 15 minutes. Diethyl oxalate (969 μL, 7.13 mmol) was added, and the reaction was refluxed for 1 hour. Upon completion of the alkylation, 30 mL of a 1:9 solution of concentrated HCl in ethanol (EtOH) was added, followed by hydroxylamine hydrochloride (496 mg, 7.13 mmol). The mixture was refluxed for 1 hour until complete formation of the oxime. The solvent was removed under reduced pressure, and the resulting residue was suspended in 100 mL of toluene. p-Toluenesulfonic acid monohydrate (TsOH) (1.29 g, 6.79 mmol) was added, and the mixture was refluxed for 40 hours. The toluene was removed under reduced pressure, and the crude mixture was dissolved in 100 mL of MeOH and stirred for 1 h. The remaining solids were removed by filtration, and the filtrate was concentrated. The crude material was purified by C18 reverse-phase chromatography (5-55% MeOH / water + 0.1% HCl) to give ethyl 4,5-dihydroisoxazolo[4,5-h]quinoline-3-carboxylate (102 mg, 6.1% yield). 1 H NMR (DMSO-d6, 400 MHz): δ 8.50 (1H, d, J = 4.8 Hz), 7.81 (1H, d, J = 7.7 Hz), 7.40 (1H, dd, J = 7.7, 4.8 Hz), 4.38 (2H, q, J = 7.1 Hz), 3.12 (2H, t, J = 7.9 Hz), 2.97 (2H, t, J = 7.9 Hz), 1.33 (3H, t, J = 7.1 Hz)

[0576] Step 2: Ethyl 4,5-dihydroisoxazolo[4,5-h]quinoline-3-carboxylate was solubilized in MeOH (4 mL) and water (1 mL). LiOH (100 μL, 3N aqueous solution) was added, and the reaction mixture was stirred for 1 h. Upon completion, the mixture was quenched with saturated aqueous NH4Cl, treated with DOWEX-120 resin until acidic, filtered, and lyophilized. The resulting compound was purified by C18 reverse-phase chromatography (10–55% MeCN / water + 0.1% HCl) to give 4,5-dihydroisoxazolo[4,5-h]quinoline-3-carboxylic acid (8.0 mg, 18% yield). 1 H NMR (DMSO-d6, 400 MHz): δ 8.49 (1H, d, J = 4.8 Hz), 7.80 (1H, d, J = 7.7 Hz), 7.39 (1H, dd, J = 7.7, 4.9 Hz), 3.10 (2H, t, J = 8.0 Hz), 2.96 (2H, t, J = 7.9 Hz)

[0577] Step 3: 4,5-Dihydroisoxazolo[4,5-h]quinoline-3-carboxylic acid (8.00 mg, 37 μmol), 2-amino-5-(methylthio)-1,3,4-thiadiazole (8.34 mg, 56 μmol), chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (TCFH) (11.4 mg, 41 μmol), and N-methylimidazole (NMI) (10 μL, 130 μmol) were stirred in N,N-dimethylformamide (DMF) (500 μL) at room temperature. After 2 h, NaOH (2N aqueous solution, 0.25 mL, 0.5 mmol) was added, and the mixture was stirred at room temperature. After 1 h, the reaction mixture was directly purified by C18 reverse-phase chromatography (10–55% MeCN / water + 0.1% formic acid) to give N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-4,5-dihydroisoxazolo[4,5-h]quinoline-3-carboxamide (2.5 mg, 20% yield). LCMS (ES, m / z) = 346.1 [M+1] + . 1H NMR (DMSO-d6, 400 MHz): δ 8.50 (1H, d, J = 4.9 Hz), 7.81 (1H, d, J = 7.7 Hz), 7.40 (1H, dd, J = 7.7, 4.8 Hz), 3.12 (2H, t, J = 7.7 Hz), 3.02 (2H, t, J = 7.8 Hz), 2.71 (3H, s)

[0578] Example 42: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(phenylthio)benzo[c]isoxazole-3-carboxamide (Compound 163) [ka] Step 1: Ethyl 5-bromobenzo[c]isoxazole-3-carboxylate (550 mg, 2.04 mmol) prepared in Example 39A was dissolved in tetrahydrofuran (THF) (10 mL) / HO (10 mL), and 1N lithium hydroxide (2.44 mL, 2.44 mmol) was added. The solution was stirred at rt until complete conversion of the starting material. Amberlite-120[H] was then added to acidify the reaction mixture, which was then removed by filtration. The filtrate was concentrated. The residue was dissolved in anhydrous CHCl (17 mL), and t-butanol (296 μL, 3.10 mmol) and triethylamine (288 μL, 2.07 mmol) were added. The solution was cooled in an ice-water bath. 1-Methylimidazole (576 μL, 7.23 mmol) and chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (TCFH) (603 mg, 2.27 mmol) were added sequentially. The reaction mixture was allowed to warm to room temperature. N,N-Dimethylformamide (DMF) (3.4 mL) was added to form a homogeneous mixture. The resulting solution was stirred overnight. The reaction mixture was then diluted with ethyl acetate (EtOAc), washed with water, brine, dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography over silica gel to give tert-butyl 5-bromobenzo[c]isoxazole-3-carboxylate (440 mg, 71% yield) as a light yellow solid. LCMS (ES, m / z) = 298.0 / 300.0 [M+1] +

[0579] Step 2: tert-Butyl 5-bromobenzo[c]isoxazole-3-carboxylate (200 mg, 0.671 mmol), thiophenol (82.7 μL, 0.805 mmol), and cesium carbonate (262 mg, 0.805 mmol) were mixed in dimethyl sulfoxide (DMSO) (6.7 mL). The mixture was stirred at rt for 10 minutes and then heated at 90° C. under light for 1 hour. Upon completion, the reaction mixture was cooled and then diluted with ethyl acetate (EtOAc). The organic phase was washed with water, then brine, and dried over sodium sulfate. The solvent was then removed, and the residue was purified by flash chromatography over silica gel to give tert-butyl 5-(phenylthio)benzo[c]isoxazole-3-carboxylate (190 mg, 87% yield). LCMS (ES, m / z) = 328.1 [M+1] +

[0580] Step 3: tert-Butyl 5-(phenylthio)benzo[c]isoxazole-3-carboxylate (60.0 mg, 0.183 mmol) and 1,3-dimethoxybenzene (48.0 μL, 0.366 mmol) were dissolved in CHCl (1.7 mL) and trifluoroacetic acid (TFA) (167 μL) was added dropwise. The solution was stirred at rt until complete. The solvent was then removed, and the resulting residue was purified by flash chromatography over silica gel to give 5-(phenylthio)benzo[c]isoxazole-3-carboxylic acid (50.0 mg, 100% yield). LCMS (ES, m / z) = 272.0 [M+1] +

[0581] Step 4: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(phenylthio)benzo[c]isoxazole-3-carboxamide was prepared according to Step 5 of Example 39A using 5-(phenylthio)benzo[c]isoxazole-3-carboxylic acid. LCMS (ES, m / z) = 401.1 [M+1] + . 1H NMR (400 MHz, DMSO-d6) δ 7.81 (1H, d, J = 9.5 Hz), 7.44-7.49 (4H, m), 7.32 (1H, d, J = 9.4 Hz), 2.72 (3H, s). [NH signal not observed]

[0582] Example 43: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(phenylsulfonyl)benzo[c]isoxazole-3-carboxamide (Compound 164) [ka] Step 1: tert-Butyl 5-(phenylthio)benzo[c]isoxazole-3-carboxylate (130 mg, 0.397 mmol), prepared in Example 42, was dissolved in CHCl (4 mL) and 3-chloroperoxybenzoic acid (mCPBA) (151 mg, 0.874 mmol) was slowly added. The resulting solution was stirred at rt. Upon completion, the reaction mixture was diluted with ethyl acetate (EtOAc), washed with 10% NaSO, water, brine, dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography over silica gel (0–30% EtOAc / hexanes) to give tert-butyl 5-(phenylsulfonyl)benzo[c]isoxazole-3-carboxylate (140 mg, 98% yield). LCMS (ES, m / z) = 360.1 [M+1] +

[0583] Step 2: tert-Butyl 5-(phenylsulfonyl)benzo[c]isoxazole-3-carboxylate (60.0 mg, 0.167 mmol) was dissolved in CHCl (1.5 mL) and trifluoroacetic acid (TFA) (152 μL) was added dropwise. The solution was stirred at rt until completion. The solvent was then removed to give 5-(phenylsulfonyl)benzo[c]isoxazole-3-carboxylic acid as a white solid (quantitative yield), which was used directly in the next step without further purification. LCMS (ES, m / z) = 304.0 [M+1] +

[0584] Step 3: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-(phenylsulfonyl)benzo[c]isoxazole-3-carboxamide was prepared according to Step 5 of Example 39A using 5-(phenylsulfonyl)benzo[c]isoxazole-3-carboxylic acid. LCMS (ES, m / z) = 433.1 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.87 (1H, s), 8.03 (2H, d, J = 7.7 Hz), 7.94 (1H, d, J = 9.4 Hz), 7.70-7.77 (2H, m), 7.65 (2H, t, J = 7.5 Hz), 2.72 (3H, s). [NH signal not observed]

[0585] Example 44: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-phenoxybenzo[c]isoxazole-3-carboxamide (Compound 165) [ka] Step 1: tert-Butyl 5-bromobenzo[c]isoxazole-3-carboxylate (200 mg, 0.671 mmol), prepared in Example 39A, phenol (94.7 mg, 1.01 mmol), and potassium phosphate tribasic (285 mg, 1.34 mmol) were mixed in toluene (3.35 mL). The mixture was degassed with argon and then [ t BuBrettPhos Pd(allyl)]OTf (107 mg, 0.134 mmol) was added and heated at 110 °C for 3 h. The reaction mixture was cooled and diluted with ethyl acetate (EtOAc). The organic phase was washed with water, brine, and dried over sodium sulfate. The solvent was then removed and the residue was purified by flash chromatography over silica gel to give tert-butyl 5-phenoxybenzo[c]isoxazole-3-carboxylate (50.0 mg, 24% yield). LCMS (ES, m / z) = 312.1 [M+1] +

[0586] Step 2: tert-Butyl 5-phenoxybenzo[c]isoxazole-3-carboxylate (50.0 mg, 0.161 mmol) was dissolved in CHCl (1.5 mL) and trifluoroacetic acid (TFA) (146 μL) was added dropwise. The solution was allowed to stir at rt overnight until complete. The solvent was then removed to give 5-phenoxybenzo[c]isoxazole-3-carboxylic acid (40 mg, 98% yield), which was used without further purification. LCMS (ES, m / z) = 256.0 [M+1]

[0587] Step 3: N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-5-phenoxybenzo[c]isoxazole-3-carboxamide was prepared according to Step 5 of Example 39A using 5-phenoxybenzo[c]isoxazole-3-carboxylic acid. LCMS (ES, m / z) = 385.1 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ 7.92 (1H, d, J = 9.5 Hz), 7.50 (2H, t, J = 7.7 Hz), 7.43 (1H, d, J = 9.7 Hz), 7.30 (1H, t, J = 7.4 Hz), 7.21 (2H, d, J = 7.9 Hz), 7.05 (1H, s), 2.71 (3H, s). [NH signal not observed]

[0588] Example 45: 5-(hydroxy(phenyl)methyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide (Compound 166) [ka] Step 1: Ethyl 5-methylbenzo[c]isoxazole-3-carboxylate (2.70 g, 13.2 mmol) was dissolved in tetrahydrofuran (THF) (22 mL) / HO (22 mL) and 1N lithium hydroxide (15.8 mL, 15.8 mmol) was added. The solution was stirred until the starting material was completely converted. Amberlite-120[H] was then added to acidify the reaction mixture and then removed by filtration. The filtrate was concentrated, and the residue was dissolved in anhydrous N,N-dimethylformamide (DMF) (45 mL), tBuOH (1.94 mL, 20.3 mmol), and triethylamine (1.89 mL, 13.5 mmol). The solution was cooled in an ice bath. 1-Methylimidazole (3.78 mL, 47.4 mmol) and chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (TCFH) (4.18 g, 14.9 mmol) were added sequentially. The reaction mixture was allowed to warm to room temperature and stirred overnight. Upon completion, the reaction mixture was diluted with ethyl acetate (EtOAc), washed with water, brine, dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography over silica gel to give tert-butyl 5-methylbenzo[c]isoxazole-3-carboxylate (2.70 g, 85% yield). LCMS (ES, m / z) = 234.1 [M+1]+

[0589] Step 2: To a solution of tert-butyl 5-methylbenzo[c]isoxazole-3-carboxylate (2.00 g, 8.57 mmol) in carbon tetrachloride (42 mL), N-bromosuccinimide (NBS) (1.83 g, 10.3 mmol) and 2,2'-azobis(2-methylpropionitrile) (AIBN) (141 mg, 0.857 mmol) were added at room temperature. The resulting mixture was stirred at 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (0–10% ethyl acetate (EtOAc) / hexanes) to afford tert-butyl 5-(bromomethyl)benzo[c]isoxazole-3-carboxylate (1.80 g, 67% yield) as a white solid. LCMS (ES, m / z) = 312.0 / 314.0 [M+1] +

[0590] Step 3: tert-Butyl 5-(bromomethyl)benzo[c]isoxazole-3-carboxylate (1.00 g, 3.20 mmol) and phenylboronic acid (391 mg, 3.20 mmol) were dissolved in dioxane (26 mL) and HO (8.7 mL), and cesium carbonate (3.13 g, 9.61 mmol) was added. The suspension was degassed and purged with nitrogen (3x). Bis(dibenzylideneacetone)palladium(0) (55.3 mg, 0.0961 mmol) was added, and the suspension was degassed with nitrogen (3x). The reaction mixture was heated to 80 °C and monitored by LCMS. After overnight, the reaction mixture was cooled to rt and filtered through Celite. The filtrate was diluted with ethyl acetate (EtOAc), washed with water, brine, and concentrated. The residue was purified by flash chromatography over silica gel to give tert-butyl 5-benzylbenzo[c]isoxazole-3-carboxylate (760 mg, 77% yield). LCMS (ES, m / z) = 310.1 [M+1] +

[0591] Step 4: To a solution of tert-butyl 5-benzylbenzo[c]isoxazole-3-carboxylate (330 mg, 1.07 mmol) in carbon tetrachloride (10 mL), N-bromosuccinimide (247 mg, 1.39 mmol) and 2,2′-azobis(2-methylpropionitrile) (17.5 mg, 0.107 mmol) were added at room temperature. The resulting mixture was stirred at 80° C. for 16 hours. The reaction mixture was then cooled, diluted with ethyl acetate (EtOAc), washed with water, brine, dried over sodium sulfate, and concentrated to give 450 mg of the crude bromo-intermediate. 250 mg of the residue was dissolved in tetrahydrofuran (THF) (5.3 mL) and water (5.3 mL), and 2N sodium hydroxide (523 μL, 1.05 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours. After completion, the reaction mixture was acidified with Amberlite IR-120[H], filtered, and concentrated. The residue was purified by C18 reverse phase chromatography to give 5-(hydroxy(phenyl)methyl)benzo[c]isoxazole-3-carboxylic acid (60.0 mg, 35% yield). LCMS (ES, m / z) = 270.1 [M+1] +

[0592] Step 5: 5-(hydroxy(phenyl)methyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide was prepared according to Step 5 of Example 39A using 5-(hydroxy(phenyl)methyl)benzo[c]isoxazole-3-carboxylic acid. LCMS (ES, m / z) = 399.1 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.11 (1H, s), 7.71 (1H, d, J = 9.3 Hz), 7.41 (3H, d, J = 6.5 Hz), 7.32 (2H, t, J = 7.4 Hz), 7.22 (1H, t, J = 7.3 Hz), 6.19 (1H, s), 5.79 (1H, s), 2.74 (3H, s). [NH signal not observed]

[0593] Example 46: 5-Benzoyl-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide (Compound 167) [ka] Step 1: To a solution of tert-butyl 5-benzylbenzo[c]isoxazole-3-carboxylate (580 mg, 1.87 mmol) in carbon tetrachloride (19 mL), N-bromosuccinimide (734 mg, 4.12 mmol) and 2,2′-azobis(2-methylpropionitrile) (30.8 mg, 0.187 mmol) were added at room temperature. The resulting mixture was stirred for 16 hours at 80° C. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (EtOAc), washed with water, brine, dried over sodium sulfate, and concentrated. The residue was dissolved in tetrahydrofuran (THF) (15.0 mL) and HO (3.75 mL), and sodium carbonate (796 mg, 7.50 mmol) was added. The resulting mixture was stirred at room temperature overnight. Upon completion, the reaction mixture was acidified with Amberlite IR-120 [H], filtered, and concentrated. The residue was purified by flash chromatography over silica gel to give tert-butyl 5-benzoylbenzo[c]isoxazole-3-carboxylate (170 mg, 28% yield). LCMS (ES, m / z) = 324.1 [M+1] +

[0594] Step 2: tert-Butyl 5-benzoylbenzo[c]isoxazole-3-carboxylate (60.0 mg, 0.186 mmol) was dissolved in CHCl (1.7 mL) and trifluoroacetic acid (TFA) (169 μL) was added dropwise. The solution was stirred at rt for 2 days. The solvent was then removed to give crude 5-benzoylbenzo[c]isoxazole-3-carboxylic acid (quantitative yield), and the resulting residue was used without further purification. LCMS (ES, m / z) = 268.1 [M+1] +

[0595] Step 3: 5-Benzoyl-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide was prepared according to Step 5 of Example 39A using crude 5-benzoylbenzo[c]isoxazole-3-carboxylic acid. LCMS (ES, m / z) = 397.1 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.36 (1H, s), 7.96 (1H, d, J = 9.3 Hz), 7.80-7.85 (3H, m), 7.73 (1H, t, J = 7.4 Hz), 7.61 (2H, t, J = 7.5 Hz), 2.71 (3H, s). [NH signal not observed]

[0596] Example 47: 7-(hydroxymethyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide (Compound 168) [ka] Step 1: A flame-dried flask was charged with 2-(3-methyl-2-nitrophenyl)acetic acid (3.00 g, 15.4 mmol), toluene (115 mL), sulfuric acid (81.9 μL, 1.54 mmol), and ethanol (EtOH) (38 mL). A condenser was attached to the flask, and the solution was refluxed for 14 hours. The solvent was removed under reduced pressure to give crude ethyl 2-(3-methyl-2-nitrophenyl)acetate (quantitative yield), which was used directly in the next step without further purification. LCMS (ES, m / z) = 224.1 [M+1] +

[0597] Step 2: Ethyl 2-(3-methyl-2-nitrophenyl)acetate (3.40 g, 15.2 mmol) was dissolved in N,N-dimethylformamide (DMF) (76 mL) and treated sequentially with triethylamine (NEt) (10.6 mL, 76.2 mmol) and chlorotrimethylsilane (TMSCl) (9.67 mL, 76.2 mmol). The resulting mixture was stirred at room temperature for 27 days. Upon completion, the reaction mixture was poured into ice-cold dilute HCl, extracted with ethyl acetate (EtOAc), and the organic phase was concentrated and purified by flash chromatography through silica gel to give ethyl 7-methylbenzo[c]isoxazole-3-carboxylate (2.90 g, 93% yield). LCMS (ES, m / z) = 206.1 [M+1] +

[0598] Step 3: To a solution of ethyl 7-methylbenzo[c]isoxazole-3-carboxylate in carbon tetrachloride (24 mL), N-bromosuccinimide (1.30 g, 7.31 mmol) and 2,2'-azobis(2-methylpropionitrile) (160 mg, 0.975 mmol) were added at room temperature. The resulting mixture was stirred for 16 hours at 80°C. The reaction mixture was then cooled to room temperature and filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography over silica gel (0–10% ethyl acetate (EtOAc) / hexanes) to give ethyl 7-(bromomethyl)benzo[c]isoxazole-3-carboxylate (660 mg, 48% yield) (LCMS (ES, m / z) = 284.0 / 286.0 [M+1]) and ethyl 7-(dibromomethyl)benzo[c]isoxazole-3-carboxylate (640 mg, 36% yield) (LCMS (ES, m / z) = 361.9 / 363.9 [M+1]). + )

[0599] Step 4: Ethyl 7-(bromomethyl)benzo[c]isoxazole-3-carboxylate (50.0 mg, 0.176 mmol) was dissolved in tetrahydrofuran (THF) (8.8 mL), and HO (8.8 mL) and potassium carbonate (53.5 mg, 0.387 mmol) were added. The resulting solution was stirred at 75 °C for 1 h. The reaction mixture was cooled to rt and acidified with Amberlite IR-120 [H]. The resin was filtered off, and the filtrate was concentrated to give crude 7-(hydroxymethyl)benzo[c]isoxazole-3-carboxylic acid (35.0 mg, quantitative yield), which was used without further purification. LCMS (ES, m / z) = 194.0 [M+1] +

[0600] Step 5: 7-(hydroxymethyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[c]isoxazole-3-carboxamide was prepared according to Step 5 of Example 39A using 7-(hydroxymethyl)benzo[c]isoxazole-3-carboxylic acid. LCMS (ES, m / z) = 323.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ 7.97 (1H, s), 7.43 (1H, d, J = 6.3 Hz), 7.28 (1H, s), 5.48 (1H, s), 4.83 (2H, s), 2.71 (3H, s). [NH signal not observed]

[0601] Example 48: 2-(2'-(6-((5-(methylthio)-1,3,4-thiadiazol-2-yl)carbamoyl)-2-oxo-2H-pyran-4-yl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 176) [ka] Step 1: Di-tert-butyl dicarbonate (3.33 g, 15.3 mmol) and 4-dimethylaminopyridine (186 mg, 1.53 mmol) were added to a solution of 4-iodophenylacetic acid (2.00 g, 7.63 mmol) in tBuOH (15.3 mL) under nitrogen. The mixture was stirred at room temperature for 24 h. The reaction mixture was then concentrated to dryness, and the crude material was purified by flash chromatography over silica gel (0-10% ethyl acetate (EtOAc) in hexanes) to afford tert-butyl 2-(4-iodophenyl)acetate as a colorless oil. 1 H NMR (400 MHz, CHCl3-d): δ 7.64 (2H, d, J = 8.1 Hz), 7.02 (2H, d, J = 7.9 Hz), 3.46 (2H, s), 1.43 (9H, s)

[0602] Step 2: tert-Butyl 2-(4-iodophenyl)acetate (400 mg, 1.26 mmol), 2-bromophenylboronic acid (177 μL, 1.51 mmol), and potassium carbonate (348 mg, 2.51 mmol) were dissolved in dioxane (5.24 mL) and HO (1.05 mL). The solution was degassed with argon, and then tetrakis(triphenylphosphine)palladium (72.6 mg, 0.0629 mmol) was added. The reaction mixture was again degassed with argon and then heated at 90 °C overnight. The reaction mixture was cooled to rt, diluted with ethyl acetate (EtOAc), washed with water, brine, dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography over silica gel (0 to 25% EtOAc / hexanes) to give tert-butyl 2-(2'-bromo-[1,1'-biphenyl]-4-yl)acetate (0.150 g, 34% yield) as a colorless oil. 1 H NMR (400 MHz, CHCl3-d): δ H 7.66 (1H, d, J = 8.0 Hz), 7.30-7.37 (6H, m), 7.17-7.21 (1H, m), 3.59 (2H, s), 1.47 (9H, s)

[0603] Step 3: tert-Butyl 2-(2'-bromo-[1,1'-biphenyl]-4-yl)acetate (550 mg, 1.58 mmol) was dissolved in dioxane (7.92 mL) and the solution was degassed with argon. Potassium acetate (466 mg, 4.75 mmol), bis(pinacolato)diboron (523 mg, 2.06 mmol), and 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) (116 mg, 0.158 mmol) were added sequentially. The solution was again degassed with argon and heated at 90 °C overnight. The solvent was then removed, and the residue was dissolved in hexane / ethyl acetate (EtOAc) (5:1). The black solid was filtered through a pad of Celite, and the filtrate was concentrated to give a brown oil, which was purified by flash chromatography over silica gel (0-20% EtOAc / hexanes) to give tert-butyl 2-(2'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-4-yl)acetate (0.58 g, 65% yield). LCMS (ES, m / z) = 417.2 [M+23] +

[0604] Step 4: tert-Butyl 2-(2'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-4-yl)acetate (200 mg, 0.507 mmol), 4-bromo-2-oxo-2H-pyran-6-carboxylic acid (133 mg, 0.609 mmol), and potassium phosphate tripotassium (323 mg, 1.52 mmol) were mixed in dioxane (2.11 mL) and HO (423 μL). The mixture was degassed with argon, after which 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) (37.1 mg, 0.0507 mmol) was added and degassed again with argon. The resulting mixture was heated at 85 °C under argon for 5 hours. Upon completion, the resulting mixture was filtered through a pad of Celite. The solvent was removed under reduced pressure and the crude material was purified by C18 reverse flash chromatography (0-50% MeCN / HO) to give 4-(4'-(2-(tert-butoxy)-2-oxoethyl)-[1,1'-biphenyl]-2-yl)-2-oxo-2H-pyran-6-carboxylic acid (0.030 g, 15% yield). LCMS (ES, m / z) = 429.1 [M+23] +

[0605] Step 5: tert-Butyl 2-(2'-(6-((5-(methylthio)-1,3,4-thiadiazol-2-yl)carbamoyl)-2-oxo-2H-pyran-4-yl)-[1,1'-biphenyl]-4-yl)acetate was prepared according to Step 5 of Example 39A using 4-(4'-(2-(tert-butoxy)-2-oxoethyl)-[1,1'-biphenyl]-2-yl)-2-oxo-2H-pyran-6-carboxylic acid. LCMS (ES, m / z) = 536.1 [M+1] +

[0606] Step 6: tert-Butyl 2-(2'-(6-((5-(methylthio)-1,3,4-thiadiazol-2-yl)carbamoyl)-2-oxo-2H-pyran-4-yl)-[1,1'-biphenyl]-4-yl)acetate (18.5 mg, 0.0344 mmol) and 1,3-dimethoxybenzene (9.02 μL, 0.0689 mmol) were dissolved in CHCl (626 μL) and trifluoroacetic acid (TFA) (62.6 μL) was added. The resulting solution was stirred at rt until the starting material was completely consumed. The solvent was then removed and the residue was purified by C18 reverse phase chromatography to give 10 mg of a brown solid, which was washed with MeOH to give 2-(2'-(6-((5-(methylthio)-1,3,4-thiadiazol-2-yl)carbamoyl)-2-oxo-2H-pyran-4-yl)-[1,1'-biphenyl]-4-yl)acetic acid (6.5 mg, 39% yield) as an off-white powder. LCMS (ES, m / z) = 480.1 [M+1]+. 1 H NMR (400 MHz, DMSO-d): δ H 7.48-7.60 (4H, m), 7.26 (4H, s), 7.00 (1H, s), 6.42 (1H, s), 3.56 (2H, s), 2.70 (3H, s). [COOH and NH signals not observed]

[0607] Example 49: 1-((3-((5-(methylthio)-1,3,4-thiadiazol-2-yl)carbamoyl)benzo[c]isoxazol-5-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (Compound 184) [ka] Step 1: A solution of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid (1.0 equiv., 500 mg, 2.59 mmol), di-tert-butyl dicarbonate (BocO) (1.5 equiv., 865 mg, 3.89 mmol), and 4-dimethylaminopyridine (DMAP) (0.5 equiv., 158 mg, 1.30 mmol) in anhydrous tetrahydrofuran (THF) (10 mL) was stirred overnight at rt under an Ar atmosphere. The reaction mixture was treated with 1 M HCl (28 mL) and stirred at rt for 10 min. The reaction mixture was diluted with 2 M NaOH. (水性) The solution was adjusted to pH 8 and extracted with ethyl acetate (EtOAc) (3 x 20 mL). The combined organic extract suspension was filtered to give crude tert-butyl 4-hydroxyquinoline-3-carboxylate (160 mg, 25% yield) as an off-white solid, which was used without further purification. LCMS (ES, m / z) = 244.1 [M+H] +

[0608] Step 2: tert-Butyl 1-((3-((5-(methylthio)-1,3,4-thiadiazol-2-yl)carbamoyl)benzo[c]isoxazol-5-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate was prepared from tert-butyl 4-hydroxyquinoline-3-carboxylate according to Steps 1 to 3 of Example 9. LCMS (ES, m / z) = 550.1 [M+H] +

[0609] Step 3: A solution of tert-butyl 1-((3-((5-(methylthio)-1,3,4-thiadiazol-2-yl)carbamoyl)benzo[c]isoxazol-5-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (1.0 equiv., 34.6 mg, 63.0 μmol) and trifluoroacetic acid (207 equiv., 998 μL, 13.0 mmol) in anhydrous dichloromethane (DCM) (5.00 mL) was stirred vigorously at rt for 32 h. The solvent was removed by rotary evaporation, and the crude was triturated with MeCN and water. The solid was filtered and dried to give 1-((3-((5-(methylthio)-1,3,4-thiadiazol-2-yl)carbamoyl)benzo[c]isoxazol-5-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (23.7 mg, 76% yield) as a light yellow solid. LCMS (ES, m / z) = 494.1 [M+H] + . 1 H NMR (DMSO-d6, 400 MHz): δ 9.37 (1H, s), 8.42 (1H, d, J = 8.1 Hz), 7.84-7.95 (4H, m), 7.64 (1H, t, J = 7.5 Hz), 7.43 (1H, d, J = 9.4 Hz), 6.00 (2H, s), 2.74 (3H, s)

[0610] Example 50: 3-amino-N-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)isoxazole-5-carboxamide (Compound 4) [ka] Step 1: tert-Butyl N-[5-[[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]carbamoyl]isoxazol-3-yl]carbamate was prepared according to Example 1 using 3-(tert-butoxycarbonylamino)isoxazole-5-carboxylic acid. LCMS (ES, m / z) = 422.44 [M+H] + . 1H NMR (DMSO-d6, 400 MHz) δ 13.80 (s, 1H), 10.69 (s, 1H), 8.15 (d, J = 7.5Hz, 1H), 7.88 (s, 1H), 7.71 (dd, J = 7.8, 1.5Hz, 1H), 7.65 - 7.51 (m, 2H), 1.50 (s, 9H)

[0611] Step 2: tert-Butyl N-[5-[[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]carbamoyl]isoxazol-3-yl]carbamate (1.00 equiv., 300 mg, 0.711 mmol) was suspended in ethyl acetate (EtOAc) (7 mL), and 4 N HCl in dioxane (2 mL) was added and stirred at rt. The mixture did not become homogeneous. After 2 h, an additional 4 N HCl in dioxane (2 mL) was added and stirred overnight. After 16 h at rt, the reaction was still incomplete. The mixture was concentrated to dryness. The crude residue was resuspended in ethyl acetate (EtOAc) (20 mL) and N,N-dimethylformamide (DMF) (1 mL), and 4 N HCl in dioxane (2 mL) was ad...

Claims

1. Formula (I): [Formula 1] [During the ceremony, Ring A is a 5-10 membered heteroaryl or a 3-10 membered heterocyclyl; R 1 is H, -SR 4 , -S(O)R 4 , -S(O) 2 R 4 , -N(R 4 ) 2 , -C.N., C. 1 -C 6 Alkyl, C 6 -C 10 aryl or 5-10 membered heteroaryl, wherein the alkyl, aryl or heteroaryl optionally has one or more R 5 provided that when ring A is 1-isoquinolinyl, R 1 is not pyridinyl; R 2 is H or C 1 -C 6 is alkyl; Each R 3 are independently halogen, -CN, -OR 8 , -NH 2 , -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 ) 2 , -SR 8 , -S(O) 2 R 8 , C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 6or replaced with Two R's 3 are C together with the atoms to which they are attached. 3 -C 8 Cycloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, where the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 7 or replaced with 2 Germinal R 3 together with the carbon atom to which they are attached form oxo; R 4 is H, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; Each R 5 are independently -OH, halogen, -C(O)OH, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl or C 2 -C 6 alkynyl, wherein the alkyl, alkoxy, alkenyl or alkynyl is optionally halogen, OH or NH 2 is substituted with; Each R 6 are independently halogen, -OH, -CO(OR 8 ), -(CH 2 ) n -NHC(O)-(CH 2 ) p -OR 8 , C.N., C. 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein said alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally selected from halogen, -OH, -NH 2 , -NHC(O)OR 8 , -(CH 2 ) n -NHC(O)R 8 , -(CH 2 ) n -NHC(O)-(CH 2 ) p -OR 8 , -(CH 2 ) n -N.H.R. 8 , -(CH 2 ) n -NHS(O)R 8 , -(CH 2 ) n -NHS(O) 2 R 8 , -(CH 2 ) n -C(O)R 8 , -(CH 2 ) n -C(O)OR 8 , -(CH 2 ) n -OR 8 , -(CH 2 ) n O(CH 2 ) n C(O)NHR 8 , C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl, C 6 -C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl or -(C 1 -C 6 Alkyl)-(C 6 -C 10 aryl) or Two R's 6 combine with the atom to which they are attached to form an atom or 2 Germinal R 6 together with the carbon atom to which they are attached form oxo; Each R 7 are independently halogen, -OH, -C(O)OR 8 , C 1 -C 6 Alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl; Two R's 7 are C together with the atoms to which they are bonded. 3 -C 8 Cycloalkyl, C 6 -C 10 forming an aryl, a 5- to 10-membered heteroaryl or a 3- to 10-membered heterocyclyl; 2 Germinal R 7 together with the carbon atom to which they are attached form oxo; R 8 is H, -OH, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl optionally comprises one or more R 9 is substituted with; R 9 Ha-(CH 2 ) n -NHC(O)-(CH 2 ) p -OR 10 , -C.N., C. 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein said alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally halogen, —OH, —NH 2 , -NHC(O)OR 10 , -(CH 2 ) n -NHC(O)R 10 , -(CH 2 ) n -NHC(O)-(CH 2 ) p -OR 10 , -(CH 2 ) n -N.H.R. 10 , -(CH 2 ) n -NHS(O)R 10 , -(CH 2 ) n -NHS(O) 2 R 10 , -(CH 2) n -C(O)R 10 , -(CH 2 ) n -C(O)OR 10 , C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl, C 6 -C 10 Aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl or -(C 1 -C 6 Alkyl)-(C 6 -C 10 aryl); R 10 is C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein said alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally contains one or more of halogen, —OH, —CO(OH), —(CH 2 ) n -NHC(O)-(CH 2 ) p -OR 8 , -C.N., C. 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl or C 6 -C 10 substituted with aryl; m is an integer from 0 to 4; n is an integer from 0 to 6; and and p is an integer from 0 to 6. or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof.

2. The compound has formula (I-a): [chemical 2] 2. The compound of claim 1, wherein:

3. Formula (I-a) is Formula (I-a-1) [C3] 3. The compound of claim 1 or claim 2, wherein:

4. Formula (I-a) is formula (I-a-1-i) [C4] 4. The compound of claim 1, wherein:

5. Formula (I-a) is formula (I-a-1-ii) [C5] [In the formula, q is 0, 1, 2, 3 or 4.] 4. The compound of claim 1, wherein:

6. Formula (I-a) is formula (I-a-2): [C6] [In the formula, m is 0, 1, 2, 3 or 4.] 3. The compound of claim 1 or claim 2, wherein:

7. Formula (I-a) is formula (I-a-2-i): [C7] [In the formula, m is 1, 2 or 3.] 7. The compound of any one of claims 1 to 2 and 6, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof.

8. Formula (I-a) is formula (I-a-2-ii) [C8] [In the formula, q is 0, 1, 2, 3 or 4.] 8. The compound of any one of claims 1 to 2 and 6 to 7, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof.

9. Formula (I-a) is a formula (I-a-5) to formula (I-a-13): [C9] [In the formula, q is 0, 1, 2, 3 or 4.] or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof, of claim 1 or 2,

10. R 1 is hydrogen, -SCH 3 , -SCH 2 CH 3 , -CH 3 , -CHF 2 , -CF 3 , -CH 2 CH 3 , -(CH 2 ) 2 CH 3 , -(CH 2 ) 4 CH 3 , -CN, -CH 2 CH 2 OCH 3 , -NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CH(CH 2 CH 3 ), -CH(C 6 H 6 )(CH 2 CH 3 2. The compound of claim 1, wherein R is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63

11. R 1 Ga-SCH 3 11. The compound of claim 10, wherein:

12. R 2 is H, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

13. R 2 13. The compound of any one of claims 1 to 12, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, wherein is methyl.

14. 14. The compound of any one of claims 1 to 13, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, wherein Ring A is a 5- or 6-membered heterocyclyl or a 5- or 6-membered heteroaryl.

15. Ring A is: [C10] [In the formula, q is 0, 1, 2, 3 or 4.] 15. The compound of any one of claims 1 to 14, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof.

16. 15. The compound of claim 14, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, wherein Ring A is a 5- or 6-membered heteroaryl.

17. Ring A is [C11] [In the formula, m is 0, 1, 2, 3 or 4, and q is 0, 1, 2, 3 or 4.] 17. The compound of claim 16, wherein:

18. Each R 3 are independently halogen, -CN, -OR 8 , -NH 2 , -NH(R 6 ), -N(R 6 )(R 7 ), -NHC(O)R 8 , -CO(OR 8 ), -C(O)R 8 , -C(O)N(R 8 ) 2 , -SR 8 , -S(O) 2 R 8 , C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally has one or more R 6 18. The compound of any one of claims 1 to 17, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, substituted with:

19. Two R's 3 Together with the intervening atoms, C 3 -C 8 Cycloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl, where the cycloalkyl, aryl, heterocyclyl, or heteroaryl optionally comprises one or more R 7 18. The compound of any one of claims 1 to 17, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, substituted with:

20. 2 Germinal R 3 or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, of any of claims 1 to 17, wherein:

21. Two R's 3 But together with the atoms to which they are bound, [C12] [In the formula, q is 0, 1, 2, 3 or 4.] 32. The compound of claim 31 , or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope or tautomer thereof, which forms:

22. R 4 C 1 -C 6 22. The compound of any one of claims 1 to 21, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, wherein R is an alkyl group.

23. R 4 23. The compound of claim 22, or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof, wherein is methyl or ethyl.

24. A compound selected from Table 1 or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, labeled isotope, or tautomer thereof.

25. 25. A pharmaceutical composition comprising a compound of any of claims 1-24 and one or more pharma- ceutically acceptable carriers.

26. A method for treating a cGAS-associated disease or disorder, comprising administering to a subject a compound of any of claims 1-25.

27. A method for modulating cGAS, comprising administering to a subject a compound of any of claims 1-26.

28. 30. A compound of any of claims 1-27 for use in the treatment of a cGAS-related disease or disorder.

29. 30. Use of a compound of any of claims 1-28 in the manufacture of a medicament for the treatment of a cGAS-related disease or disorder.

30. 30. The method, compound or use of any of claims 26 to 29, wherein the subject is a human.

31. 31. The method, compound or use of any of claims 26-30, wherein the cGAS-related disease or disorder is inflammation, an autoimmune disease, cancer, infection, a disease or disorder of the central nervous system, a metabolic disease, a cardiovascular disease, a respiratory disease, a renal disease, a liver disease, an eye disease, a skin disease, a lymphatic disease, a rheumatic disease, a psychiatric disease, graft versus host disease, allodynia, or a cGAS-related disease in a subject determined to have a germline or somatic non-silent mutation in cGAS.

32. 32. The method, compound or use of any one of claims 26 to 31, wherein the disease or disorder of the central nervous system is Parkinson's disease, Alzheimer's disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis or multiple sclerosis.

33. 32. The method, compound or use of any of claims 26 to 31, wherein the kidney disease is an acute kidney disease, a chronic kidney disease or a rare kidney disease.

34. 32. The method, compound or use of any one of claims 26 to 31, wherein the skin disease is psoriasis, hidradenitis suppurativa (HS) or atopic dermatitis.

35. 32. The method, compound or use of any of claims 26 to 31, wherein the rheumatic disease is dermatomyositis, Still's disease or juvenile idiopathic arthritis.

36. 32. The method, compound or use of any of claims 26-31, wherein the cGAS-associated disease in a subject determined to have a germline or somatic non-silent mutation in cGAS is cryopyrin-associated autoinflammatory syndrome.

37. 32. The method, compound or use of any one of claims 26 to 31, wherein the cryopyrin-associated autoinflammatory syndrome is familial cold autoinflammatory syndrome, Muckle-Wells syndrome or neonatal onset multisystem inflammatory disease.

Citation Information

Patent Citations

  • Thiadiazole or oxadiazole and their use as inhibitors of jak protein kinase

    JP2006513192A

  • Pyrone compounds and herbicides containing them

    JP2015535806A

  • cGAS antagonist compounds

    JP2019510787A

  • Pyrazolopyrimidinone compounds and uses thereof

    JP2020533376A

  • New malonitrile derivatives

    JP2023527698A

Cited By

  • Thiadiazole derivatives as inhibitors of cyclic GMP-AMP synthase and their use

    JP2026501225A

  • Thiadiazole derivatives as inhibitors of cyclic GMP-AMP synthase and their use

    JP7870987B2